<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="prp270037" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmacol Res Perspect</journal-id><journal-id journal-id-type="iso-abbrev">Pharmacol Res Perspect</journal-id><journal-id journal-id-type="pmc-domain-id">2563</journal-id><journal-id journal-id-type="pmc-domain">pharmrespersp</journal-id><journal-id journal-id-type="publisher-id">PRP2</journal-id><journal-title-group><journal-title>Pharmacology Research &amp; Perspectives</journal-title></journal-title-group><issn pub-type="epub">2052-1707</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11629119</article-id><article-id pub-id-type="pmcid-ver">PMC11629119.1</article-id><article-id pub-id-type="pmcaid">11629119</article-id><article-id pub-id-type="pmcaiid">11629119</article-id><article-id pub-id-type="pmid">39655648</article-id><article-id pub-id-type="doi">10.1002/prp2.70037</article-id><article-id pub-id-type="publisher-id">PRP270037</article-id><article-id pub-id-type="other">PRP2-2024-10-0384</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>In Vitro Hepatic Metabolism Input Parameters Support Toxicokinetic Simulations for the Formation of Methoxy Propionic Acid From &#946;&#8208;Isomer Propylene Glycol Methyl Ether</article-title></title-group><contrib-group><contrib id="prp270037-cr-0001" contrib-type="author"><name name-style="western"><surname>Werner</surname><given-names initials="S">Sophie</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0007-6531-2610</contrib-id><xref rid="prp270037-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="prp270037-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="prp270037-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="prp270037-cr-0002" contrib-type="author"><name name-style="western"><surname>Hegg</surname><given-names initials="L">Lucie</given-names></name><xref rid="prp270037-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="prp270037-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="prp270037-cr-0003" contrib-type="author"><name name-style="western"><surname>Hopf</surname><given-names initials="NB">Nancy B.</given-names></name><xref rid="prp270037-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="prp270037-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="prp270037-cr-0004" contrib-type="author"><name name-style="western"><surname>Borgatta</surname><given-names initials="M">Myriam</given-names></name><xref rid="prp270037-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="prp270037-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="prp270037-cr-0005" contrib-type="author" corresp="yes"><name name-style="western"><surname>Suter&#8208;Dick</surname><given-names initials="L">Laura</given-names></name><xref rid="prp270037-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="prp270037-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><address><email>laura.suterdick@fhnw.ch</email></address></contrib></contrib-group><aff id="prp270037-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">School of Life Sciences</named-content>
<institution>University of Applied Sciences and Arts Northwestern Switzerland</institution>
<city>Muttenz</city>
<country country="CH">Switzerland</country>
</aff><aff id="prp270037-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Pharmaceutical Sciences</named-content>
<institution>University of Basel</institution>
<city>Basel</city>
<country country="CH">Switzerland</country>
</aff><aff id="prp270037-aff-0003">
<label>
<sup>3</sup>
</label>
<institution>Swiss Centre for Applied Human Toxicology (SCAHT)</institution>
<city>Basel</city>
<country country="CH">Switzerland</country>
</aff><aff id="prp270037-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Center for Primary Care and Public Health (Unisant&#233;)</named-content>
<institution>University of Lausanne</institution>
<city>Lausanne</city>
<country country="CH">Switzerland</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence:</bold><break/>
Laura Suter&#8208;Dick (<email>laura.suterdick@fhnw.ch</email>)<break/></corresp></author-notes><pub-date pub-type="epub"><day>10</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2024</year></pub-date><volume>12</volume><issue seq="250">6</issue><issue-id pub-id-type="pmc-issue-id">473108</issue-id><issue-id pub-id-type="doi">10.1002/prp2.v12.6</issue-id><elocation-id>e70037</elocation-id><history><date date-type="received"><day>28</day><month>10</month><year>2024</year></date><date date-type="accepted"><day>01</day><month>11</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>10</day><month>12</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>10</day><month>12</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-12-17 13:25:26.610"><day>17</day><month>12</month><year>2024</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2024 The Author(s). <italic toggle="yes">Pharmacology Research &amp; Perspectives</italic> published by British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics and John Wiley &amp; Sons Ltd.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="PRP2-12-e70037.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:PRP2-12-e70037.pdf"/><abstract><title>ABSTRACT</title><p>Propylene glycol ethers (PGEs) are organic solvents commonly found as technical grade on the commercial market, as mixtures of secondary (&#945;&#8208;isomer) and primary (&#946;&#8208;isomer, generally &lt;&#8201;5%) alcohols. After handling products containing PGEs, they readily enter the human body where they are metabolized. The minor &#946;&#8208;isomer is oxidized by alcohol dehydrogenase (ADH) followed by aldehyde dehydrogenase (ALDH) to a potentially harmful metabolite. Although the enzymatic rate is needed to estimate both parent and metabolite internal exposures, kinetic data for many PGEs are still scarce. Therefore, we generated in&#160;vitro hepatic intrinsic clearance data for propylene glycol methyl ether &#946;&#8208;isomer (&#946;&#8208;PGME) and its metabolite methoxy propionic acid (2&#8208;MPA) and integrated these data into an in silico toxicokinetic (TK) model. Hepatic clearance values for the model were generated using an established in&#160;vitro 3D culture of the human HepaRG cell line and human S9 liver fraction. Our results showed the presence of ADH and ALDH and consequently, the formation of 2&#8208;MPA in the 3D HepaRG and S9 fraction, which was slow to medium. We integrated the hepatic clearance values into the TK model to predict urinary 2&#8208;MPA concentrations. The simulated urinary 2&#8208;MPA concentrations fitted well (within twofold error from observed experimental data) for both liver systems, showing that they were both able to reliably predict the hepatic clearance of &#946;&#8208;PGME. Although S9 is suitable for short&#8208;term studies, 3D cell culture models maintain metabolic competence over days and weeks. This opens the opportunity for long&#8208;term metabolism studies applying the 3D HepaRG model alone or in multi&#8208;organ systems.</p></abstract><abstract abstract-type="graphical"><p>Visual abstract. Overview of the experimental workflow. The in&#160;vitro hepatic intrinsic clearance (CL<sub>int</sub>) for propylene glycol methyl ether &#946;&#8208;isomer (&#946;&#8208;PGME) to its corresponding metabolite methoxy propionic acid (2&#8208;MPA) was determined using human liver S9 fractions and 3D HepaRG. Urinary 2&#8208;MPA concentrations were simulated by integrating the hepatic organ clearance (CL<sub>h</sub>) into a developed toxicokinetic (TK) model, following in&#160;vitro&#8208;in vivo extrapolation (IVIVE). The results were compared with existing human exposure data. Illustration created with <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://biorender.com" ext-link-type="uri">BioRender.com</ext-link>.<boxed-text position="anchor" content-type="graphic" id="prp270037-blkfxd-0001" orientation="portrait"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="PRP2-12-e70037-g006.jpg"/></boxed-text>
</p></abstract><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>Swiss Centre for Applied Human Toxicology
</institution><institution-id institution-id-type="doi">10.13039/501100011039</institution-id></institution-wrap></funding-source><award-id>SCAHT&#8208;GL 21&#8208;10</award-id></award-group></funding-group><counts><fig-count count="10"/><table-count count="8"/><page-count count="21"/><word-count count="13200"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>December 2024</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.1 mode:remove_FC converted:10.12.2024</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="prp270037-ntgp-0001"><fn fn-type="funding" id="prp270037-note-0001"><p>
<bold>Funding:</bold> This work was supported by the Swiss Centre for Applied Human Toxicology (SCAHT&#8208;GL 21&#8208;10).</p></fn></fn-group></notes></front><body id="prp270037-body-0001"><def-list list-content="abbreviations" id="prp270037-dl-0001"><title>Abbreviations</title><def-item><term id="prp270037-li-0001">2&#8208;MAA</term><def id="prp270037-li-0002"><p>methoxy acetic acid</p></def></def-item><def-item><term id="prp270037-li-0003">2&#8208;MPA</term><def id="prp270037-li-0004"><p>methoxy propionic acid</p></def></def-item><def-item><term id="prp270037-li-0005">ADH</term><def id="prp270037-li-0006"><p>alcohol dehydrogenase</p></def></def-item><def-item><term id="prp270037-li-0007">ALDH</term><def id="prp270037-li-0008"><p>aldehyde dehydrogenase</p></def></def-item><def-item><term id="prp270037-li-0009">CL<sub>h</sub>
</term><def id="prp270037-li-0010"><p>hepatic organ clearance</p></def></def-item><def-item><term id="prp270037-li-0011">CL<sub>int</sub>
</term><def id="prp270037-li-0012"><p>hepatic intrinsic clearance</p></def></def-item><def-item><term id="prp270037-li-0013">CYP</term><def id="prp270037-li-0014"><p>cytochrome P450</p></def></def-item><def-item><term id="prp270037-li-0015">EGE</term><def id="prp270037-li-0016"><p>ethylene glycol ether</p></def></def-item><def-item><term id="prp270037-li-0017">EGME</term><def id="prp270037-li-0018"><p>ethylene glycol methyl ether</p></def></def-item><def-item><term id="prp270037-li-0019">fu,<sub>b</sub>
</term><def id="prp270037-li-0020"><p>plasma binding</p></def></def-item><def-item><term id="prp270037-li-0021">fu,<sub>inc</sub>
</term><def id="prp270037-li-0022"><p>incubational binding</p></def></def-item><def-item><term id="prp270037-li-0023">GC&#8211;MS</term><def id="prp270037-li-0024"><p>gas chromatography mass&#8208;spectroscopy</p></def></def-item><def-item><term id="prp270037-li-0025">HPLC&#8208;MS/MS</term><def id="prp270037-li-0026"><p>high&#8208;performance liquid chromatography mass&#8208;spectroscopy</p></def></def-item><def-item><term id="prp270037-li-0027">IVIVE</term><def id="prp270037-li-0028"><p>in vitro&#8208;in vivo extrapolation</p></def></def-item><def-item><term id="prp270037-li-0029">
<italic toggle="yes">K</italic>
<sub>m</sub>
</term><def id="prp270037-li-0030"><p>Michaelis&#8211;Menten constant</p></def></def-item><def-item><term id="prp270037-li-0031">PGE</term><def id="prp270037-li-0032"><p>propylene glycol ether</p></def></def-item><def-item><term id="prp270037-li-0033">PGME</term><def id="prp270037-li-0034"><p>propylene glycol methyl ether</p></def></def-item><def-item><term id="prp270037-li-0035">pHH</term><def id="prp270037-li-0036"><p>primary human hepatocytes</p></def></def-item><def-item><term id="prp270037-li-0037">S9</term><def id="prp270037-li-0038"><p>human liver subcellular fraction</p></def></def-item><def-item><term id="prp270037-li-0039">TK</term><def id="prp270037-li-0040"><p>toxicokinetic</p></def></def-item><def-item><term id="prp270037-li-0041">
<italic toggle="yes">V</italic>
<sub>max</sub>
</term><def id="prp270037-li-0042"><p>maximum reaction rate</p></def></def-item></def-list><sec id="prp270037-sec-0001"><label>1</label><title>Introduction</title><p>The general population, especially workers, are exposed to a wide range of propylene glycol ethers (PGEs) over a lifetime using cleaning products, surface coatings, and other products [<xref rid="prp270037-bib-0001" ref-type="bibr">1</xref>]. PGEs are the less toxic replacement solvents for ethylene glycol ethers (EGEs) regarding hemolysis, teratogenicity, developmental and reproductive toxicity. Still, occupational exposure to solvents has been associated with numerous neurological disorders [<xref rid="prp270037-bib-0002" ref-type="bibr">2</xref>] and the evaluation of neurotoxicity is conspicuously absent for PGEs [<xref rid="prp270037-bib-0003" ref-type="bibr">3</xref>, <xref rid="prp270037-bib-0004" ref-type="bibr">4</xref>, <xref rid="prp270037-bib-0005" ref-type="bibr">5</xref>, <xref rid="prp270037-bib-0006" ref-type="bibr">6</xref>, <xref rid="prp270037-bib-0007" ref-type="bibr">7</xref>]. Recently, Hopf et&#160;al. defined a novel strategy to assess the neurotoxicity of several PGEs by combining in&#160;vitro and in silico methods with human&#8208;controlled exposure studies [<xref rid="prp270037-bib-0008" ref-type="bibr">8</xref>].</p><p>Commercial PGEs are commonly sold as technical grade mixtures of secondary (&#945;&#8208;isomer) and primary (&#946;&#8208;isomer, generally &lt;&#8201;5%) alcohols. Similar to some banned EGEs, the primary alcohol group of PGEs can be enzymatically oxidized by alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH) to alkoxy propionic acid metabolites [<xref rid="prp270037-bib-0009" ref-type="bibr">9</xref>, <xref rid="prp270037-bib-0010" ref-type="bibr">10</xref>, <xref rid="prp270037-bib-0011" ref-type="bibr">11</xref>, <xref rid="prp270037-bib-0012" ref-type="bibr">12</xref>, <xref rid="prp270037-bib-0013" ref-type="bibr">13</xref>]. Several studies have proposed that ADH class I (ADH1A/B/C) plays a major role in the metabolism of solvents [<xref rid="prp270037-bib-0010" ref-type="bibr">10</xref>, <xref rid="prp270037-bib-0011" ref-type="bibr">11</xref>, <xref rid="prp270037-bib-0014" ref-type="bibr">14</xref>] and the involvement of <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2595" ext-link-type="uri">ALDH2</ext-link> is well documented [<xref rid="prp270037-bib-0015" ref-type="bibr">15</xref>, <xref rid="prp270037-bib-0016" ref-type="bibr">16</xref>].</p><p>Although alkoxy acetic acid metabolites are reported to be responsible for the adverse effects observed for EGEs, the metabolites and their effects have yet to be assessed for PGEs. Indeed, the metabolism of the widely produced PGEs is poorly described and only a few animal and human studies exist. Based on reported in&#160;vivo studies in rats and mice, it is assumed that most propylene glycol methyl ether &#946;&#8208;isomer (&#946;&#8208;PGME) is excreted as methoxy propionic acid (2&#8208;MPA) in urine, a minor fraction exhaled as carbon dioxide (CO<sub>2</sub>), and marginally eliminated unchanged or as glucuronide and sulfate conjugate in the urine [<xref rid="prp270037-bib-0013" ref-type="bibr">13</xref>, <xref rid="prp270037-bib-0017" ref-type="bibr">17</xref>, <xref rid="prp270037-bib-0018" ref-type="bibr">18</xref>, <xref rid="prp270037-bib-0019" ref-type="bibr">19</xref>] (Figure&#160;<xref rid="prp270037-fig-0001" ref-type="fig">1</xref>). Concordantly, urinary 2&#8208;MPA concentrations were observed in volunteers exposed to mixtures of &#945;&#8208;PGME (&gt;&#8201;99.5%) and &#946;&#8208;PGME (&lt;&#8201;0.5%) in controlled exposure studies [<xref rid="prp270037-bib-0020" ref-type="bibr">20</xref>]. However, in&#160;vitro metabolism studies, which are faster and safer alternatives to animal or human studies, have not yet been reported for &#946;&#8208;PGME. Yet, knowing the metabolic clearance is important for estimating parent and metabolite internal exposures and predicting toxic effects produced in the body [<xref rid="prp270037-bib-0021" ref-type="bibr">21</xref>].</p><fig position="float" fig-type="FIGURE" id="prp270037-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Metabolic pathway proposed for &#946;&#8208;isomer propylene glycol ether. The primary alcohol group of &#946;&#8208;isomer propylene glycol ether is majorly metabolized via the alcohol dehydrogenase and aldehyde dehydrogenase to an alkoxy propionic acid metabolite. Minor pathways are proposed to be the metabolism to propylene glycol via CYP450 enzymes, followed by the exhalation of CO<sub>2</sub>, and the formation of glucuronide and sulfate conjugates by uridine diphosphate glycosyltransferases (UGTs) and sulfotransferases (SULTs); R<sub>1</sub>&#8201;=&#8201;alkyl chain. Illustration created with <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://biorender.com" ext-link-type="uri">BioRender.com</ext-link>. Data based on literature [<xref rid="prp270037-bib-0013" ref-type="bibr">13</xref>, <xref rid="prp270037-bib-0017" ref-type="bibr">17</xref>, <xref rid="prp270037-bib-0018" ref-type="bibr">18</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="PRP2-12-e70037-g004.jpg"/></fig><p>Several liver models can be considered when studying the in&#160;vitro metabolism of compounds, whereby ease&#8208;of&#8208;use systems like microsomes and cell fractions (S9), primary human hepatocyte suspensions, and 2D cultures are commonly employed for metabolic stability assays. However, their use is limited because of the short enzyme functionality [<xref rid="prp270037-bib-0022" ref-type="bibr">22</xref>]. More complex systems, such as 3D liver cultures, offer a higher degree of in&#160;vivo&#8208;like conditions as they retain their hepatic functionality and enzyme performance over multiple weeks. Thus, they can be used to determine the clearance of low turn&#8208;over compounds [<xref rid="prp270037-bib-0023" ref-type="bibr">23</xref>, <xref rid="prp270037-bib-0024" ref-type="bibr">24</xref>, <xref rid="prp270037-bib-0025" ref-type="bibr">25</xref>]. Furthermore, the toxicity of compounds and their metabolites can be directly studied in the model or after its integration within in&#160;vitro multi&#8208;organ systems [<xref rid="prp270037-bib-0022" ref-type="bibr">22</xref>]. Among liver in&#160;vitro models, primary human hepatocytes are considered the gold standard for studying in&#160;vitro metabolism, but comparable enzyme functionality has been reported in the HepaRG cell line [<xref rid="prp270037-bib-0026" ref-type="bibr">26</xref>, <xref rid="prp270037-bib-0027" ref-type="bibr">27</xref>, <xref rid="prp270037-bib-0028" ref-type="bibr">28</xref>]. In this cell line, the expression of ADH and ALDH has been presented on the gene&#8208; and protein level, whereas the metabolism of substrates has not yet been described [<xref rid="prp270037-bib-0029" ref-type="bibr">29</xref>, <xref rid="prp270037-bib-0030" ref-type="bibr">30</xref>, <xref rid="prp270037-bib-0031" ref-type="bibr">31</xref>].</p><p>In this work, our goal was to generate novel in&#160;vitro hepatic kinetic data (clearance) for the formation of 2&#8208;MPA from &#946;&#8208;PGME, which were integrated into an in silico model for estimating internal human metabolite exposure, contributing to the approach of Hopf et&#160;al. [<xref rid="prp270037-bib-0008" ref-type="bibr">8</xref>]. &#946;&#8208;PGME was the solvent chosen for the study because a calibrated toxicokinetic model for &#945;&#8208;PGME exists from Reale et&#160;al. [<xref rid="prp270037-bib-0032" ref-type="bibr">32</xref>] which can be adapted to &#946;&#8208;PGME metabolism. We hypothesized that an established 3D HepaRG model could serve as a tool to determine hepatic kinetic parameters as an alternative to commonly used human liver S9 fractions. Applying the hepatic clearance values derived from both systems (3D HepaRG and S9 fraction), we simulated in&#160;vivo urinary 2&#8208;MPA concentrations and compared the predictions to previously reported human data&#160;[<xref rid="prp270037-bib-0020" ref-type="bibr">20</xref>]. This allowed the predictive potential of both liver systems to be assessed.</p></sec><sec sec-type="materials-and-methods" id="prp270037-sec-0002"><label>2</label><title>Materials and Methods</title><sec id="prp270037-sec-0003"><label>2.1</label><title>Chemicals and S9 Fractions</title><p>2&#8208;Methoxyethanol (EGME, &gt;&#8201;99.8%), GA11 (SML2028), <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11705" ext-link-type="uri">fomepizole</ext-link> (222569), 1&#8208;Methoxy&#8208;propan&#8208;2&#8208;ol (commercial PGME, &gt;&#8201;99.5%), 2&#8208;Methoxyacetic acid (2&#8208;MAA, 97%), and 2&#8208;Methoxypropionic acid (2&#8208;MPA, 98%) were purchased from Sigma&#8208;Aldrich (St. Louis, MO, USA). 2&#8208;Methoxy&#8208;propan&#8208;1&#8208;ol (&#946;&#8208;PGME, 98%) was manufactured by AA Blocks (San Diego, CA, USA). Glycol ethers and their metabolites are listed in Table&#160;<xref rid="prp270037-tbl-0001" ref-type="table">1</xref>. Ultrapure water was obtained from a Millipore Milli&#8208;Q Plus purification system (Beford, MA, USA). Phosphate buffer was prepared in&#8208;house, adjusted to pH&#8201;7.4, and stored at 4&#176;C. All other chemicals and reagents were of analytical grade and purchased from commercial sources. Pooled adult mixed&#8208;gender human liver subcellular fraction (S9) was purchased from ThermoFisherScientific (Reinach, Switzerland; HMS9PL) and stored at &#8722;80&#176;C after aliquoting.</p><table-wrap position="float" id="prp270037-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Overview of the glycol ethers and metabolites and their physicochemical properties.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">CAS number</th><th align="center" valign="bottom" rowspan="1" colspan="1">IUPAC name</th><th align="center" valign="bottom" rowspan="1" colspan="1">Trivial name</th><th align="center" valign="bottom" rowspan="1" colspan="1">Abbreviation</th><th align="center" valign="bottom" rowspan="1" colspan="1">Molecular weight (MW)<xref rid="prp270037-note-0003" ref-type="table-fn">
<sup>a</sup>
</xref>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">logP<xref rid="prp270037-note-0003" ref-type="table-fn">
<sup>a</sup>
</xref>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">pKa<xref rid="prp270037-note-0004" ref-type="table-fn">
<sup>b</sup>
</xref>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">f</italic>u,b</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">109&#8208;86&#8208;4</td><td align="center" valign="top" rowspan="1" colspan="1">2&#8208;Methoxyethanol</td><td align="center" valign="top" rowspan="1" colspan="1">Ethylene glycol methyl ether</td><td align="center" valign="top" rowspan="1" colspan="1">EGME</td><td align="center" valign="top" rowspan="1" colspan="1">76.09</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.80</td><td align="center" valign="top" rowspan="1" colspan="1">15.1 (A)</td><td align="center" valign="top" rowspan="1" colspan="1">ND</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">625&#8208;45&#8208;6</td><td align="center" valign="top" rowspan="1" colspan="1">2&#8208;Methoxyacetic acid</td><td align="center" valign="top" rowspan="1" colspan="1">Methoxy acetic acid</td><td align="center" valign="top" rowspan="1" colspan="1">2&#8208;MAA</td><td align="center" valign="top" rowspan="1" colspan="1">90.08</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.30</td><td align="center" valign="top" rowspan="1" colspan="1">3.83 (A)</td><td align="center" valign="top" rowspan="1" colspan="1">ND</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<p>107&#8208;98&#8208;2</p>
<p>1589&#8208;47&#8208;5</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>1&#8208;Methoxypropan&#8208;2&#8208;ol</p>
<p>2&#8208;Methoxypropan&#8208;1&#8208;ol</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">Propylene glycol methyl ether</td><td align="center" valign="top" rowspan="1" colspan="1">PGME (commercial) &#946;&#8208;PGME</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>90.12</p>
<p>90.12</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>&#8722;0.49</p>
<p>&#8722;0.49</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>14.9 (A)</p>
<p>14.7 (A)</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>0.540<xref rid="prp270037-note-0005" ref-type="table-fn">
<sup>c</sup>
</xref>
</p>
<p>0.540<xref rid="prp270037-note-0005" ref-type="table-fn">
<sup>c</sup>
</xref>
</p>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<p>4324&#8208;37&#8208;2</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">2&#8208;Methoxypropionic acid</td><td align="center" valign="top" rowspan="1" colspan="1">Methoxy propionic acid</td><td align="center" valign="top" rowspan="1" colspan="1">2&#8208;MPA</td><td align="center" valign="top" rowspan="1" colspan="1">104.1</td><td align="center" valign="top" rowspan="1" colspan="1">0.10<xref rid="prp270037-note-0006" ref-type="table-fn">*</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>3.99 (A)</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>ND</p>
</td></tr></tbody></table><table-wrap-foot id="prp270037-ntgp-0002"><fn id="prp270037-note-0002"><p>Abbreviation: ND, not determined.</p></fn><fn id="prp270037-note-0003"><label>
<sup>a</sup>
</label><p>Data derived from Pubchem. PubChem (nih.gov).</p></fn><fn id="prp270037-note-0004"><label>
<sup>b</sup>
</label><p>Data derived from Chemicalize, Chemicalize&#8208;Instant Cheminformatics Solutions.</p></fn><fn id="prp270037-note-0005"><label>
<sup>c</sup>
</label><p>Measured data derived from literature [<xref rid="prp270037-bib-0032" ref-type="bibr">32</xref>].</p></fn><fn id="prp270037-note-0006"><label>*</label><p>Computed data.</p></fn></table-wrap-foot></table-wrap></sec><sec id="prp270037-sec-0004"><label>2.2</label><title>Cell Culture</title><p>The HepaRG cell line was obtained from Biopredic International (Saint Gr&#233;goire, France; HPR101) and cultured for 4&#8201;weeks in basal medium with growth supplements (Biopredic International; ADD710). Cell passage was performed using Trypsin&#8211;EDTA (Sigma, Taufkirchen, Germany; 59417C&#8208;100ML), and cells at passages below 20 were used. Cell differentiation over 2&#8201;weeks was induced using medium containing a 50:50 mixture of growth and differentiation supplements (Biopredic International; ADD720) for 4&#8201;days, following the use of medium containing solely differentiation supplements for additional 10&#8201;days. For cell aggregation, we used William's E Medium + GlutaMAX (ThermoFisherScientific; 32551087), 1&#8201;&#215;&#8201;ITS (Sigma; 11074547001), 100&#8201;nM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2768" ext-link-type="uri">dexamethasone</ext-link> (Sigma; D1756), 1% penicillin and streptomycin (P/S; Sigma; P4333&#8208;100ML), and 20% fetal bovine serum (FBS; ThermoFisherScientific; 10270&#8208;106). Exchange to serum&#8208;free supplemented William's E Medium at Day 5 after aggregation was done for all treatment conditions.</p><p>Cryopreserved primary human hepatocytes (pHH) were obtained from Lonza (Basel, Switzerland; HUCPI). Detailed donor information of the two hepatocyte lots is summarized in Table&#160;<xref rid="prp270037-supitem-0001" ref-type="supplementary-material">S1</xref>. Cells were carefully thawed and resuspended in a thawing medium (Lonza; MCHT50), before being seeded in fresh plating medium (Lonza; MP100/MP250) or aggregation medium for either plated use or 3D culturing, respectively. Plates utilized for 2D cell culture were coated 1&#8201;h before seeding with rat tail collagen type I (1.3&#8201;&#956;g/cm<sup>2</sup>, Sigma; 08115) and the medium daily exchanged with maintenance medium (Lonza; CC&#8208;3198). Similar cell aggregation (3D pHH) and treatment media were used as described for the HepaRG before. All cells were cultured at 37&#176;C with 5% CO<sub>2</sub> in a humified incubator.</p></sec><sec id="prp270037-sec-0005"><label>2.3</label><title>Cell Viability Assay</title><p>For 2D cultures, HepaRG cells were seeded 7&#8201;days prior exposure at 2.25&#8201;&#215;&#8201;10<sup>5</sup> cells/cm<sup>2</sup> in a 96&#8208;well plate (Corning, NY, USA; 353072). For 3D cultures, HepaRG cells were seeded 7&#8201;days prior exposure at 3000 cells per well to form 3D&#8208;spheroids in Nunclon Sphera 96&#8208;well U&#8208;shaped&#8208;bottom microplates (ThermoFisherScientific; 174925). The acidic pH condition resulting from metabolites in the highest treatment condition (Figure&#160;<xref rid="prp270037-supitem-0001" ref-type="supplementary-material">S1</xref>) was neutralized to pH&#8201;7.4 (measured with an electrode) using 1&#8201;N NaOH and sterilized by filtration before further diluted. For the 3D cultures, half of the medium was removed, and twofold concentrated compound solution was added. To prevent solvent evaporation, we sealed all cell plates with an adhesive gas permeable seal (ThermoFisherScientific; AB0718). Cell viability was measured for &#946;&#8208;PGME and 2&#8208;MPA, and for commercial PGME, ethanol, EGME, and 2&#8208;MAA as comparators using concentration ranges of 10&#8211;1000&#8201;mM for the glycol ethers, 1&#8211;600&#8201;mM for ethanol, and 1&#8211;25&#8201;mM for the metabolites. We assessed cell viability by measuring ATP content using the CellTiter&#8208;Glo Luminescent Cell Viability Assay (Promega, USA; G7570) at 48&#8201;h and 7&#8201;days after exposure, following the manufacturer's instructions. Luminescence was measured on a Flexstation 3 microplate reader (Molecular Devices) at 1000&#8201;ms. Following this, the EC<sub>50</sub> was calculated using GraphPad Prism.</p></sec><sec id="prp270037-sec-0006"><label>2.4</label><title>CYP Metabolism Study</title><p>HepaRG cells were seeded 7&#8201;days prior treatment in a micro&#8208;mold system generating 35&#8201;&#215;&#8201;3D&#8208;spheroids (Sigma; Z764051&#8208;6EA) in a 24&#8208;well plate (Huberlab, Aesch, Switzerland; 7.662102) at 3000 cells per spheroid. Cytochrome P450 (CYP) functional activity, as a phenotypical characteristic of hepatocytes, was assessed using non&#8208;toxic concentrations of the corresponding CYP substrates 50&#8201;&#956;M <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2858" ext-link-type="uri">testosterone</ext-link> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=263" ext-link-type="uri">CYP3A</ext-link>; Sigma; 86&#8201;500) [<xref rid="prp270037-bib-0033" ref-type="bibr">33</xref>] and 100&#8201;&#956;M <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2714" ext-link-type="uri">diclofenac</ext-link> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1326" ext-link-type="uri">CYP2C9</ext-link>; Combi&#8208;Blocks, San Diego, CA, USA; OR&#8208;0229). CYPs were induced using a reported concentration of 20&#8201;&#956;M <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2765" ext-link-type="uri">rifampicin</ext-link> (Sigma; R3501) [<xref rid="prp270037-bib-0033" ref-type="bibr">33</xref>, <xref rid="prp270037-bib-0034" ref-type="bibr">34</xref>] at Day 5 and Day 6 of aggregation phase (48 and 24&#8201;h before substrate exposure). Supernatant was collected at defined timepoints (10&#8201;min, 6&#8201;h, 24&#8201;h, and 48&#8201;h) and stored at &#8211;80&#176;C for further analysis by HPLC&#8208;MS/MS.</p></sec><sec id="prp270037-sec-0007"><label>2.5</label><title>Albumin ELISA Assay</title><p>Quantification of the albumin concentration in supernatant of 3D HepaRG unexposed or exposed to a reported toxic concentration of 16&#8201;mM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5239" ext-link-type="uri">acetaminophen</ext-link> (APAP; Sigma; A5000) [<xref rid="prp270037-bib-0035" ref-type="bibr">35</xref>] for over 48&#8201;h, was determined using the Human Albumin ELISA Kit (Bethyl laboratories, USA; E80&#8208;129) according to the manufacturer's instructions.</p></sec><sec id="prp270037-sec-0008"><label>2.6</label><title>Gene Expression Analysis</title><p>HepaRG cells and pHH were seeded at 2.25&#8201;&#215;&#8201;10<sup>5</sup> cells/cm<sup>2</sup> in a 96&#8208;well plate for 7&#8201;days. The total RNA was isolated with the Qiazol Lysis Reagent (Qiagen, Basel, Switzerland; LT&#8208;02241) and mRNA was isolated following the standard TRIzol extraction procedure with glycogen (ThermoFisherScientific; 79306). Reverse transcription was performed using the M&#8208;MLV Reverse transcriptase (Promega, D&#252;bendorf, Switzerland; M1705) and oligo dT (Qiagen; 79237). Real&#8208;time PCR was conducted with specific TaqMan probes for selected genes (see Table&#160;<xref rid="prp270037-tbl-0002" ref-type="table">2</xref>) and FastStart TaqMan Probe Master (Sigma; 4673417001). The q&#8208;RT&#8208;PCR program was following: 10&#8201;min denaturation at 95&#176;C, followed by 40&#8201;cycles of 15&#8201;s at 95&#176;C and 1&#8201;min at 60&#176;C. The Ct values were produced using the LightCycler 480II Systems (Roche Diagnostics, Rotkreuz, Switzerland) and processed on GraphPad Prism using Beta&#8208;2&#8208;Microglobulin (B2M) as the internal standard for normalization. Relative gene expression was calculated as &#8710;Ct&#8201;=&#8201;Ct of the Gene of Interest&#8212;Ct B2M.</p><table-wrap position="float" id="prp270037-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>Taqman probes of selected genes obtained from ThermoFisherScientific.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Gene of Interest</th><th align="center" valign="bottom" rowspan="1" colspan="1">Ref. Nr.</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Cytochromes P450 3A4 (CYP3A4)</td><td align="center" valign="top" rowspan="1" colspan="1">Hs00604506_m1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cytochromes P450 2B6 (CYP2B6)</td><td align="center" valign="top" rowspan="1" colspan="1">Hs04183483_g1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cytochromes P450 2E1 (CYP2E1)</td><td align="center" valign="top" rowspan="1" colspan="1">Hs00559368_m1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Alcohol dehydrogenase isoform 1A (ADH1A)</td><td align="center" valign="top" rowspan="1" colspan="1">Hs00605167_g1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Alcohol dehydrogenase isoform 1B (ADH1B)</td><td align="center" valign="top" rowspan="1" colspan="1">Hs00605175_m1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Alcohol dehydrogenase isoform 1C (ADH1C)</td><td align="center" valign="top" rowspan="1" colspan="1">Hs02383872_s1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Aldehyde dehydrogenase 2 (ALDH2)</td><td align="center" valign="top" rowspan="1" colspan="1">Hs01007998_m1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Beta&#8208;2&#8208;Microglobulin (B2M)</td><td align="center" valign="top" rowspan="1" colspan="1">Hs00187842_m1</td></tr></tbody></table></table-wrap></sec><sec id="prp270037-sec-0009"><label>2.7</label><title>Immunohistochemistry</title><p>3D HepaRG were fixed with 4% PFA (Polysciences, Warrington, PA; USA; 18814&#8208;10) for 1&#8201;h and washed in 1&#215;&#8201;PBS (Sigma; 11666789001)&#8201;+&#8201;Mg<sup>2+</sup> + Ca<sup>2+</sup>. We permeabilized with 0.5% Triton X&#8208;100 in 1&#215;&#8201;PBS (ROTH, Arlesheim, Switzerland; 3051.3) for 4&#8201;h, washed 3&#8201;&#215;&#8201;5&#8201;min, and blocked with 3% BSA (Sigma; A2153), 0.1% Triton X&#8208;100 in 1&#215;&#8201;PBS overnight at 4&#176;C. After washing again (3&#8201;&#215;&#8201;5&#8201;min), the primary antibody was incubated overnight (4&#176;C), washed (3&#8201;&#215;&#8201;1&#8201;h), and followed by the incubation of the secondary antibody overnight (4&#176;C). Washed 3D HepaRG (2&#8201;&#215;&#8201;1&#8201;h) were counterstained with DAPI (ThermoFisherScientific; 62248, 1:1000) (1&#8201;h, RT) prior to imaging.</p><p>Antibodies and the applied dilutions in 1% BSA, and 0.1% Triton X&#8208;100 are listed in Table&#160;<xref rid="prp270037-tbl-0003" ref-type="table">3</xref>. The images were taken with the Olympus Fluoview FV3000 Confocal Microscope.</p><table-wrap position="float" id="prp270037-tbl-0003" content-type="TABLE" orientation="portrait"><label>TABLE 3</label><caption><p>Antibodies used for immunohistochemistry.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Protein of interest</th><th align="center" valign="bottom" rowspan="1" colspan="1">Primary antibody</th><th align="center" valign="bottom" rowspan="1" colspan="1">Secondary antibody</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Albumin</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Rabbit monoclonal antibody</p>
<p>(Abcam, Cambridge, United Kingdom; ab207327)/1:700</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Goat anti&#8208;rabbit Alexafluor 488</p>
<p>(ThermoFisherScientific; A&#8208;11070)/1:1000</p>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<p>Cytochromes P450 3A4</p>
<p>(CYP3A4)</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Rabbit polyclonal antibody</p>
<p>(Sigma; AB1254)/1:2000</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Goat anti&#8208;rabbit Alexafluor 488</p>
<p>(ThermoFisherScientific; A&#8208;11070)/1:1000</p>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<p>Alcohol dehydrogenase 1</p>
<p>(ADH1A/B/C)</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Goat polyclonal antibody</p>
<p>(ThermoFisherScientific; PAB6725)/1:250</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Rabbit anti&#8208;goat Alexafluor 488</p>
<p>(ThermoFisherScientific; A&#8208;11078)/1:1000</p>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<p>Aldehyde dehydrogenase 2</p>
<p>(ALDH2)</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Mouse monoclonal antibody</p>
<p>(ThermoFisherScientific; MA5&#8208;17029)/1:250</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Rabbit anti&#8208;mouse Alexafluor 546</p>
<p>(ThermoFisherScientific; A&#8208;11060)/1:1000</p>
</td></tr></tbody></table></table-wrap></sec><sec id="prp270037-sec-0010"><label>2.8</label><title>Western Blot</title><p>Samples of S9 and HepaRG cell lysate were run on a 10% SDS&#8208;Page and transferred to a PVDF membrane (Sigma; GE1060004) using the Pierce Powerplot cassette and power station (ThermoFisherScientific). Protein concentration was measured according to the standard Bradford assay protocol using ROTI Nanoquant (ROTH; K880.1). Membranes were blocked for 1.5&#8201;h with 4% milk in TBS&#8208;T (0.1% Tween&#8208;20) and incubated overnight with the primary antibody at 4&#176;C. We washed the membranes with TBS&#8208;T and applied the secondary antibody for 1&#8201;h at RT. All antibodies were diluted in 3% milk in TBS&#8208;T and are listed in Table&#160;<xref rid="prp270037-tbl-0004" ref-type="table">4</xref>. Imaging was performed using the OdysseyCLx imaging system (LI&#8208;COR Biosciences, Bad Homburg, Germany).</p><table-wrap position="float" id="prp270037-tbl-0004" content-type="TABLE" orientation="portrait"><label>TABLE 4</label><caption><p>Antibodies used for Western blot.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Protein of interest</th><th align="center" valign="bottom" rowspan="1" colspan="1">Primary antibody</th><th align="center" valign="bottom" rowspan="1" colspan="1">Secondary antibody</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">
<p>Alcohol dehydrogenase 1</p>
<p>(ADH1A/B/C)</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Goat polyclonal antibody</p>
<p>(ThermoFisherScientific; PAB6725)/1:1000</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Donkey anti&#8208;goat IRDye 800CW</p>
<p>(LI&#8208;COR Biosciences; 925&#8211;32&#8201;214)/1:20000</p>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<p>Aldehyde dehydrogenase 2</p>
<p>(ALDH2)</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Mouse monoclonal antibody</p>
<p>(ThermoFisherScientific; MA5 17&#8201;029)/1:2000</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Donkey anti&#8208;mouse IRDye 800CW</p>
<p>(LI&#8208;COR Biosciences; 926&#8211;32&#8201;212)/1:20000</p>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<p>Glyceraldehyde&#8208;3&#8208;Phosphate Dehydrogenase</p>
<p>(GAPDH)</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Rabbit polyclonal antibody</p>
<p>(ThermoFisherScientific; PA1&#8208;987)/1:1000</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>Donkey anti&#8208;rabbit IRDye 680CW</p>
<p>(LI&#8208;COR Biosciences; 926&#8211;68&#8201;073)/1:20000</p>
</td></tr></tbody></table></table-wrap><p>The relative signal mean intensity was calculated using ImageJ by measuring the area of ADH1A/B/C and ALDH2 bands and normalization to the area of GAPDH.</p></sec><sec id="prp270037-sec-0011"><label>2.9</label><title>S9 Fraction Incubation for the Assessment of Michaelis&#8211;Menten Kinetics</title><p>The incubation mixture (final volume 200&#8201;&#956;L) contained S9 (2&#8201;mg/mL), 100&#8201;mM potassium phosphate buffer (pH&#8201;7.4), 3&#8201;mM MgCl<sub>2</sub>, 1&#8201;mM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=summary&amp;ligandId=2451" ext-link-type="uri">NAD</ext-link>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=summary&amp;ligandId=2451" ext-link-type="uri">
<sup>+</sup>
</ext-link> (Sigma; NAD100&#8208;RO), 1&#8201;mM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3041" ext-link-type="uri">NADPH</ext-link> (Sigma; NADPH&#8208;RO), and the respective substrate concentrations (0.1, 0.5, 0.7, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 7, and 8&#8201;mM). After 5&#8201;min of preincubation, the reaction was initiated with the addition of NAD<sup>+</sup> and NADPH, and the incubations were conducted (45&#8201;min, 300&#8201;rpm, 37&#176;C) on a Thermomixer (Eppendorf, Hamburg, Germany). Incubations without NAD<sup>+</sup> and NADPH were included as a control. Reactions were stopped by the addition of 400&#8201;&#956;L ice&#8208;cold acetonitrile (ACN; Sigma; 439134). After, the samples were vortexed and centrifuged (15&#8201;min, 2500&#8201;&#215;&#8201;<italic toggle="yes">g</italic>, 4&#176;C) and the supernatant stored at &#8722;80&#176;C for further analysis. The reaction rates were linear with respect to time of incubation and the protein concentration (Figure&#160;<xref rid="prp270037-supitem-0001" ref-type="supplementary-material">S2</xref>). Michaelis&#8211;Menten kinetic parameters (<italic toggle="yes">V</italic>
<sub>max</sub> and <italic toggle="yes">K</italic>
<sub>m</sub>) were obtained by nonlinear regression using GraphPad Prism applying the Michaelis&#8211;Menten equation. Finally, the in&#160;vitro intrinsic clearance (CL<sub>int</sub>) was calculated according to the equations described below. For the inhibition studies, only NAD<sup>+</sup> was used as co&#8208;factor and final concentrations of 50&#8201;&#956;M fomepizole [<xref rid="prp270037-bib-0036" ref-type="bibr">36</xref>] and 10&#8201;&#956;M GA11 [<xref rid="prp270037-bib-0037" ref-type="bibr">37</xref>] were applied. We selected a &#946;&#8208;PGME concentration (5&#8201;mM) below expected ADH enzyme saturation, as fomepizole is also described to inhibit CYP2E1 at ADH saturation [<xref rid="prp270037-bib-0038" ref-type="bibr">38</xref>].</p></sec><sec id="prp270037-sec-0012"><label>2.10</label><title>S9 Fraction Incubation for the Evaluation of Solvent Loss and Metabolite Formation</title><p>The incubation mixture (final volume 400&#8201;&#956;L) contained S9 (2&#8201;mg/mL), 100&#8201;mM potassium phosphate buffer (pH&#8201;7.4), 3&#8201;mM MgCl<sub>2</sub>, 1&#8201;mM NAD<sup>+</sup>, 1&#8201;mM NADPH, and the respective substrate concentration (700&#8201;&#956;M &#946;&#8208;PGME). The applied substrate concentration was eightfold below the determined <italic toggle="yes">K</italic>
<sub>m</sub> value. After 5&#8201;min of preincubation, the reaction was initiated with the addition of NAD<sup>+</sup> and NADPH, and the incubations conducted (45&#8201;min, 300&#8201;rpm, 37&#176;C) on a Thermomixer (Eppendorf). Incubations without NAD<sup>+</sup> and NADPH were included as a control. At defined timepoints (1, 12, 23, 34, and 45&#8201;min), the reactions were stopped by the addition of 80&#8201;&#956;L ice&#8208;cold ACN to 40&#8201;&#956;L collected sample. The samples were vortexed, centrifuged (15&#8201;min, 2500&#8201;&#215;&#8201;<italic toggle="yes">g</italic>, 4&#176;C) and stored at &#8722;80&#176;C for further analysis. The reaction rates were linear with respect to time of incubation and the protein concentration (Figure&#160;<xref rid="prp270037-supitem-0001" ref-type="supplementary-material">S2</xref>). The in&#160;vitro CL<sub>int</sub> was calculated according to the equations described below.</p></sec><sec id="prp270037-sec-0013"><label>2.11</label><title>Assessment of Metabolite Formation in the 3D Liver Models</title><p>3D HepaRG and 3D pHH were seeded 7&#8201;days before treatment into the 96&#8208;well ultra&#8208;low attachment Elplasia plate (Corning; 4442) with 219&#8201;000 cells per well to form 79&#8201;&#215;&#8201;3D&#8208;spheroids in micro&#8208;arrays (2772 cells/spheroid) per incubation, following centrifugation (2&#8201;min, 300&#8201;&#215;&#8201;<italic toggle="yes">g</italic>). For treatment, 100&#8201;&#956;L medium from the well was removed and 50&#8201;&#956;L of threefold concentrated &#946;&#8208;PGME solution was added to the remaining 100&#8201;&#956;L in the well for the final solvent concentration (5&#8201;mM). As the experimental set&#8208;up required a high nominal concentration of &#946;&#8208;PGME to meet the limit of quantification for the formed metabolite 2&#8208;MPA, the applied substrate concentration was higher than for the S9 incubations. Still, the concentration was slightly below the previously determined <italic toggle="yes">K</italic>
<sub>m</sub> value. At defined time&#8208;points within the first hour (1&#8242;, 15&#8242;, 30&#8242;, 45&#8242;, only for HepaRG), and at 1&#8201;h, 6&#8201;h, and 24&#8201;h (HepaRG and pHH), the supernatant was collected, and the samples quenched with ice&#8208;cold ACN. The samples were stored at &#8722;80&#176;C for further analysis. All incubations were performed at 37&#176;C, 5% CO<sub>2</sub> in a humidified incubator and the plates covered with a gas permeable seal. Before analysis, samples were centrifuged (20&#8201;min, 2500&#8201;&#215;&#8201;<italic toggle="yes">g</italic>, 4&#176;C). The in&#160;vitro CLint was calculated according to the equations described below. For comparison of metabolite production within the 3D HepaRG and 3D pHHs, the amount of metabolite (pmol) was normalized for each biological repeat to the protein amount present per incubation (&#956;g) (Table&#160;<xref rid="prp270037-supitem-0001" ref-type="supplementary-material">S5</xref>). Determination of the protein content per incubation was performed using the Pierce BCA Protein assay kit (ThermoFisherScientific; 23225) according to the manufacturer's instructions.</p></sec><sec id="prp270037-sec-0014"><label>2.12</label><title>Chemical Analytical Methods</title><p>(1) 2&#8208;MPA concentrations were quantified with a high&#8208;performance liquid chromatography (HPLC) with quadrupole mass spectrometer detection (MS/MS). The samples were injected into the HPLC (1200 Series Gradient HPLC system, Agilent, Santa Clara, CA, USA) equipped with a C18 column (InfinityLab Poroshell 120 CS&#8208;C18 column (2.1&#8201;&#215;&#8201;50&#8201;mm, 2.7&#8201;&#956;m), Agilent; 699775942) connected to the MS/MS in electrospray ionization (ESI) mode (Triple Quadrupole 6475 mass spectrometer, Agilent) with a data acquisition software (MassHunter Quantitative Analysis 10.1, Agilent). (2) &#946;&#8208;PGME concentrations were quantified with gas chromatography (GC) with MS detection. The samples were injected into a GC (Agilent; 6890N) equipped with a capillary column (Rxi&#8208;624Sil, 60&#8201;m, 0.25&#8201;mm ID, 1.4&#8201;&#956;m, Restek, Bad Soden, Germany) coupled to the MS (5973 Network mass selective detector, Agilent) with a data acquisition software (Agilent MassHunter Quantitative Analysis 10.0). (3) Diclofenac, 4&#8208;OH&#8208;diclofenac, 6&#946;&#8208;OH&#8208;testosterone, and testosterone were quantified with a HPLC with MS/MS detection. The samples were injected into the HPLC (Agilent 1260 Infinity II Prime LC system, Agilent) equipped with a C8 column (ZORBAX SB&#8208;C8 column (4.6&#8201;&#215;&#8201;50&#8201;mm, 1.8&#8201;&#956;m), Agilent; 822975906) connected to the MS/MS in ESI mode (Triple Quadrupole 6475, Agilent) with a data acquisition software (MassHunter LCMS Acquisition Console and MassHunter Quantitative Analysis 10.1, Agilent). Additional information on the chemical analytical methods is provided in the <xref rid="prp270037-supitem-0001" ref-type="supplementary-material">Supporting Information</xref>.</p></sec><sec id="prp270037-sec-0015"><label>2.13</label><title>Calculation of the In&#160;Vitro Clearance and Processing to Hepatic Organ Clearance</title><p>The in&#160;vitro CL<sub>int</sub> for the solvent loss and the metabolite formation was determined according to Equation&#160;(<xref rid="prp270037-disp-0001" ref-type="disp-formula">1</xref>) for the S9 incubations and Equation&#160;(<xref rid="prp270037-disp-0002" ref-type="disp-formula">2</xref>) for the cell incubations [<xref rid="prp270037-bib-0039" ref-type="bibr">39</xref>]:<disp-formula id="prp270037-disp-0001"><label>(1)</label><mml:math id="jats-math-1" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>CL</mml:mi><mml:mrow><mml:mi>int</mml:mi><mml:mo>,</mml:mo><mml:mtext>in vitro</mml:mtext></mml:mrow></mml:msub><mml:mspace width="0.25em"/><mml:mfenced close="]" open="["><mml:mrow><mml:mi>&#956;L</mml:mi><mml:mo>/</mml:mo><mml:mi>min</mml:mi><mml:mo>/</mml:mo><mml:mi>mg</mml:mi></mml:mrow></mml:mfenced><mml:mo linebreak="goodbreak">=</mml:mo><mml:mfrac><mml:mrow><mml:mo>&#177;</mml:mo><mml:mi>k</mml:mi><mml:mspace width="0.25em"/><mml:mfenced close="]" open="["><mml:mrow><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:mi>min</mml:mi></mml:mrow></mml:mfenced><mml:mo>&#215;</mml:mo><mml:mtext>volume</mml:mtext><mml:mspace width="0.25em"/><mml:mfenced close="]" open="["><mml:mi>&#956;L</mml:mi></mml:mfenced><mml:mspace width="0.25em"/></mml:mrow><mml:mrow><mml:mi mathvariant="normal">S</mml:mi><mml:mn>9</mml:mn><mml:mspace width="0.25em"/><mml:mtext>protein</mml:mtext><mml:mspace width="0.25em"/><mml:mfenced close="]" open="["><mml:mi>mg</mml:mi></mml:mfenced></mml:mrow></mml:mfrac></mml:mrow></mml:mrow></mml:math></disp-formula>
<disp-formula id="prp270037-disp-0002"><label>(2)</label><mml:math id="jats-math-2" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>CL</mml:mi><mml:mrow><mml:mi>int</mml:mi><mml:mo>,</mml:mo><mml:mtext>in vitro</mml:mtext></mml:mrow></mml:msub><mml:mspace width="0.25em"/><mml:mfenced close="]" open="["><mml:mrow><mml:mi>&#956;L</mml:mi><mml:mo>/</mml:mo><mml:mi>min</mml:mi><mml:mo>/</mml:mo><mml:mtext>Million cells</mml:mtext></mml:mrow></mml:mfenced><mml:mo linebreak="goodbreak">=</mml:mo><mml:mfrac><mml:mrow><mml:mo>&#177;</mml:mo><mml:mi>k</mml:mi><mml:mspace width="0.25em"/><mml:mfenced close="]" open="["><mml:mrow><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:mi>min</mml:mi></mml:mrow></mml:mfenced><mml:mo>&#215;</mml:mo><mml:mtext>volume</mml:mtext><mml:mspace width="0.25em"/><mml:mfenced close="]" open="["><mml:mi>&#956;L</mml:mi></mml:mfenced></mml:mrow><mml:mrow><mml:mtext>cell number</mml:mtext><mml:mspace width="0.25em"/><mml:mfenced close="]" open="["><mml:mtext>Million cells</mml:mtext></mml:mfenced></mml:mrow></mml:mfrac></mml:mrow></mml:mrow></mml:math></disp-formula>where the elimination constant (&#8722;<italic toggle="yes">k</italic>) and the formation constant (<italic toggle="yes">k</italic>) were derived from the slope of the linear regression from the ln&#8208;transformed % of solvent remaining versus the incubation time and the ln&#8208;transformed metabolite concentration versus the incubation time, respectively.</p><p>The in&#160;vitro CL<sub>int</sub> for the S9 incubations was calculated as following:<disp-formula id="prp270037-disp-0003"><label>(3)</label><mml:math id="jats-math-3" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>CL</mml:mi><mml:mrow><mml:mi>int</mml:mi><mml:mo>,</mml:mo><mml:mtext>in vitro</mml:mtext></mml:mrow></mml:msub><mml:mspace width="0.25em"/><mml:mfenced close="]" open="["><mml:mrow><mml:mi>&#956;L</mml:mi><mml:mo>/</mml:mo><mml:mi>min</mml:mi><mml:mo>/</mml:mo><mml:mi>mg</mml:mi></mml:mrow></mml:mfenced><mml:mo linebreak="goodbreak">=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>V</mml:mi><mml:mi mathvariant="italic">max</mml:mi></mml:msub><mml:mspace width="0.25em"/><mml:mfenced close="]" open="["><mml:mrow><mml:mtext>nmol</mml:mtext><mml:mo>/</mml:mo><mml:mi>min</mml:mi><mml:mo>/</mml:mo><mml:mi>mg</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mi>m</mml:mi></mml:msub><mml:mfenced close="]" open="["><mml:mi>&#956;M</mml:mi></mml:mfenced></mml:mrow></mml:mfrac></mml:mrow></mml:mrow></mml:math></disp-formula>where <italic toggle="yes">V</italic>
<sub>max</sub> is the maximum velocity and <italic toggle="yes">K</italic>
<sub>m</sub> the Michaelis&#8211;Menten constant, both predicted from GraphPad Prism.</p><p>The in&#160;vivo hepatic intrinsic clearance (CL<sub>int, in&#160;vivo</sub>) was calculated using physiological scaling factors for hepatocellularity [<xref rid="prp270037-bib-0040" ref-type="bibr">40</xref>, <xref rid="prp270037-bib-0041" ref-type="bibr">41</xref>], for the protein [<xref rid="prp270037-bib-0042" ref-type="bibr">42</xref>], and liver weight [<xref rid="prp270037-bib-0043" ref-type="bibr">43</xref>] according to Equations&#160;(<xref rid="prp270037-disp-0004" ref-type="disp-formula">4</xref> and <xref rid="prp270037-disp-0005" ref-type="disp-formula">5</xref>):<disp-formula id="prp270037-disp-0004"><label>(4)</label><mml:math id="jats-math-4" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mtable><mml:mtr><mml:mtd columnalign="left"><mml:mrow><mml:msub><mml:mi>CL</mml:mi><mml:mrow><mml:mi>int</mml:mi><mml:mo>,</mml:mo><mml:mtext>in vivo</mml:mtext></mml:mrow></mml:msub><mml:mspace width="0.25em"/><mml:mfenced close="]" open="["><mml:mrow><mml:mi>mL</mml:mi><mml:mo>/</mml:mo><mml:mi>min</mml:mi><mml:mo>/</mml:mo><mml:mi>kg</mml:mi></mml:mrow></mml:mfenced><mml:mo linebreak="goodbreak">=</mml:mo><mml:msub><mml:mi>CL</mml:mi><mml:mrow><mml:mi>int</mml:mi><mml:mo>,</mml:mo><mml:mtext>in vitro</mml:mtext></mml:mrow></mml:msub><mml:mo linebreak="goodbreak">&#215;</mml:mo><mml:mn>121</mml:mn><mml:mfrac><mml:mrow><mml:mi>mg</mml:mi><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">S</mml:mi><mml:mn>9</mml:mn><mml:mspace width="0.25em"/><mml:mtext>protein</mml:mtext></mml:mrow><mml:mrow><mml:mi>g</mml:mi><mml:mspace width="0.25em"/><mml:mtext>liver</mml:mtext></mml:mrow></mml:mfrac></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="left"><mml:mspace width="13em"/><mml:mrow><mml:mo linebreak="goodbreak">&#215;</mml:mo><mml:mn>25.7</mml:mn><mml:mspace width="0.25em"/><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">g</mml:mi><mml:mspace width="0.25em"/><mml:mtext>liver</mml:mtext></mml:mrow><mml:mrow><mml:mi>kg</mml:mi><mml:mspace width="0.25em"/><mml:mtext>bodyweight</mml:mtext></mml:mrow></mml:mfrac></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mrow></mml:math></disp-formula>
<disp-formula id="prp270037-disp-0005"><label>(5)</label><mml:math id="jats-math-5" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mtable><mml:mtr><mml:mtd columnalign="left"><mml:mrow><mml:msub><mml:mi>CL</mml:mi><mml:mrow><mml:mi>int</mml:mi><mml:mo>,</mml:mo><mml:mtext>in vivo</mml:mtext></mml:mrow></mml:msub><mml:mspace width="0.25em"/><mml:mfenced close="]" open="["><mml:mrow><mml:mi>mL</mml:mi><mml:mo>/</mml:mo><mml:mi>min</mml:mi><mml:mo>/</mml:mo><mml:mi>kg</mml:mi></mml:mrow></mml:mfenced><mml:mo linebreak="goodbreak">=</mml:mo><mml:msub><mml:mi>CL</mml:mi><mml:mrow><mml:mi>int</mml:mi><mml:mo>,</mml:mo><mml:mtext>in vitro</mml:mtext></mml:mrow></mml:msub><mml:mo linebreak="goodbreak">&#215;</mml:mo><mml:mn>117.5</mml:mn><mml:mspace width="0.25em"/><mml:mfrac><mml:mrow><mml:msup><mml:mn>10</mml:mn><mml:mn>6</mml:mn></mml:msup><mml:mspace width="0.25em"/><mml:mtext>cells</mml:mtext></mml:mrow><mml:mrow><mml:mi>g</mml:mi><mml:mspace width="0.25em"/><mml:mtext>liver</mml:mtext></mml:mrow></mml:mfrac></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="left"><mml:mspace width="13em"/><mml:mrow><mml:mo linebreak="goodbreak">&#215;</mml:mo><mml:mn>25.7</mml:mn><mml:mspace width="0.25em"/><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">g</mml:mi><mml:mspace width="0.25em"/><mml:mtext>liver</mml:mtext></mml:mrow><mml:mrow><mml:mi>kg</mml:mi><mml:mspace width="0.25em"/><mml:mtext>bodyweight</mml:mtext></mml:mrow></mml:mfrac></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mrow></mml:math></disp-formula>
</p><p>The hepatic organ clearance (CL<sub>h</sub>) was predicted using the well&#8208;stirred liver model according to Equation&#160;(<xref rid="prp270037-disp-0006" ref-type="disp-formula">6</xref>) [<xref rid="prp270037-bib-0044" ref-type="bibr">44</xref>]:<disp-formula id="prp270037-disp-0006"><label>(6)</label><mml:math id="jats-math-6" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>CL</mml:mi><mml:mi mathvariant="normal">h</mml:mi></mml:msub><mml:mspace width="0.25em"/><mml:mfenced close="]" open="["><mml:mrow><mml:mi>mL</mml:mi><mml:mo>/</mml:mo><mml:mi>min</mml:mi><mml:mo>/</mml:mo><mml:mi>kg</mml:mi></mml:mrow></mml:mfenced><mml:mo linebreak="goodbreak">=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>Q</mml:mi><mml:mi>H</mml:mi></mml:msub><mml:mspace width="0.25em"/><mml:mfenced close="]" open="["><mml:mrow><mml:mi>mL</mml:mi><mml:mo>/</mml:mo><mml:mi>min</mml:mi><mml:mo>/</mml:mo><mml:mi>kg</mml:mi></mml:mrow></mml:mfenced><mml:mo>&#215;</mml:mo><mml:msub><mml:mi>CL</mml:mi><mml:mrow><mml:mi>int</mml:mi><mml:mo>,</mml:mo><mml:mtext>in vivo</mml:mtext></mml:mrow></mml:msub><mml:mspace width="0.25em"/><mml:mfenced close="]" open="["><mml:mrow><mml:mi>&#956;L</mml:mi><mml:mo>/</mml:mo><mml:mi>min</mml:mi><mml:mo>/</mml:mo><mml:mi>kg</mml:mi></mml:mrow></mml:mfenced><mml:mo>&#215;</mml:mo><mml:mfrac><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi>u</mml:mi><mml:mo>,</mml:mo><mml:mi>b</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi>u</mml:mi><mml:mo>,</mml:mo><mml:mi>inc</mml:mi></mml:mrow></mml:msub></mml:mfrac></mml:mrow><mml:mrow><mml:msub><mml:mi>Q</mml:mi><mml:mi>H</mml:mi></mml:msub><mml:mspace width="0.25em"/><mml:mfenced close="]" open="["><mml:mrow><mml:mi>mL</mml:mi><mml:mo>/</mml:mo><mml:mi>min</mml:mi><mml:mo>/</mml:mo><mml:mi>kg</mml:mi></mml:mrow></mml:mfenced><mml:mo>+</mml:mo><mml:msub><mml:mi>CL</mml:mi><mml:mrow><mml:mi>int</mml:mi><mml:mo>,</mml:mo><mml:mtext>in vivo</mml:mtext></mml:mrow></mml:msub><mml:mspace width="0.25em"/><mml:mfenced close="]" open="["><mml:mrow><mml:mi>&#956;L</mml:mi><mml:mo>/</mml:mo><mml:mi>min</mml:mi><mml:mo>/</mml:mo><mml:mi>kg</mml:mi></mml:mrow></mml:mfenced><mml:mo>&#215;</mml:mo><mml:mfrac><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi>u</mml:mi><mml:mo>,</mml:mo><mml:mi>b</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi>u</mml:mi><mml:mo>,</mml:mo><mml:mi>inc</mml:mi></mml:mrow></mml:msub></mml:mfrac></mml:mrow></mml:mfrac></mml:mrow></mml:mrow></mml:math></disp-formula>where <italic toggle="yes">Q</italic>
<sub>H</sub> is the hepatic blood flow (20.7&#8201;mL/min/kg) [<xref rid="prp270037-bib-0045" ref-type="bibr">45</xref>]. Incubational binding for the test system (<italic toggle="yes">f</italic>
<sub>u</sub>,<sub>inc</sub>) was predicted using the IQVIVE platform (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.qivivetools.wur.nl/" ext-link-type="uri">qivivetools.wur.nl</ext-link>), taking into account the physicochemical properties of the compounds. For the S9 incubations, the S9 protein concentration (2&#8201;mg/mL) was considered and the Hallifax and Houston method applied [<xref rid="prp270037-bib-0046" ref-type="bibr">46</xref>]. For the 3D HepaRG experiments, the cell concentration (1.46&#8201;&#215;&#8201;10<sup>6</sup> cells/mL) was considered and the Kilford method applied [<xref rid="prp270037-bib-0047" ref-type="bibr">47</xref>]. A measured plasma binding value (<italic toggle="yes">f</italic>
<sub>u</sub>,<sub>b</sub>) for PGME was used [<xref rid="prp270037-bib-0032" ref-type="bibr">32</xref>].</p></sec><sec id="prp270037-sec-0016"><label>2.14</label><title>&#946;&#8208;PGME Toxicokinetic Model Development and Calibration</title><p>The compartmental toxicokinetic (TK) model developed for &#945;&#8208;PGME from Reale et&#160;al. [<xref rid="prp270037-bib-0032" ref-type="bibr">32</xref>], included the excretion of parent compound and the metabolism of &#945;&#8208;PGME to propylene glycol (PG) and conjugation products. This TK model was adapted for the present study to incorporate metabolism of &#946;&#8208;PGME to 2&#8208;MPA, with equal physiological parameters used for both isomers. Due to the low excretion of conjugated &#946;&#8208;PGME (3%) and the minimal amounts (below the limit of quantification) of the parent compound (&#946;&#8208;PGME) [<xref rid="prp270037-bib-0048" ref-type="bibr">48</xref>], these metabolic routes were excluded and only the formation of PG and the main metabolite 2&#8208;MPA were included. Table&#160;<xref rid="prp270037-tbl-0005" ref-type="table">5</xref> summarizes the 2&#8208;MPA specific parameters derived from literature and computer tools, and the generated in&#160;vitro predicted hepatic organ clearance (CL<sub>h</sub>). The CL<sub>h</sub> value obtained from solvent loss measurement was used under the assumption that the clearance of &#946;&#8208;PGME loss was expected to be equal to the clearance of 2&#8208;MPA formation, with 2&#8208;MPA being the main metabolite. The kinetic constant for the metabolism of &#946;&#8208;PGME to PG was not available from literature, therefore, we used a literature kinetic constant of EGME to ethylene glycol (EG). As &#946;&#8208;PGME is structurally and chemically similar to EGME, we assumed that their metabolism to PG and EG, respectively, were comparable.</p><table-wrap position="float" id="prp270037-tbl-0005" content-type="TABLE" orientation="portrait"><label>TABLE 5</label><caption><p>Parameters used in the &#946;&#8208;PGME toxicokinetic model, in addition to the ones already reported in Reale et&#160;al. [<xref rid="prp270037-bib-0032" ref-type="bibr">32</xref>].</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Parameters</th><th align="center" valign="bottom" rowspan="1" colspan="1">Symbol</th><th align="center" valign="bottom" rowspan="1" colspan="1">Units</th><th align="center" valign="bottom" rowspan="1" colspan="1">Values</th><th align="center" valign="bottom" rowspan="1" colspan="1">References</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="5" valign="top" rowspan="1">
<bold>2&#8208;MPA&#8208;specific parameters</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Molecular weight</td><td align="center" valign="top" rowspan="1" colspan="1">MW<sub>MPA</sub>
</td><td align="center" valign="top" rowspan="1" colspan="1">[g/mol]</td><td align="center" valign="top" rowspan="1" colspan="1">104.105</td><td align="center" valign="top" rowspan="1" colspan="1">Comptox Chemicals Dashboard (CCD)<xref rid="prp270037-note-0007" ref-type="table-fn">
<sup>a</sup>
</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Blood&#8208;air partition coefficient</td><td align="center" valign="top" rowspan="1" colspan="1">Pba<sub>MPA</sub>
</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">200&#8201;357</td><td align="center" valign="top" rowspan="1" colspan="1">Kramer et&#160;al. [<xref rid="prp270037-bib-0049" ref-type="bibr">49</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Central&#8208;air partition coefficient</td><td align="center" valign="top" rowspan="1" colspan="1">Pca<sub>MPA</sub>
</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">243&#8201;185</td><td align="center" valign="top" rowspan="1" colspan="1">Tibaldi et&#160;al. [<xref rid="prp270037-bib-0050" ref-type="bibr">50</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Brain&#8211;blood partition coefficient</td><td align="center" valign="top" rowspan="1" colspan="1">PBR<sub>MPA</sub>
</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">0.71</td><td align="center" valign="top" rowspan="1" colspan="1">Rodgers &amp; Rowland [<xref rid="prp270037-bib-0051" ref-type="bibr">51</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Unbound fraction in plasma</td><td align="center" valign="top" rowspan="1" colspan="1">Fu,p<sub>MPA</sub>
</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">0.46</td><td align="center" valign="top" rowspan="1" colspan="1">Sipes et&#160;al. [<xref rid="prp270037-bib-0052" ref-type="bibr">52</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Blood&#8208;to&#8208;plasma ratio</td><td align="center" valign="top" rowspan="1" colspan="1">Rb<sub>MPA</sub>
</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">0.98</td><td align="center" valign="top" rowspan="1" colspan="1">ADMET predictor Software</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Urinary excretion rate of 2&#8208;MPA</td><td align="center" valign="top" rowspan="1" colspan="1">K<sub>MPA</sub>
</td><td align="center" valign="top" rowspan="1" colspan="1">[1/h]</td><td align="center" valign="top" rowspan="1" colspan="1">0.09</td><td align="center" valign="top" rowspan="1" colspan="1">Devanth&#233;ry et&#160;al. [<xref rid="prp270037-bib-0020" ref-type="bibr">20</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Unbound fraction in brain</td><td align="center" valign="top" rowspan="1" colspan="1">Fu,B<sub>MPA</sub>
</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">0.53</td><td align="center" valign="top" rowspan="1" colspan="1">Watanabe et&#160;al. [<xref rid="prp270037-bib-0053" ref-type="bibr">53</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Permeability coefficient (BBB)</td><td align="center" valign="top" rowspan="1" colspan="1">Pe<sub>MPA</sub>
</td><td align="center" valign="top" rowspan="1" colspan="1">[cm/min]</td><td align="center" valign="top" rowspan="1" colspan="1">0.006</td><td align="center" valign="top" rowspan="1" colspan="1">Kerns et&#160;al. [<xref rid="prp270037-bib-0054" ref-type="bibr">54</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Kinetic constant EGME &#8594; EG (ethylene glycol)</td><td align="center" valign="top" rowspan="1" colspan="1">CLmet<sub>PG</sub>
</td><td align="center" valign="top" rowspan="1" colspan="1">[L/h/Kg]</td><td align="center" valign="top" rowspan="1" colspan="1">0.3</td><td align="center" valign="top" rowspan="1" colspan="1">Gargas et&#160;al. [<xref rid="prp270037-bib-0055" ref-type="bibr">55</xref>]</td></tr></tbody></table><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><tbody valign="top"><tr><td align="left" colspan="5" valign="top" rowspan="1">
<bold>In vitro predicted hepatic organ clearance (CL</bold>
<sub>
<bold>h</bold>
</sub>
<bold>)</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">S9, metabolite formation, calculated (<italic toggle="yes">V</italic>
<sub>max</sub>/<italic toggle="yes">K</italic>
<sub>m</sub>)</td><td align="center" valign="top" rowspan="1" colspan="1">CLmet<sub>MPA</sub>
</td><td align="center" valign="top" rowspan="1" colspan="1">[L/h/Kg]</td><td align="center" valign="top" rowspan="1" colspan="1">0.0216</td><td align="center" valign="top" rowspan="1" colspan="1">Predicted<xref rid="prp270037-note-0008" ref-type="table-fn">
<sup>b</sup>
</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">S9, solvent loss, measured</td><td align="center" valign="top" rowspan="1" colspan="1">CLmet<sub>MPA</sub>
</td><td align="center" valign="top" rowspan="1" colspan="1">[L/h/Kg]</td><td align="center" valign="top" rowspan="1" colspan="1">0.3000</td><td align="center" valign="top" rowspan="1" colspan="1">Predicted<xref rid="prp270037-note-0008" ref-type="table-fn">
<sup>b</sup>
</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">S9, metabolite formation, measured</td><td align="center" valign="top" rowspan="1" colspan="1">CLmet<sub>MPA</sub>
</td><td align="center" valign="top" rowspan="1" colspan="1">[L/h/Kg]</td><td align="center" valign="top" rowspan="1" colspan="1">0.9840</td><td align="center" valign="top" rowspan="1" colspan="1">Predicted<xref rid="prp270037-note-0008" ref-type="table-fn">
<sup>b</sup>
</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">3D HepaRG, metabolite formation, measured</td><td align="center" valign="top" rowspan="1" colspan="1">CLmet<sub>MPA</sub>
</td><td align="center" valign="top" rowspan="1" colspan="1">[L/h/Kg]</td><td align="center" valign="top" rowspan="1" colspan="1">0.5442</td><td align="center" valign="top" rowspan="1" colspan="1">Predicted<xref rid="prp270037-note-0008" ref-type="table-fn">
<sup>b</sup>
</xref>
</td></tr></tbody></table><table-wrap-foot id="prp270037-ntgp-0003"><fn id="prp270037-note-0007"><label>
<sup>a</sup>
</label><p>CompTox Chemicals Dashboard (epa.gov).</p></fn><fn id="prp270037-note-0008"><label>
<sup>b</sup>
</label><p>Predicted values based on the measured in&#160;vitro CL<sub>int</sub> applying in&#160;vitro&#8208;in vivo extrapolation as described in the methods section.</p></fn></table-wrap-foot></table-wrap><p>The adapted TK model included a central compartment representing the body fluids, a brain compartment to compute &#946;&#8208;PGME brain concentrations, and a blood&#8211;brain barrier to assess the &#946;&#8208;PGME rate for entering the brain (Figure&#160;<xref rid="prp270037-fig-0002" ref-type="fig">2</xref>). We assumed that &#946;&#8208;PGME is mainly metabolized in the liver (disregarding other tissues that may metabolize &#946;&#8208;PGME) and that the isomer distributions are equal in the central compartment; 2&#8208;MPA distributes in the same central compartment as the parent compound; and lastly, the central and brain TK compartment diffusions for &#946;&#8208;PGME and 2&#8208;MPA are the same as for the &#945;&#8208;isomer. Finally, the model was run with a fraction of 0.3% &#946;&#8208;PGME in Berkeley Madonna software (version 8.3.18, University of California, USA) based on reported literature data&#160;[<xref rid="prp270037-bib-0020" ref-type="bibr">20</xref>].</p><fig position="float" fig-type="FIGURE" id="prp270037-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>Developed &#946;&#8208;PGME toxicokinetic model in the present study. The simulation model for &#946;&#8208;isomer propylene glycol methyl ether (&#946;&#8208;PGME) and methoxy propionic acid (2&#8208;MPA) was based on the model of Reale et&#160;al. [<xref rid="prp270037-bib-0032" ref-type="bibr">32</xref>]. Arrows represent flow rates, expressed as mg/h, and rectangles represent model compartments. ADH, alcohol dehydrogenase; ALDH, aldehyde dehydrogenase; CLmetMPA, clearance of the formation of 2&#8208;MPA; CLmetPG, clearance of the formation of propylene glycol; kMPA, urinary excretion rate of 2&#8208;MPA.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="PRP2-12-e70037-g002.jpg"/></fig></sec><sec id="prp270037-sec-0017"><label>2.15</label><title>TK Model Evaluation</title><p>We used published data&#160;[<xref rid="prp270037-bib-0020" ref-type="bibr">20</xref>] from a human study (exposure to 99.7% &#945;&#8208;PGME, 0.3% &#946;&#8208;PGME) to evaluate the developed &#946;&#8208;isomer TK model. Key information on the pharmacokinetic dataset used for model evaluation is summarized in Table&#160;<xref rid="prp270037-tbl-0006" ref-type="table">6</xref>. We could not validate the TK model due to the lack of experimental data; however, we used three criteria to evaluate the TK model: (1) Model performance according to the WHO criteria stating that a model is acceptable if its predicted values match with the experimental kinetic profiles within a twofold difference [<xref rid="prp270037-bib-0056" ref-type="bibr">56</xref>]; (2) goodness&#8208;of&#8208;fit assessed with linear regressions with an acceptable fit defined as a coefficient of determination (<italic toggle="yes">R</italic>
<sup>2</sup>) equal or higher than 0.75 [<xref rid="prp270037-bib-0057" ref-type="bibr">57</xref>]; and (3) mean absolute percentage error (MAPE) was acceptable if MAPE &lt;&#8201;50%, good if MAPE &lt;&#8201;20%, and &gt;&#8201;10%, and excellent if MAPE &lt;&#8201;10% [<xref rid="prp270037-bib-0058" ref-type="bibr">58</xref>]. Microsoft Excel 2016 was used to calculate linear regression and MAPE.</p><table-wrap position="float" id="prp270037-tbl-0006" content-type="TABLE" orientation="portrait"><label>TABLE 6</label><caption><p>Pharmacokinetic study on PGME in humans used for &#946;&#8208;TK model development and evaluation.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Exposure concentration</th><th align="center" valign="bottom" rowspan="1" colspan="1">Duration</th><th align="center" valign="bottom" rowspan="1" colspan="1">Measured concentration</th><th align="center" valign="bottom" rowspan="1" colspan="1">Matrix</th><th align="center" valign="bottom" rowspan="1" colspan="1">Number of time points</th><th align="center" valign="bottom" rowspan="1" colspan="1">References</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">95&#8201;ppm</td><td align="center" valign="top" rowspan="1" colspan="1">6&#8201;h with 30&#8242; break after 3&#8201;h</td><td align="center" valign="top" rowspan="1" colspan="1">C<sub>urMPA</sub>
</td><td align="center" valign="top" rowspan="1" colspan="1">Urine</td><td align="center" valign="top" rowspan="1" colspan="1">9</td><td align="center" valign="top" rowspan="1" colspan="1">Devanth&#233;ry et&#160;al. [<xref rid="prp270037-bib-0020" ref-type="bibr">20</xref>]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">50&#8201;ppm</td><td align="center" valign="top" rowspan="1" colspan="1">6&#8201;h with 30&#8242; break after 3&#8201;h</td><td align="center" valign="top" rowspan="1" colspan="1">C<sub>urMPA</sub>
</td><td align="center" valign="top" rowspan="1" colspan="1">Urine</td><td align="center" valign="top" rowspan="1" colspan="1">7</td><td align="center" valign="top" rowspan="1" colspan="1">Devanth&#233;ry et&#160;al. [<xref rid="prp270037-bib-0020" ref-type="bibr">20</xref>]</td></tr></tbody></table><table-wrap-foot id="prp270037-ntgp-0004"><fn id="prp270037-note-0009"><p>
<italic toggle="yes">Note:</italic> C<sub>urMPA</sub>: 2&#8208;MPA concentration in urine. PGME consisted of 99.7% &#945;&#8208;PGME and 0.3% &#946;&#8208;PGME.</p></fn></table-wrap-foot></table-wrap></sec><sec id="prp270037-sec-0018"><label>2.16</label><title>Sensitivity Analysis and Uncertainty Analysis</title><p>A sensitivity analysis was performed to identify model parameters (<italic toggle="yes">p</italic>) that had the greatest influence on the model output, for example the 48&#8201;h area under the curves (AUC) of 2&#8208;MPA in urine and blood. MS Excel 2016 was used to perform sensitivity analysis. Normalized sensitivity coefficients (NSC) of the TK model output to any selected parameter of the model were calculated as follows:<disp-formula id="prp270037-disp-0007"><label>(7)</label><mml:math id="jats-math-7" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>NSC</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mo>(</mml:mo><mml:mo>&#8710;</mml:mo><mml:mtext>output</mml:mtext><mml:mo>/</mml:mo><mml:mspace width="0.25em"/><mml:mtext>output)</mml:mtext></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mo>&#8710;</mml:mo><mml:mi>p</mml:mi><mml:mspace width="0.25em"/><mml:mo>/</mml:mo><mml:mi>p</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mfrac></mml:mrow></mml:mrow></mml:math></disp-formula>where <italic toggle="yes">&#916;output</italic> and <italic toggle="yes">&#916;p</italic> are the differences between output and <italic toggle="yes">p</italic> values, respectively, before and after increasing <italic toggle="yes">p</italic> by 1%. Parameters were categorized depending on the influence they had on the output parameters following these criteria: low impact if |NSC|&#8201;&lt;&#8201;0.2, medium impact if 0.2&#8201;&#8804;&#8201;|NSC|&#8201;&lt;&#8201;0.5, high impact if |NSC|&#8201;&#8805;&#8201;0.5 [<xref rid="prp270037-bib-0056" ref-type="bibr">56</xref>]. The uncertainty of parameters with high impact on model output (|NSC|&#8201;&#8805;&#8201;0.5) was qualitatively assessed depending on the parameter source following these criteria [<xref rid="prp270037-bib-0058" ref-type="bibr">58</xref>, <xref rid="prp270037-bib-0059" ref-type="bibr">59</xref>]: low uncertainty, if a parameter value was obtained from human data parameters or verified through successful use in physiologically based pharmacokinetic models; medium uncertainty, if a parameter value was obtained from a different species with a high probability that scaling holds across species; high uncertainty, if a value was not available for a parameter and assumptions had to be made.</p></sec><sec id="prp270037-sec-0019"><label>2.17</label><title>Statistical Analysis</title><p>Data representation and statistical analysis were performed using Microsoft Excel (Microsoft, Redmond, WA) and GraphPad Prism (GraphPad Software, San Diego, CA, USA; Version 10.0.2). Data are expressed as mean values &#177; SD. For the statistical analysis of two groups, we used the Student's <italic toggle="yes">t</italic>&#8208;test. One&#8208;way ANOVA was used for statistical analysis of multiple concentrations of the same treatment. For multiple concentrations and different treatments, we used two&#8208;way ANOVA. <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05 was considered as significant (*<italic toggle="yes">p</italic>&#8201;&#8804;&#8201;0.05; **<italic toggle="yes">p</italic>&#8201;&#8804;&#8201;0.01; ***<italic toggle="yes">p</italic>&#8201;&#8804;&#8201;0.001, ****<italic toggle="yes">p</italic>&#8201;&#8804;&#8201;0.0001).</p></sec><sec id="prp270037-sec-0020"><label>2.18</label><title>Nomenclature of Targets and Ligands</title><p>Key protein targets and ligands in this article are hyperlinked to corresponding entries in <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.guidetopharmacology.org" ext-link-type="uri">http://www.guidetopharmacology.org</ext-link>, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY [<xref rid="prp270037-bib-0060" ref-type="bibr">60</xref>, <xref rid="prp270037-bib-0061" ref-type="bibr">61</xref>, <xref rid="prp270037-bib-0062" ref-type="bibr">62</xref>], and are permanently archived in the Concise Guide to PHARMACOLOGY 2019/20 [<xref rid="prp270037-bib-0063" ref-type="bibr">63</xref>].</p></sec></sec><sec sec-type="results" id="prp270037-sec-0021"><label>3</label><title>Results</title><sec id="prp270037-sec-0022"><label>3.1</label><title>The 3D HepaRG Model Displays Key Hepatocellular and Metabolic Functions</title><p>Immunostainings (Figure&#160;<xref rid="prp270037-fig-0003" ref-type="fig">3A</xref>) showed the presence of albumin in 3D HepaRG cultured over 7&#8201;days. Albumin was observed intracellularly in untreated HepaRG cells (CTR) and released into the medium (78.4&#8201;&#177;&#8201;22.9&#8201;ng/mL) (Figure&#160;<xref rid="prp270037-fig-0003" ref-type="fig">3B</xref>). The albumin secretion was significantly reduced (1.78&#8201;&#177;&#8201;0.68&#8201;ng/mL) by treating the cells with the hepatotoxicant acetaminophen (APAP), proving the ability of the cells to respond to hepatotoxic effects. The 3D cultures were able to metabolize two known reference drugs, namely testosterone and diclofenac, which are substrates for CYP3A and CYP2C9, respectively. As illustrated in Figure&#160;<xref rid="prp270037-fig-0003" ref-type="fig">3C</xref>, the HepaRG successfully converted the test compounds to their hydroxylated metabolites over 48&#8201;h, indicating active phase I metabolism. We observed higher metabolite formation for HepaRG cells preincubated with 20&#8201;&#956;M rifampicin, mostly for testosterone metabolism. The in&#160;vitro intrinsic hepatic clearance (CL<sub>int</sub>) of testosterone was higher than for diclofenac. Concordantly, immunostainings of 3D HepaRG showed significant induction of <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1337" ext-link-type="uri">CYP3A4</ext-link> by rifampicin: As depicted in Figure&#160;<xref rid="prp270037-fig-0003" ref-type="fig">3D/E</xref>, the integrated density/area DAPI for the induced cells was higher than for the uninduced cells.</p><fig position="float" fig-type="FIGURE" id="prp270037-fig-0003" orientation="portrait"><label>FIGURE 3</label><caption><p>Proof for hepatic functionality of 3D HepaRG. (A) 3D HepaRG were stained for albumin (green) and counterstained with DAPI (blue). Scale bar representing 100&#8201;&#956;m. (B) 3D HepaRG were exposed to 16&#8201;mM APAP (acetaminophen, positive control) for 48&#8201;h. Albumin was measured using the Bethyl Laboratories ELISA kit. Data are expressed as albumin concentration (ng/mL) per 3D HepaRG spheroid. <italic toggle="yes">N</italic>&#8201;=&#8201;2 independent biological experiments with six to eight technical replicates. Bar graphs represent single measurements with mean &#177; SD; statistical analysis based on an unpaired <italic toggle="yes">t</italic>&#8208;test: ****<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.0001. (C) Uninduced and induced (20&#8201;&#956;M rifampicin) 3D HepaRG were exposed to 50&#8201;&#956;M testosterone and 100&#8201;&#956;M diclofenac for over 48&#8201;h. Conversion of testosterone and diclofenac into 6&#946;&#8208;hydroxy testosterone and 4&#8208;hydroxy diclofenac, respectively, was determined at 6, 24, and 48&#8201;h by HPLC&#8208;MS/MS. Data are expressed as concentrations (mM) calculated using calibration curves. Area under the curve in arbitrary units (AUC) was used for calculating 6&#946;&#8208;hydroxy testosterone and 4&#8208;hydroxy diclofenac; <italic toggle="yes">N</italic>&#8201;=&#8201;1 biological experiment with two technical replicates. Statistical analysis based on an unpaired <italic toggle="yes">t</italic>&#8208;test: ***<italic toggle="yes">p</italic>&#8201;&#8804;&#8201;0.001, **<italic toggle="yes">p</italic>&#8201;&#8804;&#8201;0.01, *<italic toggle="yes">p</italic>&#8201;&#8804;&#8201;0.05. (D) Uninduced and induced (20&#8201;&#956;M rifampicin) 3D HepaRG were stained for CYP3A4 (green) and counterstained with DAPI (blue). Scale bar representing 100&#8201;&#956;m. (E) Immunostaining images (<italic toggle="yes">n</italic>&#8201;=&#8201;2&#8211;4) were quantified for CYP3A4 using ImageJ. Bar graphs represent mean &#177; SD; statistical analysis based on an unpaired <italic toggle="yes">t</italic>&#8208;test: *<italic toggle="yes">p</italic>&#8201;&#8804;&#8201;0.05.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-7" orientation="portrait" xlink:href="PRP2-12-e70037-g001.jpg"/></fig><p>More importantly, HepaRG cells also expressed the enzymes directly involved in the metabolism of PGME. Figure&#160;<xref rid="prp270037-fig-0004" ref-type="fig">4A</xref> shows the results for q&#8208;RT&#8208;PCR calculated as &#8710;Ct (in comparison with B2M expression) for the isoforms ADH1A, ADH1B, ADH1C, and ALDH2. ADH1B showed the highest relative gene expression across all models; HepaRG, primary human hepatocytes (pHH) and human total liver RNA as a comparator. ADH1A expression was lower, but similar in all tested models. Expression of ADH1C in HepaRG was similar to that in pHH and slightly lower than in RNA isolated from fresh liver tissue. ALDH2 expression in HepaRG was lower than in pHH and fresh tissue. Furthermore, immunostainings of the 3D HepaRG confirmed the protein expression of ADH1A/B/C and ALDH2 in the cells (Figure&#160;<xref rid="prp270037-fig-0004" ref-type="fig">4B</xref>). In addition, Western blot results showed distinctive bands for ADH1A/B/C and ALDH2 for HepaRG and pHH cell lysates (Figure&#160;<xref rid="prp270037-fig-0004" ref-type="fig">4C</xref>), whereby the signal mean intensity relative to GAPDH was marginally higher for pHH compared to HepaRG (Figure&#160;<xref rid="prp270037-fig-0004" ref-type="fig">4D</xref>). For both cell culture models, ALDH2 was considered abundant, with a higher expression level than GAPDH.</p><fig position="float" fig-type="FIGURE" id="prp270037-fig-0004" orientation="portrait"><label>FIGURE 4</label><caption><p>Confirmation of ADH1A/B/C and ALDH2 in 3D HepaRG and comparison to other liver systems. (A) Gene expression of ADH1A, ADH1B, ADH1C and ALDH2 in primary human hepatocytes (pHH), HepaRG, and human liver total RNA was detected using q&#8208;RT&#8208;PCR; <italic toggle="yes">N</italic>&#8201;=&#8201;3 independent biological repeats with two to four technical replicates for each pHH donor, four to six technical replicates for HepaRG and <italic toggle="yes">N</italic>&#8201;=&#8201;1 biological experiment with two technical replicates for human liver total RNA. Bar graphs represent mean &#177; SD; statistical analysis based on one&#8208;way ANOVA followed by Dunnett's pairwise comparison: *<italic toggle="yes">p</italic>&#8201;&#8804;&#8201;0.05; ***<italic toggle="yes">p</italic>&#8201;&#8804;&#8201;0.001; ****<italic toggle="yes">p</italic>&#8201;&#8804;&#8201;0.0001. (B) 3D HepaRG were stained for ADH1A/B/C (green), ALDH2 (red), and counterstained with DAPI (blue). Scale bar representing 100&#8201;&#956;m. (C) Western blot of ALDH2, ADH1A/B/C, and GAPDH (loading control) in pHH and HepaRG cell lysate. (D) Signal mean intensity relative to GAPDH for the target proteins was determined using ImageJ. Cell lysate from both pHH donors was each used in total <italic toggle="yes">N</italic>&#8201;=&#8201;2 independent Western blots for ADH1A/B/C, and two to three times in total <italic toggle="yes">N</italic>&#8201;=&#8201;5 independent Western blots for ALDH2. HepaRG cell lysate was used in <italic toggle="yes">N</italic>&#8201;=&#8201;2 independent Western blots for ADH1A/B/C, and <italic toggle="yes">N</italic>&#8201;=&#8201;6 independent Western blots for ALDH2. Bar graphs represent mean &#177; SD; statistical analysis based on an unpaired <italic toggle="yes">t</italic>&#8208;test.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-9" orientation="portrait" xlink:href="PRP2-12-e70037-g008.jpg"/></fig></sec><sec id="prp270037-sec-0023"><label>3.2</label><title>Effects of the Solvents and Their Metabolites on Liver Cells</title><p>Relative cell viability (cellular ATP content) measurements showed that 3D HepaRG cultures were fairly resistant to all treatments with EC<sub>50</sub> values in the millimolar range (Figure&#160;<xref rid="prp270037-fig-0005" ref-type="fig">5A</xref> and Table&#160;<xref rid="prp270037-tbl-0007" ref-type="table">7</xref>). For all substances, EC<sub>50</sub> values were lower after 7&#8201;days of treatment than after 48&#8201;h exposure. A comparison of the calculated EC<sub>50</sub> values shows that EGME appeared to be less toxic than commercial PGME and &#946;&#8208;PGME. Notably, we observed initially higher ATP content (100%&#8211;130%) for all compounds after exposure over 7&#8201;days. Compared to the solvents &#946;&#8208;PGME and EGME, the metabolites showed approximately fourfold (2&#8208;MPA) and 50&#8208;fold (2&#8208;MAA) higher toxicities, increasing with longer exposure time. Interestingly, 2&#8208;MAA (EGME metabolite) was more toxic than 2&#8208;MPA (&#946;&#8208;PGME metabolite), although &#946;&#8208;PGME and commercial PGME seemed to be more toxic than EGME. Compared to 2D cultures, the 3D HepaRG were more sensitive as indicated by the lower EC<sub>50</sub> values.</p><fig position="float" fig-type="FIGURE" id="prp270037-fig-0005" orientation="portrait"><label>FIGURE 5</label><caption><p>Effects of glycol ethers, metabolites, and ethanol on HepaRG. (A) Cells were exposed to EGME, commercial PGME, &#946;&#8208;PGME, ethanol, 2&#8208;MAA, and 2&#8208;MPA for 48&#8201;h (2D: <styled-content style="color:#4472C4">&#9679;</styled-content>, 3D: <styled-content style="color:#4472C4">&#9650;</styled-content>) and 7&#8201;days (2D: &#9679;, 3D: &#9650;). Viability was assessed using the CellTiter&#8208;Glo Luminescent Cell Viability Assay and expressed as relative ATP content (% of untreated control), <italic toggle="yes">N</italic>&#8201;=&#8201;3&#8211;4 independent biological repeats with three technical replicates. Graphs represent mean &#177; SD. (B) Gene expression of ADH1C, ALDH2, CYP3A4, CYP2E1, and CYP2B6 after treatment with EGME, commercial PGME, and ethanol for 7&#8201;days was detected using q&#8208;RT&#8208;PCR; <italic toggle="yes">N</italic>&#8201;=&#8201;3 independent biological repeats with two to three technical replicates. Bar graphs represent mean &#177; SD; statistical analysis based on two&#8208;way ANOVA followed by Dunnett's pairwise comparison: ***<italic toggle="yes">p</italic>&#8201;&#8804;&#8201;0.001; ****<italic toggle="yes">p</italic>&#8201;&#8804;&#8201;0.0001.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-11" orientation="portrait" xlink:href="PRP2-12-e70037-g007.jpg"/></fig><table-wrap position="float" id="prp270037-tbl-0007" content-type="TABLE" orientation="portrait"><label>TABLE 7</label><caption><p>EC<sub>50</sub> values and the corresponding 95% confidence interval (CI) for EGME, commercial PGME, &#946;&#8208;PGME, ethanol, 2&#8208;MAA, and 2&#8208;MPA assessed on 2D and 3D HepaRG cultures upon 48&#8201;h or 7&#8201;days of exposure.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="center" colspan="2" valign="bottom" rowspan="1">2D HepaRG (48&#8201;h)</th><th align="center" colspan="2" valign="bottom" rowspan="1">2D HepaRG (7&#8201;days)</th><th align="center" colspan="2" valign="bottom" rowspan="1">3D HepaRG (48&#8201;h)</th><th align="center" colspan="2" valign="bottom" rowspan="1">3D HepaRG (7&#8201;days)</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1">EC<sub>50</sub> [mM]</th><th align="center" valign="bottom" rowspan="1" colspan="1">95% CI</th><th align="center" valign="bottom" rowspan="1" colspan="1">EC<sub>50</sub> [mM]</th><th align="center" valign="bottom" rowspan="1" colspan="1">95% CI</th><th align="center" valign="bottom" rowspan="1" colspan="1">EC<sub>50</sub> [mM]</th><th align="center" valign="bottom" rowspan="1" colspan="1">95% CI</th><th align="center" valign="bottom" rowspan="1" colspan="1">EC<sub>50</sub> [mM]</th><th align="center" valign="bottom" rowspan="1" colspan="1">95% CI</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">EGME</td><td align="center" valign="top" rowspan="1" colspan="1">NA</td><td align="center" valign="top" rowspan="1" colspan="1">NA</td><td align="center" valign="top" rowspan="1" colspan="1">NA</td><td align="center" valign="top" rowspan="1" colspan="1">NA</td><td align="center" valign="top" rowspan="1" colspan="1">326</td><td align="center" valign="top" rowspan="1" colspan="1">261&#8211;397</td><td align="center" valign="top" rowspan="1" colspan="1">171</td><td align="center" valign="top" rowspan="1" colspan="1">139&#8211;205</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PGME</td><td align="center" valign="top" rowspan="1" colspan="1">NA</td><td align="center" valign="top" rowspan="1" colspan="1">NA</td><td align="center" valign="top" rowspan="1" colspan="1">NA</td><td align="center" valign="top" rowspan="1" colspan="1">NA</td><td align="center" valign="top" rowspan="1" colspan="1">226</td><td align="center" valign="top" rowspan="1" colspan="1">194&#8211;262</td><td align="center" valign="top" rowspan="1" colspan="1">96</td><td align="center" valign="top" rowspan="1" colspan="1">73&#8211;126</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#946;&#8208;PGME</td><td align="center" valign="top" rowspan="1" colspan="1">NA</td><td align="center" valign="top" rowspan="1" colspan="1">NA</td><td align="center" valign="top" rowspan="1" colspan="1">NA</td><td align="center" valign="top" rowspan="1" colspan="1">NA</td><td align="center" valign="top" rowspan="1" colspan="1">162</td><td align="center" valign="top" rowspan="1" colspan="1">146&#8211;183</td><td align="center" valign="top" rowspan="1" colspan="1">86</td><td align="center" valign="top" rowspan="1" colspan="1">75&#8211;99</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ethanol</td><td align="center" valign="top" rowspan="1" colspan="1">NA</td><td align="center" valign="top" rowspan="1" colspan="1">NA</td><td align="center" valign="top" rowspan="1" colspan="1">NA</td><td align="center" valign="top" rowspan="1" colspan="1">NA</td><td align="center" valign="top" rowspan="1" colspan="1">610</td><td align="center" valign="top" rowspan="1" colspan="1">464&#8211;898</td><td align="center" valign="top" rowspan="1" colspan="1">NA</td><td align="center" valign="top" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2&#8208;MAA</td><td align="center" valign="top" rowspan="1" colspan="1">31</td><td align="center" valign="top" rowspan="1" colspan="1">27&#8211;45</td><td align="center" valign="top" rowspan="1" colspan="1">16</td><td align="center" valign="top" rowspan="1" colspan="1">15&#8211;17</td><td align="center" valign="top" rowspan="1" colspan="1">11</td><td align="center" valign="top" rowspan="1" colspan="1">5&#8211;15</td><td align="center" valign="top" rowspan="1" colspan="1">9</td><td align="center" valign="top" rowspan="1" colspan="1">8&#8211;10</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2&#8208;MPA</td><td align="center" valign="top" rowspan="1" colspan="1">81</td><td align="center" valign="top" rowspan="1" colspan="1">ND</td><td align="center" valign="top" rowspan="1" colspan="1">34</td><td align="center" valign="top" rowspan="1" colspan="1">31&#8211;40</td><td align="center" valign="top" rowspan="1" colspan="1">46</td><td align="center" valign="top" rowspan="1" colspan="1">ND</td><td align="center" valign="top" rowspan="1" colspan="1">26</td><td align="center" valign="top" rowspan="1" colspan="1">23&#8211;30</td></tr></tbody></table><table-wrap-foot id="prp270037-ntgp-0005"><fn id="prp270037-note-0010"><p>Abbreviations: NA, not available; ND, not determinable.</p></fn></table-wrap-foot></table-wrap><p>Regarding metabolic inductions, q&#8208;RT&#8208;PCR results showed a significant concentration&#8208;dependent increase (30&#8208; to 60&#8208;fold) of the relative gene expression of the phase I CYP450 enzymes CYP3A4 and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1324" ext-link-type="uri">CYP2B6</ext-link> after 7&#8208;day exposure to EGME, commercial PGME, and ethanol in HepaRG (Figure&#160;<xref rid="prp270037-fig-0005" ref-type="fig">5B</xref>). On the contrary, the expression of <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1330" ext-link-type="uri">CYP2E1</ext-link>, ADH1C, and ALDH2 was not induced by the exposure to the solvents.</p></sec><sec id="prp270037-sec-0024"><label>3.3</label><title>Determination of Hepatic Kinetic Parameters in Human Liver S9 Incubations</title><p>We confirmed ADH1A/B/C and ALDH2 protein presence in human liver S9 fraction by Western blot (Figure&#160;<xref rid="prp270037-fig-0006" ref-type="fig">6A</xref>). Results showed distinctive bands for both enzymes with signal mean intensities relative to GAPDH of 1.27&#8201;&#177;&#8201;0.60 for ADH1A/B/C and 1.73&#8201;&#177;&#8201;0.47 for ALDH2 (Figure&#160;<xref rid="prp270037-fig-0006" ref-type="fig">6B</xref>).</p><fig position="float" fig-type="FIGURE" id="prp270037-fig-0006" orientation="portrait"><label>FIGURE 6</label><caption><p>Hepatic kinetic of &#946;&#8208;PGME conversion to 2&#8208;MPA using human liver S9 fractions. (A) Western blot of ALDH2, ADH1A/B/C, and GAPDH (loading control) in S9 cell lysate. (B) Signal mean intensity relative to GAPDH for the target proteins was determined using ImageJ (<italic toggle="yes">N</italic>&#8201;=&#8201;2&#8211;4 independent biological repeats). Bar graphs represent mean &#177; SD; statistical analysis based on an unpaired <italic toggle="yes">t</italic>&#8208;test. (C) Representative velocity against substrate concentration plot for Michaelis&#8211;Menten kinetics in S9 incubations. 2&#8208;MPA was quantified using HPLC&#8208;MS/MS. The Michaelis&#8211;Menten curve was fitted to the data using Graphpad Prism and <italic toggle="yes">K</italic>
<sub>m</sub> and <italic toggle="yes">V</italic>
<sub>max</sub> predicted. Data points represent mean &#177; SD of <italic toggle="yes">N</italic>&#8201;=&#8201;3 independent incubations with two technical replicates. (D) Solvent (&#946;&#8208;PGME) loss&#8208;time profile (&#9650;) and 2&#8208;MPA metabolite formation (&#9632;) in S9 incubations. Data points represent mean &#177; SD of <italic toggle="yes">N</italic>&#8201;=&#8201;3 independent incubations with two technical replicates. (E) Ln of % remaining parent (&#9650;) and ln of metabolite concentration (&#9632;) versus time profile in S9 incubations. The in&#160;vitro CL<sub>int</sub> was calculated from the slope as described in the methods section. Data points represent mean &#177; SD of <italic toggle="yes">N</italic>&#8201;=&#8201;3 independent incubations summarizing calculated slopes derived from each single graph. The dotted line represents the parent value at time&#8208;point 1&#8201;min. (F) Inhibition of 2&#8208;MPA formation. 2&#8208;MPA was quantified after sampling at time&#8208;point 45&#8201;min for control incubations (CTR) and incubations applying 50&#8201;&#956;M fomepizole and 10&#8201;&#956;M GA11. Data points represent <italic toggle="yes">N</italic>&#8201;=&#8201;3 incubations with two technical replicates. Bar graphs represent mean &#177; SD; statistical analysis based on one&#8208;way ANOVA followed by Dunnett's pairwise comparison; *<italic toggle="yes">p</italic>&#8201;&#8804;&#8201;0.05, **<italic toggle="yes">p</italic>&#8201;&#8804;&#8201;0.01.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-13" orientation="portrait" xlink:href="PRP2-12-e70037-g009.jpg"/></fig><p>Next, we determined the Michaelis&#8211;Menten kinetics <italic toggle="yes">K</italic>
<sub>m</sub> and maximum reaction rate (<italic toggle="yes">V</italic>
<sub>max</sub>) using the S9 incubations. Figure&#160;<xref rid="prp270037-fig-0006" ref-type="fig">6C</xref> illustrates the resulting &#946;&#8208;PGME concentration versus velocity plot. Results revealed a <italic toggle="yes">K</italic>
<sub>m</sub> value of 5572&#8201;&#177;&#8201;2171&#8201;&#956;M and <italic toggle="yes">V</italic>
<sub>max</sub> of 1.04&#8201;&#177;&#8201;0.28&#8201;nmol/min/mg for the reaction of &#946;&#8208;PGME to 2&#8208;MPA (Table&#160;<xref rid="prp270037-tbl-0008" ref-type="table">8</xref>). The in&#160;vitro hepatic intrinsic (CL<sub>int</sub>) for <italic toggle="yes">V</italic>
<sub>max</sub>/<italic toggle="yes">K</italic>
<sub>m</sub> was calculated as 0.19&#8201;&#177;&#8201;0.03&#8201;&#956;L/min/mg.</p><table-wrap position="float" id="prp270037-tbl-0008" content-type="TABLE" orientation="portrait"><label>TABLE 8</label><caption><p>Obtained Michaelis&#8211;Menten kinetic parameters (<italic toggle="no">V</italic>
<sub>max</sub>, <italic toggle="no">K</italic>
<sub>m</sub>) from human liver subcellular fraction (S9) incubations, in&#160;vitro hepatic intrinsic clearance (CL<sub>int,</sub> in&#160;vitro) calculated on <italic toggle="no">V</italic>
<sub>max</sub>/<italic toggle="no">K</italic>
<sub>m</sub> and measured from S9 and 3D HepaRG metabolism studies, predicted in&#160;vivo hepatic intrinsic clearance (CL<sub>int, in&#160;vivo</sub>) and in&#160;vitro predicted hepatic organ clearance (CL<sub>h</sub>). Data represent mean values &#177; SD.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">&#946;&#8208;PGME &#8594;&#8201;2&#8208;MPA</th><th align="center" valign="bottom" rowspan="1" colspan="1">S9 incubations</th><th align="center" valign="bottom" rowspan="1" colspan="1">3D HepaRG</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">V</italic>
</bold>
<sub>
<bold>max</bold>
</sub>
<bold>[nmol/min/mg]</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1.04&#8201;&#177;&#8201;0.28</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">K</italic>
</bold>
<sub>
<bold>m</bold>
</sub>
<bold>[&#956;M]</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">5572&#8201;&#177;&#8201;2171</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr></tbody></table><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="bottom" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1">Calculated</th><th align="center" valign="bottom" rowspan="1" colspan="1">Measured</th><th align="center" valign="bottom" rowspan="1" colspan="1">Measured</th><th align="center" valign="bottom" rowspan="1" colspan="1">Measured</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="bottom" rowspan="1" colspan="1">(<italic toggle="yes">V</italic>max/<italic toggle="yes">K</italic>m)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Solvent loss</th><th align="center" valign="bottom" rowspan="1" colspan="1">Metabolite formation</th><th align="center" valign="bottom" rowspan="1" colspan="1">Metabolite formation</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>
<italic toggle="yes">f</italic>
</bold>
<sub>
<bold>u,inc</bold>
</sub>
<xref rid="prp270037-note-0011" ref-type="table-fn">
<sup>
<bold>a</bold>
</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.87</td><td align="center" valign="top" rowspan="1" colspan="1">0.87</td><td align="center" valign="top" rowspan="1" colspan="1">0.87</td><td align="center" valign="top" rowspan="1" colspan="1">0.94</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>CL<sub>int, in&#160;vitro</sub> [&#956;L/min/mg]</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.19&#8201;&#177;&#8201;0.03</td><td align="center" valign="top" rowspan="1" colspan="1">3.80&#8201;&#177;&#8201;2.14</td><td align="center" valign="top" rowspan="1" colspan="1">40.9&#8201;&#177;&#8201;5.19</td><td align="center" valign="top" rowspan="1" colspan="1">9.62&#8201;&#177;&#8201;0.85<xref rid="prp270037-note-0012" ref-type="table-fn">
<sup>b</sup>
</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>CL<sub>int, in&#160;vitro</sub> [&#956;L/min/10</bold>
<sup>
<bold>6</bold>
</sup>
<bold>cells]</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">9.34&#8201;&#177;&#8201;0.83</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Predicted CL</bold>
<sub>
<bold>int, in&#160;vivo</bold>
</sub>
<bold>[mL/min/kg]</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.60&#8201;&#177;&#8201;0.09</td><td align="center" valign="top" rowspan="1" colspan="1">11.8&#8201;&#177;&#8201;6.67</td><td align="center" valign="top" rowspan="1" colspan="1">127&#8201;&#177;&#8201;16.1</td><td align="center" valign="top" rowspan="1" colspan="1">28.2&#8201;&#177;&#8201;2.50</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Predicted CL</bold>
<sub>
<bold>h</bold>
</sub>
<bold>[mL/min/kg]</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.36&#8201;&#177;&#8201;0.05</td><td align="center" valign="top" rowspan="1" colspan="1">5.03&#8201;&#177;&#8201;2.52</td><td align="center" valign="top" rowspan="1" colspan="1">16.4&#8201;&#177;&#8201;0.47</td><td align="center" valign="top" rowspan="1" colspan="1">9.07&#8201;&#177;&#8201;0.44</td></tr></tbody></table><table-wrap-foot id="prp270037-ntgp-0006"><fn id="prp270037-note-0011"><label>
<sup>a</sup>
</label><p>Data derived from IQVIVE, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.qivivetools.wur.nl/" ext-link-type="uri">https://www.qivivetools.wur.nl</ext-link>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.qivivetools.wur.nl/" ext-link-type="uri">.</ext-link>
</p></fn><fn id="prp270037-note-0012"><label>
<sup>b</sup>
</label><p>Converted from 9.34&#8201;&#177;&#8201;0.83&#8201;&#956;L/min/10<sup>6</sup> cells, using 117.5&#8201;&#215;&#8201;10<sup>6</sup> cells/g liver and 121&#8201;mg&#8201;S9 protein/g liver.</p></fn></table-wrap-foot></table-wrap><p>We illustrated the results for the 2&#8208;MPA metabolite formation and &#946;&#8208;PGME depletion experiments in Figure&#160;<xref rid="prp270037-fig-0006" ref-type="fig">6D</xref>, following a linear manner over 45&#8201;min. We calculated the measured in&#160;vitro CL<sub>int</sub> for the solvent loss from the ln of % remaining parent solvent as 3.80&#8201;&#177;&#8201;2.14&#8201;&#956;L/min/mg (Figure&#160;<xref rid="prp270037-fig-0006" ref-type="fig">6E</xref> and Table&#160;<xref rid="prp270037-tbl-0008" ref-type="table">8</xref>). The measured in&#160;vitro CL<sub>int</sub> calculated from the ln of % 2&#8208;MPA metabolite concentration was 40.9&#8201;&#177;&#8201;5.19&#8201;&#956;L/min/mg. Both values appeared to be higher than the in&#160;vitro CL<sub>int</sub> calculated from <italic toggle="yes">V</italic>
<sub>max</sub>/<italic toggle="yes">K</italic>
<sub>m</sub>.</p><p>Further, studies applying a competitive inhibitor for ADH (fomepizole&#8201;=&#8201;4&#8208;methyl pyrazole) and for ALDH (GA11&#8201;=&#8201;2,6&#8208;diphenylimidazo[1,2&#8208;a]pyridine) showed a significantly reduced 2&#8208;MPA formation compared to control incubations (Figure&#160;<xref rid="prp270037-fig-0006" ref-type="fig">6F</xref>).</p><p>Finally, we performed hepatic organ clearance (CL<sub>h</sub>) predictions through in&#160;vitro&#8208;in vivo extrapolation (IVIVE) based on the in&#160;vitro CL<sub>int</sub> obtained from the performed measurements as well as the in&#160;vitro CL<sub>int</sub> calculated from <italic toggle="yes">K</italic>
<sub>m</sub> and <italic toggle="yes">V</italic>
<sub>max</sub>. Although the determined in&#160;vitro CL<sub>int</sub> based on the metabolite formation (40.9&#8201;&#177;&#8201;5.19&#8201;&#956;L/min/mg) was much higher than for the solvent loss (3.80&#8201;&#177;&#8201;2.14&#8201;&#956;L/min/mg), the in&#160;vitro predicted CL<sub>h</sub> values showed to be nearly within threefold deviation (metabolite formation: 16.4&#8201;&#177;&#8201;0.47&#8201;mL/min/kg; solvent loss: 5.00&#8201;&#177;&#8201;2.52&#8201;mL/min/kg). Besides, the calculated in&#160;vitro predicted CL<sub>h</sub> (<italic toggle="yes">K</italic>
<sub>m</sub>/<italic toggle="yes">V</italic>
<sub>max</sub>), 0.36&#8201;&#177;&#8201;0.05&#8201;mL/min/kg, was much lower than the measured values. All values are summarized in Table&#160;<xref rid="prp270037-tbl-0008" ref-type="table">8</xref>.</p></sec><sec id="prp270037-sec-0025"><label>3.4</label><title>Assessment of Hepatic Kinetic Parameters in the 3D HepaRG Model</title><p>Given linear 2&#8208;MPA formation within the first hour, we calculated the measured in&#160;vitro CL<sub>int</sub> in the 3D HepaRG from the ln of % 2&#8208;MPA metabolite concentration within 60&#8201;min (Figure&#160;<xref rid="prp270037-fig-0007" ref-type="fig">7A,B</xref>). The in&#160;vitro CL<sub>int</sub> for the &#946;&#8208;PGME loss was not determined, as only a small quantity of the 5&#8201;mM applied &#946;&#8208;PGME was metabolized, and the obtained depletion curves were not reliably measurable with the analytical methods. The in&#160;vitro CL<sub>int</sub> for the metabolite formation was 9.34&#8201;&#177;&#8201;0.83&#8201;&#956;L/min/10<sup>6</sup> cells or 9.62&#8201;&#177;&#8201;0.85&#8201;&#956;L/min/mg after applying the previously described scaling factors (summarized in Table&#160;<xref rid="prp270037-tbl-0008" ref-type="table">8</xref>). Similar to the S9 incubations, clearance was greater than the in&#160;vitro CL<sub>int</sub> calculated from <italic toggle="yes">V</italic>
<sub>max</sub>/<italic toggle="yes">K</italic>
<sub>m</sub>. In comparison to the measured in&#160;vitro CL<sub>int</sub> in the S9 incubations, the in&#160;vitro CL<sub>int</sub> determined in the 3D HepaRG appeared to be smaller. Nevertheless, the in&#160;vitro predicted CL<sub>h</sub> values following IVIVE were close within twofold deviation.</p><fig position="float" fig-type="FIGURE" id="prp270037-fig-0007" orientation="portrait"><label>FIGURE 7</label><caption><p>Long&#8208;term metabolism profile in 3D HepaRG and 3D primary human hepatocytes and hepatic kinetic for &#946;&#8208;PGME conversion to 2&#8208;MPA using 3D HepaRG. (A) 2&#8208;MPA metabolite formation within the first hour (&#9632;) in 3D HepaRG. Data points represent mean &#177; SD of <italic toggle="yes">N</italic>&#8201;=&#8201;3 independent incubations with two technical replicates. (B) Ln of 2&#8208;MPA concentration (&#9632;) versus time profile in 3D HepaRG. The in&#160;vitro CL<sub>int</sub> was calculated from the slope as described in the methods section. Data points represent mean &#177; SD of <italic toggle="yes">N</italic>&#8201;=&#8201;3 independent incubations summarizing calculated slopes derived from each single graph. The dotted line represents the parent value at time&#8208;point 1&#8201;min. (C) 2&#8208;MPA formation&#8208;time profile in 3D HepaRG and 3D primary human hepatocytes (pHH). 3D&#8208;spheroids were exposed to 5&#8201;mM &#946;&#8208;PGME and the conversion into 2&#8208;MPA was determined at 1, 6, and 24&#8201;h by HPLC&#8208;MS/MS. Data are expressed as amount of metabolite formed per incubational protein content (pmol/&#956;g) calculated using calibration curves; <italic toggle="yes">N</italic>&#8201;=&#8201;3 independent biological repeats with two technical replicates (HepaRG) and <italic toggle="yes">N</italic>&#8201;=&#8201;2 independent biological repeats using each pHH donor once with one to two technical replicates. Graphs represent mean &#177; SD.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-15" orientation="portrait" xlink:href="PRP2-12-e70037-g010.jpg"/></fig><p>Simultaneous incubations with 3D HepaRG and 3D primary human hepatocytes (pHH) showed higher concentrations of 2&#8208;MPA at 1 and 6&#8201;h for the 3D pHH than for the 3D HepaRG, yet the amount of formed metabolite was similar at the end of the incubation (Figure&#160;<xref rid="prp270037-fig-0007" ref-type="fig">7C</xref>). Artifacts due to stability, adsorption, or evaporation of &#946;&#8208;PGME and 2&#8208;MPA over time are unlikely based on our data (Figures&#160;<xref rid="prp270037-supitem-0001" ref-type="supplementary-material">S3</xref> and <xref rid="prp270037-supitem-0001" ref-type="supplementary-material">S4</xref>).</p></sec><sec id="prp270037-sec-0026"><label>3.5</label><title>Implementation of In&#160;Vitro Data Into the Simulation Model</title><p>We generated simulations applying the &#946;&#8208;isomer PGME toxicokinetic (TK) model integrating the in&#160;vitro predicted hepatic organ clearance (CL<sub>h</sub>) values (Table&#160;<xref rid="prp270037-tbl-0008" ref-type="table">8</xref>). No calibration was carried out and no parameters were fitted, enabling both sets of experimental data&#160;[<xref rid="prp270037-bib-0020" ref-type="bibr">20</xref>] (PGME exposure at 95&#8201;ppm and 50&#8201;ppm) to be used for model evaluation. Figure&#160;<xref rid="prp270037-fig-0008" ref-type="fig">8</xref> illustrates the comparisons of predicted urinary 2&#8208;MPA concentrations versus experimental data. Our results show a low fit for the simulations based on the in&#160;vitro predicted CL<sub>h</sub> calculated for S9 (<italic toggle="yes">V</italic>
<sub>max</sub>/<italic toggle="yes">K</italic>
<sub>m</sub>) with R<sup>2</sup>&#8201;=&#8201;0.16 (below the acceptable threshold of 0.75) and a MAPE of 64.1% (unacceptable). Most data points were out of twofold range from observed data (Figure&#160;<xref rid="prp270037-fig-0009" ref-type="fig">9A</xref>). In contrast, the model predictions using in&#160;vitro predicted CL<sub>h</sub> from S9 (solvent loss) correlated well with the observed data with <italic toggle="yes">R</italic>
<sup>2</sup>&#8201;=&#8201;0.87 and a MAPE of 23.9% (acceptable). Similar fits presented the simulations based on the in&#160;vitro predicted CL<sub>h</sub> from S9 (metabolite formation) with <italic toggle="yes">R</italic>
<sup>2</sup>&#8201;=&#8201;0.93 and a MAPE of 21.5% (acceptable) and 3D HepaRG (metabolite formation) with <italic toggle="yes">R</italic>
<sup>2</sup>&#8201;=&#8201;0.92 and a MAPE of 22.4% (acceptable). Those predictions were all within twofold error from observed data (Figure&#160;<xref rid="prp270037-fig-0009" ref-type="fig">9B&#8211;D</xref>).</p><fig position="float" fig-type="FIGURE" id="prp270037-fig-0008" orientation="portrait"><label>FIGURE 8</label><caption><p>Toxicokinetic model evaluation: Comparison of predicted versus experimental data. Predicted urinary 2&#8208;MPA concentrations (lines) based on in&#160;vitro predicted CL<sub>h</sub> from S9 fraction (<italic toggle="yes">V</italic>
<sub>max</sub>/<italic toggle="yes">K</italic>
<sub>m</sub>), S9 fraction (solvent loss), S9 (metabolite formation), and 3D HepaRG (metabolite formation) were compared to experimental data (dots) derived from Devanth&#233;ry et&#160;al. [<xref rid="prp270037-bib-0020" ref-type="bibr">20</xref>]. The dip in concentration at 3&#8201;h observed in the graphs is due to a 30&#8208;min break from exposure as described in Table&#160;<xref rid="prp270037-tbl-0006" ref-type="table">6</xref>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-17" orientation="portrait" xlink:href="PRP2-12-e70037-g005.jpg"/></fig><fig position="float" fig-type="FIGURE" id="prp270037-fig-0009" orientation="portrait"><label>FIGURE 9</label><caption><p>Plot of predicted versus experimental data and results of sensitivity analysis. Observed urinary 2&#8208;MPA concentrations measured by Devanth&#233;ry et&#160;al. [<xref rid="prp270037-bib-0020" ref-type="bibr">20</xref>] were plotted versus concentrations predicted by our toxicokinetic model using the clearance value determined with (A) S9 fraction (<italic toggle="yes">V</italic>
<sub>max</sub>/<italic toggle="yes">K</italic>
<sub>m</sub>), (B) S9 fraction (solvent loss), (C) S9 fraction (metabolite formation), and (D) 3D HepaRG model (metabolite formation). The middle line is the line of unity, and the outer lines represent twofold deviations. (E) Normalized sensitivity coefficients (NSC) for the area under the concentration curves (AUC) of unbound 2&#8208;MPA in blood and urine and unbound &#946;&#8208;PGME in blood. Only parameters with medium or high impact on the output (|NSC|&#8201;&#8805;&#8201;0.2) are shown in the graph. Abbreviations for the parameters can be found in Table&#160;<xref rid="prp270037-tbl-0005" ref-type="table">5</xref>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-19" orientation="portrait" xlink:href="PRP2-12-e70037-g003.jpg"/></fig><p>Results from the sensitivity analysis are shown in Figure&#160;<xref rid="prp270037-fig-0009" ref-type="fig">9E</xref>, whereby the parameters with medium or high impact (|NSC|&#8201;&#8805;&#8201;0.2) on the selected output are illustrated. We observed that all three selected area under the curves (AUC) outputs (2&#8208;MPA urine concentration, 2&#8208;MPA blood concentration, and &#946;&#8208;PGME blood concentration) were highly sensitive to cardiac output (QCC<sub>rest</sub>), &#946;&#8208;PGME pulmonary retention (<italic toggle="yes">R</italic>
<sub>pulm</sub>), and the percentage of &#946;&#8208;isomer PGME present in the mixture used for the exposure experiment (Beta_percent). Additionally, AUC of unbound &#946;&#8208;PGME in blood was highly sensitive to &#946;&#8208;PGME unbound fraction in plasma (Fu,p) and to &#946;&#8208;PGME blood&#8208;toplasma ratio (<italic toggle="yes">R</italic>
<sub>b</sub>). The AUC of 2&#8208;MPA in blood was highly sensitive to 2&#8208;MPA unbound fraction in plasma (Fu,p_<sub>MPA</sub>), 2&#8208;MPA blood&#8208;to&#8208;plasma ratio (Rb_<sub>MPA</sub>), blood&#8208;air partition coefficient (PC) of 2&#8208;MPA (Pba_<sub>MPA</sub>), central&#8208;air PC of 2&#8208;MPA (Pca_<sub>MPA</sub>), and to the urinary excretion rate of 2&#8208;MPA (<italic toggle="yes">K</italic>
<sub>MPA</sub>). Among the parameters with high impact, those with high uncertainty were Pba_<sub>MPA</sub>, Pca_<sub>MPA</sub> Rb_<sub>MPA</sub>, and Fu,p_<sub>MPA</sub> (Table&#160;<xref rid="prp270037-supitem-0001" ref-type="supplementary-material">S6</xref>).</p></sec></sec><sec sec-type="discussion" id="prp270037-sec-0027"><label>4</label><title>Discussion</title><p>In this study, we used a 3D HepaRG liver model and human liver S9 fraction to assess the hepatic clearance of &#946;&#8208;isomer propylene glycol methyl ether (&#946;&#8208;PGME) as in&#160;vitro input data for a newly developed toxicokinetic (TK) model.</p><p>Our results show that HepaRG cultured in 3D&#8208;spheroids successfully metabolized the solvent &#946;&#8208;PGME. This stable&#160;3D&#8208;cellular model could satisfy the increasing demand for determining the clearance of compounds with high metabolic stability and/or with prolonged exposure [<xref rid="prp270037-bib-0025" ref-type="bibr">25</xref>]. In this context, short&#8208;term in&#160;vitro assays such as S9 incubations are of limited use due to their short&#8208;lived enzyme activity&#160;[<xref rid="prp270037-bib-0064" ref-type="bibr">64</xref>]. Active metabolism of 3D HepaRG was expected based on the gene and protein expression levels of the metabolizing enzymes derived from 2D HepaRG, which were comparable to those detected in 2D primary human hepatocytes. From a quantitative point of view, the amount of 2&#8208;MPA initially formed by the 3D HepaRG was approximately two&#8208; to threefold lower than that detected with 3D primary human hepatocytes. This discrepancy may be attributed to a slightly lower enzyme activity in the cell line. Alternatively, inter&#8208;individual variation on hepatocyte donors may have played a role. Both primary hepatocyte donors used in this study were African Americans, and may have been carriers of the alcohol dehydrogenase (ADH1B*3) gene variant exclusive to populations of African ancestry [<xref rid="prp270037-bib-0065" ref-type="bibr">65</xref>]. While we did not genotype the cells, we specifically observed high gene expression of ADH1B in HepaRG and human liver total reference RNA, but not in these primary hepatocytes lots. Although we showed ADH and aldehyde dehydrogenase (ALDH) enzyme presence in 3D HepaRG, these data cannot conclusively demonstrate that these enzymes were responsible for the metabolism of PGME, as HepaRGs are known for expressing a wide range of enzymes [<xref rid="prp270037-bib-0029" ref-type="bibr">29</xref>]. However, we demonstrated the specific conversion of &#946;&#8208;PGME by inhibiting this pathway in S9 incubations. Using the ADH inhibitor fomepizole significantly reduced 2&#8208;MPA formation, which was expected because of its wide application in the treatment of patients suffering from methanol or ethylene glycol poisoning [<xref rid="prp270037-bib-0036" ref-type="bibr">36</xref>, <xref rid="prp270037-bib-0066" ref-type="bibr">66</xref>]. Furthermore, we confirmed the in&#160;vitro inhibitory potential of GA11, previously described only through computational approaches as an inhibitor of ALDH2 [<xref rid="prp270037-bib-0037" ref-type="bibr">37</xref>].</p><p>In comparison to published rat studies that reported more than 60% of &#946;&#8208;PGME being excreted as 2&#8208;MPA [<xref rid="prp270037-bib-0019" ref-type="bibr">19</xref>, <xref rid="prp270037-bib-0048" ref-type="bibr">48</xref>], we observed low metabolism of &#946;&#8208;PGME in&#160;vitro. This could have resulted from species differences, extra&#8208;hepatic metabolism of &#946;&#8208;PGME, or possibly analytical sensitivity and capacity issues [<xref rid="prp270037-bib-0067" ref-type="bibr">67</xref>]. As our experiments using 3D HepaRG and S9 exhibited the formation of 2&#8208;MPA inversely parallel to the depletion of &#946;&#8208;PGME, we do not expect that other metabolic reactions have occurred that would significantly exceed 2&#8208;MPA generation. We would like to highlight here, that the greater clearance values measured for the 2&#8208;MPA formation than the &#946;&#8208;PGME loss derived from the S9 incubations could be due to the use of different analytical techniques for compound quantification, introducing potential interdependent errors.</p><p>To this date, no in&#160;vivo or in&#160;vitro metabolic kinetic studies reporting the Michaelis&#8211;Menten parameters (<italic toggle="yes">K</italic>
<sub>m</sub>, <italic toggle="yes">V</italic>
<sub>max</sub>) for the conversion of &#946;&#8208;PGME to 2&#8208;MPA are known. Aligning our results for Michaelis&#8211;Menten kinetics with an existing study performed on EGME using human hepatocytes, we find values in a similar range (millimolar) with a reported <italic toggle="yes">K</italic>
<sub>m</sub> of 1700&#8201;&#956;M and <italic toggle="yes">V</italic>
<sub>max</sub> of 61.3&#8201;nmol/h/10<sup>6</sup> cells [<xref rid="prp270037-bib-0004" ref-type="bibr">4</xref>, <xref rid="prp270037-bib-0005" ref-type="bibr">5</xref>]. This results in a calculated in&#160;vitro CL<sub>int</sub> of 0.62&#8201;&#956;L/min/mg applying the scaling factors from our study, which can be classified as a low clearance rate, [<xref rid="prp270037-bib-0068" ref-type="bibr">68</xref>] resulting in a slow metabolite generation. Similarly, the calculated in&#160;vitro CL<sub>int</sub> (<italic toggle="yes">V</italic>
<sub>max</sub>/<italic toggle="yes">K</italic>
<sub>m</sub>) for &#946;&#8208;PGME obtained in our study was low. Despite the low reported hepatic clearance, EGME is a known toxicant that has been described for adverse effects on the testis, bone marrow, the central nervous system, and many more, because of its metabolite methoxy acetic acid (2&#8208;MAA) [<xref rid="prp270037-bib-0004" ref-type="bibr">4</xref>, <xref rid="prp270037-bib-0006" ref-type="bibr">6</xref>]. Therefore, we conclude that we cannot exclude adverse effects by 2&#8208;MPA, especially as 2&#8208;MPA showed an approximately four times lower EC<sub>50</sub> value in 3D HepaRG cultures than &#946;&#8208;PGME. Moreover, based on the overall generated in&#160;vitro predicted CL<sub>h</sub> values, we would propose that &#946;&#8208;PGME is a low to medium clearance compound, considering reported clearance rankings [<xref rid="prp270037-bib-0068" ref-type="bibr">68</xref>, <xref rid="prp270037-bib-0069" ref-type="bibr">69</xref>, <xref rid="prp270037-bib-0070" ref-type="bibr">70</xref>]. In translation to the human body, this suggests that &#946;&#8208;PGME would exhibit moderate persistence before being metabolized into the potentially harmful metabolite 2&#8208;MPA.</p><p>Although the calculated clearance (<italic toggle="yes">V</italic>
<sub>max</sub>/<italic toggle="yes">K</italic>
<sub>m</sub>) for &#946;&#8208;PGME was close to the reported value for EGME, the performed TK simulations resulted in a low fit compared to the experimental data.</p><p>Generally, we observed underprediction of the experimental urinary 2&#8208;MPA concentrations for all simulated curves, though not as significant as for those using the calculated clearance (<italic toggle="yes">V</italic>
<sub>max</sub>/<italic toggle="yes">K</italic>
<sub>m</sub>). It has become recognized that in&#160;vitro data tend to underestimate the observed metabolic clearance in humans [<xref rid="prp270037-bib-0071" ref-type="bibr">71</xref>]. Reasons represent the use of standard biological scaling factors, extrinsic factors such as storage conditions and/or the preparation process, the absence of appropriate correction for non&#8208;specific binding, as well as extra&#8208;hepatic metabolism in&#160;vivo [<xref rid="prp270037-bib-0067" ref-type="bibr">67</xref>, <xref rid="prp270037-bib-0072" ref-type="bibr">72</xref>, <xref rid="prp270037-bib-0073" ref-type="bibr">73</xref>]. However, we cannot explain whether the notable underestimation of the calculated in&#160;vitro CL<sub>int</sub> (<italic toggle="yes">V</italic>
<sub>max</sub>/<italic toggle="yes">K</italic>
<sub>m</sub>) derived from an underpredicted <italic toggle="yes">V</italic>
<sub>max</sub> value or an overpredicted <italic toggle="yes">K</italic>
<sub>m</sub> value.</p><p>Next, we argue that 3D HepaRG represents a more physiological system compared to the S9 fraction. It requires that compounds permeate into the cells to be metabolized and takes into consideration the full range of enzymes and cofactors, which allows for evaluation of the metabolism via ADH/ALDH in the presence of other physiological metabolic routes [<xref rid="prp270037-bib-0029" ref-type="bibr">29</xref>, <xref rid="prp270037-bib-0074" ref-type="bibr">74</xref>]. In our study, we showed the active performance of Phase I metabolism in an inducible manner and the secretion of albumin comparable to reported levels, two phenotypical characteristics for hepatocytes [<xref rid="prp270037-bib-0033" ref-type="bibr">33</xref>, <xref rid="prp270037-bib-0075" ref-type="bibr">75</xref>]. Moreover, the similar simulation outcomes for the 3D HepaRG and the S9 incubations confirmed effective ADH and ALDH enzyme activities in HepaRG and we expect a high (not clearance&#8208;limiting) permeability of &#946;&#8208;PGME into the cells.</p><p>In the context of &#946;&#8208;PGME, the linear formation of 2&#8208;MPA within the first hour did not necessitate a complex, long&#8208;lasting in&#160;vitro system for the determination of the hepatic kinetic parameter. Besides, the S9 incubations showed to deliver reliable input data as well. Nevertheless, the characterized 3D HepaRG model can serve as a tool to study the metabolism of other compounds converted via the ADH/ALDH pathway, especially low&#8208;turnover compounds that require a longer incubation time. Moreover, these more complex cell cultures can be maintained for days and weeks and are hence suitable for implementation into more complex, multiorgan systems such as Organ on Chip (OOC) or microphysiological systems (MPS) [<xref rid="prp270037-bib-0076" ref-type="bibr">76</xref>, <xref rid="prp270037-bib-0077" ref-type="bibr">77</xref>]. This would greatly help to better understand adverse effects of &#946;&#8208;PGME and its metabolite in the body and under chronic exposure.</p><p>In comparison to simpler liver systems like the S9 cell fraction, the advanced 3D HepaRG model moreover offers the possibility for studying direct hepatocellular toxicity caused by the formed metabolite over extended incubation periods [<xref rid="prp270037-bib-0078" ref-type="bibr">78</xref>]. Given the low observed metabolite formation in the 3D HepaRG, we propose that the evaluated cytotoxicity of the solvents is primarily due to the induction of cell permeability rather than caused by the metabolites [<xref rid="prp270037-bib-0079" ref-type="bibr">79</xref>]. Furthermore, we observed viability curves initially exceeding 100%, which could be explained by an adaptive metabolic cell response after first compound exposures. Previous chronic toxicity studies in animals using EGEs have shown the induction of liver enzymes and changes in liver weights [<xref rid="prp270037-bib-0017" ref-type="bibr">17</xref>, <xref rid="prp270037-bib-0080" ref-type="bibr">80</xref>, <xref rid="prp270037-bib-0081" ref-type="bibr">81</xref>]. In line with this, we observed increased gene expression of CYP3A4 and CYP2B6 after treatment of HepaRG with non&#8208;cytotoxic concentrations of EGME, commercial PGME, and ethanol, but not for CYP2E1, ADH1A/B/C, and ALDH2. This was unexpected given the reported induction effects described after alcohol exposure [<xref rid="prp270037-bib-0038" ref-type="bibr">38</xref>]. So far, the significance of these findings for humans is not clear, as high in&#160;vitro concentrations were applied and a prediction of human liver exposure concentrations would be needed. However, our results may be relevant since occupational exposures take place over a lifetime and cumulative mixture effects cannot be excluded. In addition, as many chemicals are substrates, inhibitors, or inducers of CYP3A4 and CYP2C9, drug interactions after long&#8208;term exposure to the solvents should be considered [<xref rid="prp270037-bib-0082" ref-type="bibr">82</xref>]. Moreover, polymorphism of the ALDH2 enzyme is well known and should be taken into account [<xref rid="prp270037-bib-0016" ref-type="bibr">16</xref>].</p><p>In summary, using the established 3D HepaRG model, we were able to generate in&#160;vitro hepatic kinetic data for the conversion of &#946;&#8208;PGME to 2&#8208;MPA that reliably predicted the in&#160;vivo situation in a similar magnitude (twofold) to S9 fraction. We conclude that the 3D HepaRG model can be used to generate in&#160;vitro hepatic metabolism and clearance data for compounds metabolized via ADH and ALDH. Moreover, it offers a promising tool to simultaneously study enzyme induction and metabolite&#8208;induced hepatotoxicity and to be integrated into multiorgan systems. Future studies should provide further liver input data on other PGEs for the TK model, which will help fill the gap of knowledge on metabolism and systemic toxicity of PGEs.</p></sec><sec id="prp270037-sec-0031"><title>Author Contributions</title><p>Sophie Werner, Lucie Hegg, Nancy B. Hopf, Laura Suter&#8208;Dick participated in research design. Sophie Werner conducted experiments. Sophie Werner contributed new reagents or analytic tools. Sophie Werner, Lucie Hegg performed data analysis. Sophie Werner, Lucie Hegg, Nancy B. Hopf, Myriam Borgatta, Laura Suter&#8208;Dick wrote or contributed to the writing of the manuscript.</p></sec><sec sec-type="COI-statement" id="prp270037-sec-0032"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="prp270037-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>
Data S1.
</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="PRP2-12-e70037-s001.pdf" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="prp270037-sec-0028"><title>Acknowledgments</title><p>We would like to thank Timm Hettich and Andr&#233; B&#252;ttler at the FHNW for their valuable assistance in the development of the analytical methods. We thank the Swiss Centre for Applied Human Toxicity (SCAHT), as well as our home institutions (FHNW, Unisant&#233;) for funding the research.</p></ack><sec sec-type="data-availability" id="prp270037-sec-0030"><title>Data Availability Statement</title><p>The authors declare that all the data supporting the findings of this study are available within the paper and its <xref rid="prp270037-supitem-0001" ref-type="supplementary-material">Supporting Information</xref>.</p></sec><ref-list content-type="cited-references" id="prp270037-bibl-0001"><title>References</title><ref id="prp270037-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="prp270037-cit-0001"><string-name name-style="western"><given-names>M.</given-names><surname>Borgatta</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Hechon</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Wild</surname></string-name>, and <string-name name-style="western"><given-names>N. B.</given-names><surname>Hopf</surname></string-name>, &#8220;<article-title>Influence of Collection and Storage Materials on Glycol Ether Concentrations in Urine and Blood</article-title>,&#8221; <source>Science of the Total Environment</source><volume>792</volume> (<year>2021</year>): <elocation-id>148196</elocation-id>, <pub-id pub-id-type="doi">10.1016/j.scitotenv.2021.148196</pub-id>.<pub-id pub-id-type="pmid">34153747</pub-id></mixed-citation></ref><ref id="prp270037-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="prp270037-cit-0002"><string-name name-style="western"><given-names>R. C.</given-names><surname>Brown</surname></string-name>, <string-name name-style="western"><given-names>A. H.</given-names><surname>Lockwood</surname></string-name>, and <string-name name-style="western"><given-names>B. R.</given-names><surname>Sonawane</surname></string-name>, &#8220;<article-title>Neurodegenerative Diseases: An Overview of Environmental Risk Factors</article-title>,&#8221; <source>Environmental Health Perspectives</source><volume>113</volume>, no. <issue>9</issue> (<year>2005</year>): <fpage>1250</fpage>&#8211;<lpage>1256</lpage>, <pub-id pub-id-type="doi">10.1289/ehp.7567</pub-id>.<pub-id pub-id-type="pmid">16140637</pub-id><pub-id pub-id-type="pmcid">PMC1280411</pub-id></mixed-citation></ref><ref id="prp270037-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="prp270037-cit-0003"><string-name name-style="western"><given-names>A.</given-names><surname>Cicolella</surname></string-name>, &#8220;<article-title>Glycol Ethers: A Ubiquitous Family of Toxic Chemicals: A Plea for REACH Regulation</article-title>,&#8221; <source>Annals of the New York Academy of Sciences</source><volume>1076</volume> (<year>2006</year>): <fpage>784</fpage>&#8211;<lpage>789</lpage>, <pub-id pub-id-type="doi">10.1196/annals.1371.049</pub-id>.<pub-id pub-id-type="pmid">17119255</pub-id></mixed-citation></ref><ref id="prp270037-bib-0004"><label>4</label><mixed-citation publication-type="book" id="prp270037-cit-0004"><collab collab-type="authors">ECETOC</collab>
, <source>The Toxicology of Glycol Ethers and Its Relevance to Man</source>, vol. <volume>I</volume>, <edition designator="4">4th ed.</edition> (<publisher-loc>Brussels, Belgium</publisher-loc>: <publisher-name>Technical Report No. 95, <italic toggle="yes">Technical Report</italic></publisher-name>, <year>2005</year>), <fpage>159</fpage>&#8211;<lpage>162</lpage>. I(95), <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.ecetoc.org/wp-content/uploads/2014/08/ECETOC-TR-095-Vol-I.pdf%0Ahttp://www.ecetoc.org/wp-content/uploads/2014/08/ECETOC-TR-095-Vol-II.pdf" ext-link-type="uri">http://www.ecetoc.org/wp&#8208;content/uploads/2014/08/ECETOC&#8208;TR&#8208;095&#8208;Vol&#8208;I.pdf%0Ahttp://www.ecetoc.org/wp&#8208;content/uploads/2014/08/ECETOC&#8208;TR&#8208;095&#8208;Vol&#8208;II.pdf</ext-link>.</mixed-citation></ref><ref id="prp270037-bib-0005"><label>5</label><mixed-citation publication-type="book" id="prp270037-cit-0005"><collab collab-type="authors">ECETOC</collab>
, <source>The Toxicology of Glycol Ethers and Its Relevance to Man</source>, vol. <volume>II</volume>, <edition designator="4">4th ed.</edition> (<publisher-loc>Brussels, Belgium</publisher-loc>: <publisher-name>Substance Profiles. <italic toggle="yes">Technical Report</italic></publisher-name>, <year>2005</year>), <fpage>159</fpage>&#8211;<lpage>162</lpage>. II(95), <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.ecetoc.org/wpcontent/uploads/2014/08/ECETOC-TR-095-Vol-I.pdf%0Ahttp://www.ecetoc.org/wpcontent/uploads/2014/08/ECETOC-TR-095-Vol-II.pdf" ext-link-type="uri">http://www.ecetoc.org/wpcontent/uploads/2014/08/ECETOC&#8208;TR&#8208;095&#8208;Vol&#8208;I.pdf%0Ahttp://www.ecetoc.org/wpcontent/uploads/2014/08/ECETOC&#8208;TR&#8208;095&#8208;Vol&#8208;II.pdf</ext-link>.</mixed-citation></ref><ref id="prp270037-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="prp270037-cit-0006"><string-name name-style="western"><given-names>G.</given-names><surname>Bagchi</surname></string-name> and <string-name name-style="western"><given-names>D. J.</given-names><surname>Waxman</surname></string-name>, &#8220;<article-title>Toxicity of Ethylene Glycol Monomethyl Ether: Impact on Testicular Gene Expression</article-title>,&#8221; <source>International Journal of Andrology</source><volume>31</volume>, no. <issue>2</issue> (<year>2008</year>): <fpage>269</fpage>&#8211;<lpage>274</lpage>, <pub-id pub-id-type="doi">10.1111/j.1365-2605.2007.00846.x</pub-id>.<pub-id pub-id-type="pmid">18179559</pub-id><pub-id pub-id-type="pmcid">PMC3286123</pub-id></mixed-citation></ref><ref id="prp270037-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="prp270037-cit-0007"><string-name name-style="western"><given-names>L.</given-names><surname>Multigner</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Catala</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Cordier</surname></string-name>, et&#160;al., &#8220;<article-title>The INSERM Expert Review on Glycol Ethers: Findings and Recommendations</article-title>,&#8221; <source>Toxicology Letters</source><volume>156</volume>, no. <issue>1 SPEC. ISS</issue> (<year>2005</year>): <fpage>29</fpage>&#8211;<lpage>37</lpage>, <pub-id pub-id-type="doi">10.1016/j.toxlet.2003.12.077</pub-id>.<pub-id pub-id-type="pmid">15705485</pub-id></mixed-citation></ref><ref id="prp270037-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="prp270037-cit-0008"><string-name name-style="western"><given-names>N. B.</given-names><surname>Hopf</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Suter&#8208;Dick</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Huwyler</surname></string-name>, et&#160;al., &#8220;<article-title>Novel Strategy to Assess the Neurotoxicity of Organic Solvents Such as Glycol Ethers: Protocol for Combining in Vitro and in Silico Methods With Human&#8208;Controlled Exposure Experiments</article-title>,&#8221; <source>JMIR Research Protocols</source><volume>13</volume> (<year>2024</year>): <elocation-id>e50300</elocation-id>, <pub-id pub-id-type="doi">10.2196/50300</pub-id>.<pub-id pub-id-type="pmid">38236630</pub-id><pub-id pub-id-type="pmcid">PMC10835597</pub-id></mixed-citation></ref><ref id="prp270037-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="prp270037-cit-0009"><string-name name-style="western"><given-names>E. W.</given-names><surname>Carney</surname></string-name>, <string-name name-style="western"><given-names>L. H.</given-names><surname>Pottenger</surname></string-name>, <string-name name-style="western"><given-names>K. A.</given-names><surname>Johnson</surname></string-name>, et&#160;al., &#8220;<article-title>Significance of 2&#8208;Methoxypropionic Acid Formed From &#946;&#8208;Propylene Glycol Monomethyl Ether: Integration of Pharmacokinetic and Developmental Toxicity Assessments in Rabbits</article-title>,&#8221; <source>Toxicological Sciences</source><volume>71</volume>, no. <issue>2</issue> (<year>2003</year>): <fpage>217</fpage>&#8211;<lpage>228</lpage>, <pub-id pub-id-type="doi">10.1093/toxsci/71.2.217</pub-id>.<pub-id pub-id-type="pmid">12563107</pub-id></mixed-citation></ref><ref id="prp270037-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="prp270037-cit-0010"><string-name name-style="western"><given-names>L.</given-names><surname>Aasmoe</surname></string-name>, <string-name name-style="western"><given-names>J. O.</given-names><surname>Winberg</surname></string-name>, and <string-name name-style="western"><given-names>J.</given-names><surname>Aarbakke</surname></string-name>, &#8220;<article-title>The Role of Liver Alcohol Dehydrogenase Isoenzymes in the Oxidation of Glycolethers in Male and Female Rats</article-title>,&#8221; <source>Toxicology and Applied Pharmacology</source><volume>150</volume>, no. <issue>1</issue> (<year>1998</year>): <fpage>86</fpage>&#8211;<lpage>90</lpage>, <pub-id pub-id-type="doi">10.1006/taap.1998.8410</pub-id>.<pub-id pub-id-type="pmid">9630456</pub-id></mixed-citation></ref><ref id="prp270037-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="prp270037-cit-0011"><string-name name-style="western"><given-names>L.</given-names><surname>Aasmoe</surname></string-name> and <string-name name-style="western"><given-names>J.</given-names><surname>Aarbakke</surname></string-name>, &#8220;<article-title>Sex&#8208;Dependent Induction of Alcohol Dehydrogenase Activity in Rats</article-title>,&#8221; <source>Biochemical Pharmacology</source><volume>57</volume>, no. <issue>9</issue> (<year>1999</year>): <fpage>1067</fpage>&#8211;<lpage>1072</lpage>, <pub-id pub-id-type="doi">10.1016/S0006-2952(99)00003-9</pub-id>.<pub-id pub-id-type="pmid">10796077</pub-id></mixed-citation></ref><ref id="prp270037-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="prp270037-cit-0012"><string-name name-style="western"><given-names>M. T.</given-names><surname>Moslen</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Kaphalia</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Balasubramanian</surname></string-name>, <string-name name-style="western"><given-names>Y. M.</given-names><surname>Yina</surname></string-name>, and <string-name name-style="western"><given-names>W. W.</given-names><surname>Au</surname></string-name>, &#8220;<article-title>Species Differences in Testicular and Hepatic Biotransformation of 2&#8208;Methoxyethanol</article-title>,&#8221; <source>Toxicology</source><volume>96</volume>, no. <issue>3</issue> (<year>1995</year>): <fpage>217</fpage>&#8211;<lpage>224</lpage>, <pub-id pub-id-type="doi">10.1016/0300-483X(94)02921-G</pub-id>.<pub-id pub-id-type="pmid">7900162</pub-id></mixed-citation></ref><ref id="prp270037-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="prp270037-cit-0013"><string-name name-style="western"><given-names>R. R.</given-names><surname>Miller</surname></string-name>, <string-name name-style="western"><given-names>E. A.</given-names><surname>Hermann</surname></string-name>, <string-name name-style="western"><given-names>P. W.</given-names><surname>Langvardt</surname></string-name>, <string-name name-style="western"><given-names>M. J.</given-names><surname>McKenna</surname></string-name>, and <string-name name-style="western"><given-names>B. A.</given-names><surname>Schwetz</surname></string-name>, &#8220;<article-title>Comparative Metabolism and Disposition of Ethylene Glycol Monomethyl Ether and Propylene Glycol Monomethyl Ether in Male Rats</article-title>,&#8221; <source>Toxicology and Applied Pharmacology</source><volume>67</volume>, no. <issue>2</issue> (<year>1983</year>): <fpage>229</fpage>&#8211;<lpage>237</lpage>, <pub-id pub-id-type="doi">10.1016/0041-008X(83)90229-6</pub-id>.<pub-id pub-id-type="pmid">6836577</pub-id></mixed-citation></ref><ref id="prp270037-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="prp270037-cit-0014"><string-name name-style="western"><given-names>D. W.</given-names><surname>Crabb</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Matsumoto</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Chang</surname></string-name>, and <string-name name-style="western"><given-names>M.</given-names><surname>You</surname></string-name>, &#8220;<article-title>Overview of the Role of Alcohol Dehydrogenase and Aldehyde Dehydrogenase and Their Variants in the Genesis of Alcohol&#8208;Related Pathology</article-title>,&#8221; <source>Proceedings of the Nutrition Society</source><volume>63</volume>, no. <issue>1</issue> (<year>2004</year>): <fpage>49</fpage>&#8211;<lpage>63</lpage>, <pub-id pub-id-type="doi">10.1079/pns2003327</pub-id>.<pub-id pub-id-type="pmid">15099407</pub-id></mixed-citation></ref><ref id="prp270037-bib-0015"><label>15</label><mixed-citation publication-type="book" id="prp270037-cit-0015"><string-name name-style="western"><given-names>Y.</given-names><surname>Wang</surname></string-name> and <string-name name-style="western"><given-names>W.</given-names><surname>He</surname></string-name>, <source>Endogenous Mitochondrial Aldehyde Dehydrogenase&#8208;2 as an Antioxidant in Liver</source> (<publisher-loc>Wuhan, China</publisher-loc>: <publisher-name>Elsevier Inc.</publisher-name>, <year>2018</year>), <fpage>247</fpage>&#8211;<lpage>259</lpage>, <pub-id pub-id-type="doi">10.1016/B978-0-12-803951-9.00021-5</pub-id>.</mixed-citation></ref><ref id="prp270037-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="prp270037-cit-0016"><string-name name-style="western"><given-names>W.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Xu</surname></string-name>, and <string-name name-style="western"><given-names>Y.</given-names><surname>Gao</surname></string-name>, &#8220;<article-title>Aldehyde Dehydrogenase, Liver Disease and Cancer</article-title>,&#8221; <source>International Journal of Biological Sciences</source><volume>16</volume>, no. <issue>6</issue> (<year>2020</year>): <fpage>921</fpage>&#8211;<lpage>934</lpage>, <pub-id pub-id-type="doi">10.7150/ijbs.42300</pub-id>.<pub-id pub-id-type="pmid">32140062</pub-id><pub-id pub-id-type="pmcid">PMC7053332</pub-id></mixed-citation></ref><ref id="prp270037-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="prp270037-cit-0017"><string-name name-style="western"><given-names>R. A.</given-names><surname>Corley</surname></string-name>, <string-name name-style="western"><given-names>R. A.</given-names><surname>Gies</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Wu</surname></string-name>, and <string-name name-style="western"><given-names>K. K.</given-names><surname>Weitz</surname></string-name>, &#8220;<article-title>Development of a Physiologically Based Pharmacokinetic Model for Propylene Glycol Monomethyl Ether and Its Acetate in Rats and Humans</article-title>,&#8221; <source>Toxicology Letters</source><volume>156</volume>, no. <issue>1 SPEC. ISS</issue> (<year>2005</year>): <fpage>193</fpage>&#8211;<lpage>213</lpage>, <pub-id pub-id-type="doi">10.1016/j.toxlet.2003.12.078</pub-id>.<pub-id pub-id-type="pmid">15705496</pub-id></mixed-citation></ref><ref id="prp270037-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="prp270037-cit-0018"><string-name name-style="western"><given-names>R. R.</given-names><surname>Miller</surname></string-name>, <string-name name-style="western"><given-names>E. A.</given-names><surname>Hermann</surname></string-name>, and <string-name name-style="western"><given-names>J. T.</given-names><surname>Young</surname></string-name>, &#8220;<article-title>Ethylene Glycol Monomethyl Ether and Propylene Glycol Monomethyl Ether: Metabolism, Disposition, and Subchronic Inhalation Toxicity Studies</article-title>,&#8221; <source>Environmental Health Perspectives</source><volume>57</volume> (<year>1984</year>): <fpage>233</fpage>&#8211;<lpage>239</lpage>, <pub-id pub-id-type="doi">10.1289/ehp.8457233</pub-id>.<pub-id pub-id-type="pmid">6499808</pub-id><pub-id pub-id-type="pmcid">PMC1568305</pub-id></mixed-citation></ref><ref id="prp270037-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="prp270037-cit-0019"><string-name name-style="western"><given-names>S.</given-names><surname>Scandinavian</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Sato</surname></string-name>, and <string-name name-style="western"><given-names>T.</given-names><surname>Nakajima</surname></string-name>, &#8220;<article-title>Pharmacokinetics of Organic Solvent Vapors in Relation to Their Toxicity Author(s): Akio Sato and Tamie Nakajima Published by&#8201;: The Scandinavian Journal of Work</article-title>,&#8221; <source>Environment &amp; Health, the Finnish Institute of Occupational Health, the Danish National</source><volume>13</volume>, no. <issue>2</issue> (<year>1987</year>): <fpage>81</fpage>&#8211;<lpage>93</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.5271/sjweh.2075</pub-id><pub-id pub-id-type="pmid">3299685</pub-id></mixed-citation></ref><ref id="prp270037-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="prp270037-cit-0020"><string-name name-style="western"><given-names>A.</given-names><surname>Devanth&#233;ry</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Berode</surname></string-name>, <string-name name-style="western"><given-names>P. O.</given-names><surname>Droz</surname></string-name>, and <string-name name-style="western"><given-names>J.</given-names><surname>Pulkkinen</surname></string-name>, &#8220;<article-title>Propylene Glycol Monomethyl Ether Occupational Exposure (PGME). 4. Analysis of 2&#8208;Methoxypropionic Acid in Urine</article-title>,&#8221; <source>International Archives of Occupational and Environmental Health</source><volume>76</volume>, no. <issue>2</issue> (<year>2003</year>): <fpage>151</fpage>&#8211;<lpage>155</lpage>, <pub-id pub-id-type="doi">10.1007/s00420-002-0401-x</pub-id>.<pub-id pub-id-type="pmid">12733088</pub-id></mixed-citation></ref><ref id="prp270037-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="prp270037-cit-0021"><string-name name-style="western"><given-names>L. Z.</given-names><surname>Benet</surname></string-name> and <string-name name-style="western"><given-names>P.</given-names><surname>Zia&#8208;Amirhosseini</surname></string-name>, &#8220;<article-title>Basic Principles of Pharmacokinetics</article-title>,&#8221; <source>Toxicologic Pathology</source><volume>23</volume>, no. <issue>2</issue> (<year>1995</year>): <fpage>115</fpage>&#8211;<lpage>123</lpage>, <pub-id pub-id-type="doi">10.1177/019262339502300203</pub-id>.<pub-id pub-id-type="pmid">7569664</pub-id></mixed-citation></ref><ref id="prp270037-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="prp270037-cit-0022"><string-name name-style="western"><given-names>M.</given-names><surname>Ingelman&#8208;Sundberg</surname></string-name> and <string-name name-style="western"><given-names>V. M.</given-names><surname>Lauschke</surname></string-name>, &#8220;<article-title>3D Human Liver Spheroids for Translational Pharmacology and Toxicology</article-title>,&#8221; <source>Basic &amp; Clinical Pharmacology &amp; Toxicology</source><volume>130</volume>, no. <issue>1</issue> (<year>2021</year>): <fpage>5</fpage>&#8211;<lpage>15</lpage>, <pub-id pub-id-type="doi">10.1111/bcpt.13587</pub-id>.<pub-id pub-id-type="pmid">33872466</pub-id></mixed-citation></ref><ref id="prp270037-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="prp270037-cit-0023"><string-name name-style="western"><given-names>B.</given-names><surname>Bonn</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Svanberg</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Janefeldt</surname></string-name>, <string-name name-style="western"><given-names>I.</given-names><surname>Hultman</surname></string-name>, and <string-name name-style="western"><given-names>K.</given-names><surname>Grime</surname></string-name>, &#8220;<article-title>Determination of Human Hepatocyte Intrinsic Clearance for Slowly Metabolized Compounds: Comparison of a Primary Hepatocyte/Stromal Cell Co&#8208;Culture With Plated Primary Hepatocytes and hepaRG</article-title>,&#8221; <source>Drug Metabolism and Disposition</source><volume>44</volume>, no. <issue>4</issue> (<year>2016</year>): <fpage>527</fpage>&#8211;<lpage>533</lpage>, <pub-id pub-id-type="doi">10.1124/dmd.115.067769</pub-id>.<pub-id pub-id-type="pmid">26851239</pub-id></mixed-citation></ref><ref id="prp270037-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="prp270037-cit-0024"><string-name name-style="western"><given-names>C. M.</given-names><surname>Smith</surname></string-name>, <string-name name-style="western"><given-names>C. K.</given-names><surname>Nolan</surname></string-name>, <string-name name-style="western"><given-names>M. A.</given-names><surname>Edwards</surname></string-name>, et&#160;al., &#8220;<article-title>A Comprehensive Evaluation of Metabolic Activity and Intrinsic Clearance in Suspensions and Monolayer Cultures of Cryopreserved Primary Human Hepatocytes</article-title>,&#8221; <source>Journal of Pharmaceutical Sciences</source><volume>101</volume>, no. <issue>10</issue> (<year>2012</year>): <fpage>3989</fpage>&#8211;<lpage>4002</lpage>, <pub-id pub-id-type="doi">10.1002/jps.23262</pub-id>.<pub-id pub-id-type="pmid">22806329</pub-id></mixed-citation></ref><ref id="prp270037-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="prp270037-cit-0025"><string-name name-style="western"><given-names>L.</given-names><surname>Di</surname></string-name> and <string-name name-style="western"><given-names>R. S.</given-names><surname>Obach</surname></string-name>, &#8220;<article-title>Addressing the Challenges of Low Clearance in Drug Research</article-title>,&#8221; <source>AAPS Journal</source><volume>17</volume>, no. <issue>2</issue> (<year>2015</year>): <fpage>352</fpage>&#8211;<lpage>357</lpage>, <pub-id pub-id-type="doi">10.1208/s12248-014-9691-7</pub-id>.<pub-id pub-id-type="pmid">25567366</pub-id><pub-id pub-id-type="pmcid">PMC4365098</pub-id></mixed-citation></ref><ref id="prp270037-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="prp270037-cit-0026"><string-name name-style="western"><given-names>A.</given-names><surname>Guillouzo</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Corlu</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Aninat</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Glaise</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Morel</surname></string-name>, and <string-name name-style="western"><given-names>C.</given-names><surname>Guguen&#8208;Guillouzo</surname></string-name>, &#8220;<article-title>The Human Hepatoma HepaRG Cells: A Highly Differentiated Model for Studies of Liver Metabolism and Toxicity of Xenobiotics</article-title>,&#8221; <source>Chemico&#8208;Biological Interactions</source><volume>168</volume>, no. <issue>1</issue> (<year>2007</year>): <fpage>66</fpage>&#8211;<lpage>73</lpage>, <pub-id pub-id-type="doi">10.1016/j.cbi.2006.12.003</pub-id>.<pub-id pub-id-type="pmid">17241619</pub-id></mixed-citation></ref><ref id="prp270037-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="prp270037-cit-0027"><string-name name-style="western"><given-names>U.</given-names><surname>Zanelli</surname></string-name>, <string-name name-style="western"><given-names>N. P.</given-names><surname>Caradonna</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Hallifax</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Turlizzi</surname></string-name>, and <string-name name-style="western"><given-names>J. B.</given-names><surname>Houston</surname></string-name>, &#8220;<article-title>Comparison of Cryopreserved HepaRG Cells With Cryopreserved Human Hepatocytes for Prediction of Clearance for 26 Drugs</article-title>,&#8221; <source>Drug Metabolism and Disposition</source><volume>40</volume>, no. <issue>1</issue> (<year>2012</year>): <fpage>104</fpage>&#8211;<lpage>110</lpage>, <pub-id pub-id-type="doi">10.1124/dmd.111.042309</pub-id>.<pub-id pub-id-type="pmid">21998403</pub-id></mixed-citation></ref><ref id="prp270037-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="prp270037-cit-0028"><string-name name-style="western"><given-names>C.</given-names><surname>Aninat</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Piton</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Glaise</surname></string-name>, et&#160;al., &#8220;<article-title>Expression of Cytochromes P450, Conjugating Enzymes and Nuclear Receptors in Human Hepatoma HepaRG Cells</article-title>,&#8221; <source>Drug Metabolism and Disposition</source><volume>34</volume>, no. <issue>1</issue> (<year>2006</year>): <fpage>75</fpage>&#8211;<lpage>83</lpage>, <pub-id pub-id-type="doi">10.1124/dmd.105.006759</pub-id>.<pub-id pub-id-type="pmid">16204462</pub-id></mixed-citation></ref><ref id="prp270037-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="prp270037-cit-0029"><string-name name-style="western"><given-names>S. N.</given-names><surname>Hart</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Li</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Nakamoto</surname></string-name>, <string-name name-style="western"><given-names>E. A.</given-names><surname>Subileau</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Steen</surname></string-name>, and <string-name name-style="western"><given-names>X. B.</given-names><surname>Zhong</surname></string-name>, &#8220;<article-title>A Comparison of Whole Genome Gene Expression Profiles of HepaRG Cells and HepG2 Cells to Primary Human Hepatocytes and Human Liver Tissues</article-title>,&#8221; <source>Drug Metabolism and Disposition</source><volume>38</volume>, no. <issue>6</issue> (<year>2010</year>): <fpage>988</fpage>&#8211;<lpage>994</lpage>, <pub-id pub-id-type="doi">10.1124/dmd.109.031831</pub-id>.<pub-id pub-id-type="pmid">20228232</pub-id><pub-id pub-id-type="pmcid">PMC2879958</pub-id></mixed-citation></ref><ref id="prp270037-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="prp270037-cit-0030"><string-name name-style="western"><given-names>E. A.</given-names><surname>Attignon</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Distel</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Le&#8208;Grand</surname></string-name>, et&#160;al., &#8220;<article-title>Down&#8208;Regulation of the Expression of Alcohol Dehydrogenase 4 and CYP2E1 by the Combination of &#945;&#8208;Endosulfan and Dioxin in HepaRG Human Cells</article-title>,&#8221; <source>Toxicology in Vitro: An International Journal Published in Association With BIBRA</source><volume>45</volume>, no. <issue>June</issue> (<year>2017</year>): <fpage>309</fpage>&#8211;<lpage>317</lpage>, <pub-id pub-id-type="doi">10.1016/j.tiv.2017.06.029</pub-id>.<pub-id pub-id-type="pmid">28673560</pub-id></mixed-citation></ref><ref id="prp270037-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="prp270037-cit-0031"><string-name name-style="western"><given-names>K.</given-names><surname>Ishida</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Kaji</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Sato</surname></string-name>, et&#160;al., &#8220;<article-title>Sulforaphane Ameliorates Ethanol Plus Carbon Tetrachlorideinduced Liver Fibrosis in Mice Through the Nrf2&#8208;Mediated Antioxidant Response and Acetaldehyde Metabolization With Inhibition of the LPS/TLR4 Signaling Pathway</article-title>,&#8221; <source>Journal of Nutritional Biochemistry</source><volume>89</volume> (<year>2021</year>): <elocation-id>108573</elocation-id>, <pub-id pub-id-type="doi">10.1016/j.jnutbio.2020.108573</pub-id>.<pub-id pub-id-type="pmid">33388347</pub-id></mixed-citation></ref><ref id="prp270037-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="prp270037-cit-0032"><string-name name-style="western"><given-names>E.</given-names><surname>Reale</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Sandstrom</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Culot</surname></string-name>, et&#160;al., &#8220;<article-title>Predicting Human Neurotoxicity of Propylene Glycol Methyl Ether (PGME) by Implementing In&#160;Vitro Neurotoxicity Results Into Toxicokinetic Modelling</article-title>,&#8221; <source>Science of the Total Environment</source><volume>886</volume>, no. <issue>February</issue> (<year>2023</year>): <elocation-id>163767</elocation-id>, <pub-id pub-id-type="doi">10.1016/j.scitotenv.2023.163767</pub-id>.<pub-id pub-id-type="pmid">37156387</pub-id></mixed-citation></ref><ref id="prp270037-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="prp270037-cit-0033"><string-name name-style="western"><given-names>C. J.</given-names><surname>Messner</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Premand</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Gaiser</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Kluser</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Kubler</surname></string-name>, and <string-name name-style="western"><given-names>L.</given-names><surname>Suter&#8208;Dick</surname></string-name>, &#8220;<article-title>Exosomal microRNAs Release as a Sensitive Marker for Drug&#8208;Induced Liver Injury In&#160;Vitro</article-title>,&#8221; <source>Applied In&#160;Vitro Toxicology</source><volume>6</volume>, no. <issue>3</issue> (<year>2020</year>): <fpage>77</fpage>&#8211;<lpage>89</lpage>, <pub-id pub-id-type="doi">10.1089/aivt.2020.0008</pub-id>.</mixed-citation></ref><ref id="prp270037-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="prp270037-cit-0034"><string-name name-style="western"><given-names>B.</given-names><surname>Berger</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Donzelli</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Maseneni</surname></string-name>, et&#160;al., &#8220;<article-title>Comparison of Liver Cell Models Using the Basel Phenotyping Cocktail</article-title>,&#8221; <source>Frontiers in Pharmacology</source><volume>7</volume>, no. <issue>NOV</issue> (<year>2016</year>): <fpage>1</fpage>&#8211;<lpage>12</lpage>, <pub-id pub-id-type="doi">10.3389/fphar.2016.00443</pub-id>.<pub-id pub-id-type="pmid">27917125</pub-id><pub-id pub-id-type="pmcid">PMC5116554</pub-id></mixed-citation></ref><ref id="prp270037-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="prp270037-cit-0035"><string-name name-style="western"><given-names>C. J.</given-names><surname>Messner</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Schmidt</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>&#214;zkul</surname></string-name>, et&#160;al., &#8220;<article-title>Identification of miR&#8208;199a&#8208;5p, miR&#8208;214&#8208;3p and miR&#8208;99b&#8208;5p as Fibrosis&#8208;Specific Extracellular Biomarkers and Promoters of HSC Activation</article-title>,&#8221; <source>International Journal of Molecular Sciences</source><volume>22</volume> (<year>2021</year>): <elocation-id>9799</elocation-id>.<pub-id pub-id-type="pmid">34575957</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms22189799</pub-id><pub-id pub-id-type="pmcid">PMC8464755</pub-id></mixed-citation></ref><ref id="prp270037-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="prp270037-cit-0036"><string-name name-style="western"><given-names>B.</given-names><surname>M&#233;garbane</surname></string-name>, &#8220;<article-title>Treatment of Patients With Ethylene Glycol or Methanol Poisoning: Focus on Fomepizole</article-title>,&#8221; <source>Open Access Emergency Medicine</source><volume>2</volume> (<year>2010</year>): <fpage>67</fpage>&#8211;<lpage>75</lpage>, <pub-id pub-id-type="doi">10.2147/OAEM.S5346</pub-id>.<pub-id pub-id-type="pmid">27147840</pub-id><pub-id pub-id-type="pmcid">PMC4806829</pub-id></mixed-citation></ref><ref id="prp270037-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="prp270037-cit-0037"><string-name name-style="western"><given-names>L.</given-names><surname>Quattrini</surname></string-name>, <string-name name-style="western"><given-names>E. L. M.</given-names><surname>Gelardi</surname></string-name>, <string-name name-style="western"><given-names>V.</given-names><surname>Coviello</surname></string-name>, et&#160;al., &#8220;<article-title>Imidazo[1,2&#8208; a]Pyridine Derivatives as Aldehyde Dehydrogenase Inhibitors: Novel Chemotypes to Target Glioblastoma Stem Cells</article-title>,&#8221; <source>Journal of Medicinal Chemistry</source><volume>63</volume>, no. <issue>9</issue> (<year>2020</year>): <fpage>4603</fpage>&#8211;<lpage>4616</lpage>, <pub-id pub-id-type="doi">10.1021/acs.jmedchem.9b01910</pub-id>.<pub-id pub-id-type="pmid">32223240</pub-id></mixed-citation></ref><ref id="prp270037-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="prp270037-cit-0038"><string-name name-style="western"><given-names>S.</given-names><surname>Zakhari</surname></string-name>, &#8220;<article-title>Overview: How Is Alcohol Metabolized by the Body?</article-title>,&#8221; <source>Alcohol Research &amp; Health</source><volume>29</volume>, no. <issue>4</issue> (<year>2006</year>): <fpage>245</fpage>&#8211;<lpage>254</lpage>.<pub-id pub-id-type="pmid">17718403</pub-id><pub-id pub-id-type="pmcid">PMC6527027</pub-id></mixed-citation></ref><ref id="prp270037-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="prp270037-cit-0039"><string-name name-style="western"><given-names>R. S.</given-names><surname>Obach</surname></string-name>, <string-name name-style="western"><given-names>J. G.</given-names><surname>Baxter</surname></string-name>, <string-name name-style="western"><given-names>T. E.</given-names><surname>Liston</surname></string-name>, et&#160;al., &#8220;<article-title>The Prediction of Human Pharmacokinetic Parameters From Preclinical and In&#160;Vitro Metabolism Data</article-title>,&#8221; <source>Journal of Pharmacology and Experimental Therapeutics</source><volume>283</volume>, no. <issue>1</issue> (<year>1997</year>): <fpage>46</fpage>&#8211;<lpage>58</lpage>.<pub-id pub-id-type="pmid">9336307</pub-id></mixed-citation></ref><ref id="prp270037-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="prp270037-cit-0040"><string-name name-style="western"><given-names>Z.</given-names><surname>Barter</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Bayliss</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Beaune</surname></string-name>, et&#160;al., &#8220;<article-title>Scaling Factors for the Extrapolation of in Vivo Metabolic Drug Clearance From in Vitro Data: Reaching a Consensus on Values of Human Micro&#8208;Somal Protein and Hepatocellularity per Gram of Liver</article-title>,&#8221; <source>Current Drug Metabolism</source><volume>8</volume>, no. <issue>1</issue> (<year>2006</year>): <fpage>33</fpage>&#8211;<lpage>45</lpage>, <pub-id pub-id-type="doi">10.2174/138920007779315053</pub-id>.<pub-id pub-id-type="pmid">17266522</pub-id></mixed-citation></ref><ref id="prp270037-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="prp270037-cit-0041"><string-name name-style="western"><given-names>H.</given-names><surname>Musther</surname></string-name>, <string-name name-style="western"><given-names>M. D.</given-names><surname>Harwood</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Yang</surname></string-name>, <string-name name-style="western"><given-names>D. B.</given-names><surname>Turner</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Rostami&#8208;Hodjegan</surname></string-name>, and <string-name name-style="western"><given-names>M.</given-names><surname>Jamei</surname></string-name>, &#8220;<article-title>The Constraints, Construction, and Verification of a Strain&#8208;Specific Physiologically Based Pharmacokinetic Rat Model</article-title>,&#8221; <source>Journal of Pharmaceutical Sciences</source><volume>106</volume>, no. <issue>9</issue> (<year>2017</year>): <fpage>2826</fpage>&#8211;<lpage>2838</lpage>, <pub-id pub-id-type="doi">10.1016/j.xphs.2017.05.003</pub-id>.<pub-id pub-id-type="pmid">28495566</pub-id></mixed-citation></ref><ref id="prp270037-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="prp270037-cit-0042"><string-name name-style="western"><given-names>J.</given-names><surname>Houston</surname></string-name> and <string-name name-style="western"><given-names>A.</given-names><surname>Galetin</surname></string-name>, &#8220;<article-title>Methods for Predicting in Vivo Pharmacokinetics Using Data From in Vitro Assays</article-title>,&#8221; <source>Current Drug Metabolism</source><volume>9</volume>, no. <issue>9</issue> (<year>2008</year>): <fpage>940</fpage>&#8211;<lpage>951</lpage>, <pub-id pub-id-type="doi">10.2174/138920008786485164</pub-id>.<pub-id pub-id-type="pmid">18991591</pub-id></mixed-citation></ref><ref id="prp270037-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="prp270037-cit-0043"><string-name name-style="western"><given-names>B.</given-names><surname>Davies</surname></string-name> and <string-name name-style="western"><given-names>T.</given-names><surname>Morris</surname></string-name>, &#8220;<article-title>Physiological Parameters in Laboratory Animals and Humans</article-title>,&#8221; <source>Pharmaceutical Research</source><volume>10</volume>, no. <issue>7</issue> (<year>1993</year>): <fpage>1093</fpage>&#8211;<lpage>1095</lpage>, <pub-id pub-id-type="doi">10.1023/a:1018943613122</pub-id>.<pub-id pub-id-type="pmid">8378254</pub-id></mixed-citation></ref><ref id="prp270037-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="prp270037-cit-0044"><string-name name-style="western"><given-names>K. S.</given-names><surname>Pang</surname></string-name> and <string-name name-style="western"><given-names>M.</given-names><surname>Rowland</surname></string-name>, &#8220;<article-title>Hepatic Clearance of Drugs. I. Theoretical Considerations of a &#8220;Wellstirred&#8221; Model and a &#8220;Parallel Tube&#8221; Model. Influence of Hepatic Blood Flow, Plasma and Blood Cell Binding, and the Hepatocellular Enzymatic Activity on Hepatic Drug Clearance</article-title>,&#8221; <source>Journal of Pharmacokinetics and Biopharmaceutics</source><volume>5</volume>, no. <issue>6</issue> (<year>1977</year>): <fpage>625</fpage>&#8211;<lpage>653</lpage>, <pub-id pub-id-type="doi">10.1007/BF01059688</pub-id>.<pub-id pub-id-type="pmid">599411</pub-id></mixed-citation></ref><ref id="prp270037-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="prp270037-cit-0045"><string-name name-style="western"><given-names>R. J.</given-names><surname>Riley</surname></string-name>, <string-name name-style="western"><given-names>D. F.</given-names><surname>McGinnity</surname></string-name>, and <string-name name-style="western"><given-names>R. P.</given-names><surname>Austin</surname></string-name>, &#8220;<article-title>A Unified Model for Predicting Human Hepatic, Metabolic Clearance From In&#160;Vitro Intrinsic Clearance Data in Hepatocytes and Microsomes</article-title>,&#8221; <source>Drug Metabolism and Disposition</source><volume>33</volume>, no. <issue>9</issue> (<year>2005</year>): <fpage>1304</fpage>&#8211;<lpage>1311</lpage>, <pub-id pub-id-type="doi">10.1124/dmd.105.004259</pub-id>.<pub-id pub-id-type="pmid">15932954</pub-id></mixed-citation></ref><ref id="prp270037-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="prp270037-cit-0046"><string-name name-style="western"><given-names>R. P.</given-names><surname>Austin</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Barton</surname></string-name>, and <string-name name-style="western"><given-names>R. J.</given-names><surname>Riley</surname></string-name>, &#8220;<article-title>Response to &#8220;Binding of Drugs to Hepatic Microsomes: Comment and Assessment of Current Prediction Methodology With Recommendation for Improvement&#8221;</article-title>,&#8221; <source>Drug Metabolism and Disposition</source><volume>34</volume>, no. <issue>4</issue> (<year>2006</year>): <fpage>727</fpage>, <pub-id pub-id-type="doi">10.1124/dmd.105.009142</pub-id>.<pub-id pub-id-type="pmid">16552024</pub-id></mixed-citation></ref><ref id="prp270037-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="prp270037-cit-0047"><string-name name-style="western"><given-names>P. J.</given-names><surname>Kilford</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Gertz</surname></string-name>, <string-name name-style="western"><given-names>J. B.</given-names><surname>Houston</surname></string-name>, and <string-name name-style="western"><given-names>A.</given-names><surname>Galetin</surname></string-name>, &#8220;<article-title>Hepatocellular Binding of Drugs: Correction for Unbound Fraction in Hepatocyte Incubations Using Microsomal Binding or Drug Lipophilicity Data</article-title>,&#8221; <source>Drug Metabolism and Disposition</source><volume>36</volume>, no. <issue>7</issue> (<year>2008</year>): <fpage>1194</fpage>&#8211;<lpage>1197</lpage>, <pub-id pub-id-type="doi">10.1124/dmd.108.020834</pub-id>.<pub-id pub-id-type="pmid">18411401</pub-id></mixed-citation></ref><ref id="prp270037-bib-0048"><label>48</label><mixed-citation publication-type="journal" id="prp270037-cit-0048"><string-name name-style="western"><given-names>R. R.</given-names><surname>Miller</surname></string-name>, <string-name name-style="western"><given-names>P. W.</given-names><surname>Langvardt</surname></string-name>, <string-name name-style="western"><given-names>L. L.</given-names><surname>Calhoun</surname></string-name>, and <string-name name-style="western"><given-names>M. A.</given-names><surname>Yahrmarkt</surname></string-name>, &#8220;<article-title>Metabolism and Disposition of Propylene Glycol Monomethyl Ether (PGME) Beta Isomer in Male Rats</article-title>,&#8221; <source>Toxicology and Applied Pharmacology</source><volume>83</volume>, no. <issue>1</issue> (<year>1986</year>): <fpage>170</fpage>&#8211;<lpage>177</lpage>, <pub-id pub-id-type="doi">10.1016/0041-008X(86)90334-0</pub-id>.<pub-id pub-id-type="pmid">3513376</pub-id></mixed-citation></ref><ref id="prp270037-bib-0049"><label>49</label><mixed-citation publication-type="journal" id="prp270037-cit-0049"><string-name name-style="western"><given-names>C.</given-names><surname>Kramer</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Mochalski</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Unterkofler</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Agapiou</surname></string-name>, <string-name name-style="western"><given-names>V.</given-names><surname>Ruzsanyi</surname></string-name>, and <string-name name-style="western"><given-names>K. R.</given-names><surname>Liedl</surname></string-name>, &#8220;<article-title>Prediction of Blood:Air and Fat:Air Partition Coefficients of Volatile Organic Compounds for the Interpretation of Data in Breath Gas Analysis</article-title>,&#8221; <source>Journal of Breath Research</source><volume>10</volume>, no. <issue>1</issue> (<year>2016</year>): <fpage>1</fpage>&#8211;<lpage>10</lpage>, <pub-id pub-id-type="doi">10.1088/1752-7155/10/1/017103</pub-id>.<pub-id pub-id-type="pmcid">PMC4957668</pub-id><pub-id pub-id-type="pmid">26815030</pub-id></mixed-citation></ref><ref id="prp270037-bib-0050"><label>50</label><mixed-citation publication-type="journal" id="prp270037-cit-0050"><string-name name-style="western"><given-names>R.</given-names><surname>Tibaldi</surname></string-name>, <string-name name-style="western"><given-names>W.</given-names><surname>Ten Berge</surname></string-name>, and <string-name name-style="western"><given-names>D.</given-names><surname>Drolet</surname></string-name>, &#8220;<article-title>Dermal Absorption of Chemicals: Estimation by IH SkinPerm</article-title>,&#8221; <source>Journal of Occupational and Environmental Hygiene</source><volume>11</volume>, no. <issue>1</issue> (<year>2014</year>): <fpage>19</fpage>&#8211;<lpage>31</lpage>, <pub-id pub-id-type="doi">10.1080/15459624.2013.831983</pub-id>.<pub-id pub-id-type="pmid">24283333</pub-id></mixed-citation></ref><ref id="prp270037-bib-0051"><label>51</label><mixed-citation publication-type="journal" id="prp270037-cit-0051"><string-name name-style="western"><given-names>T.</given-names><surname>Rodgers</surname></string-name> and <string-name name-style="western"><given-names>M.</given-names><surname>Rowland</surname></string-name>, &#8220;<article-title>Physiologically Based Pharmacokinetic Modelling 2: Predicting the Tissue Distribution of Acids, Very Weak Bases, Neutrals and Zwitterions</article-title>,&#8221; <source>Journal of Pharmaceutical Sciences</source><volume>95</volume>, no. <issue>6</issue> (<year>2006</year>): <fpage>1238</fpage>&#8211;<lpage>1257</lpage>, <pub-id pub-id-type="doi">10.1002/jps.20502</pub-id>.<pub-id pub-id-type="pmid">16639716</pub-id></mixed-citation></ref><ref id="prp270037-bib-0052"><label>52</label><mixed-citation publication-type="journal" id="prp270037-cit-0052"><string-name name-style="western"><given-names>N. S.</given-names><surname>Sipes</surname></string-name>, <string-name name-style="western"><given-names>J. F.</given-names><surname>Wambaugh</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Pearce</surname></string-name>, et&#160;al., &#8220;<article-title>An Intuitive Approach for Predicting Potential Human Health Risk With the Tox21 10k Library</article-title>,&#8221; <source>Environmental Science &amp; Technology</source><volume>51</volume>, no. <issue>18</issue> (<year>2017</year>): <elocation-id>1078610796</elocation-id>, <pub-id pub-id-type="doi">10.1021/acs.est.7b00650</pub-id>.<pub-id pub-id-type="pmcid">PMC5657440</pub-id><pub-id pub-id-type="pmid">28809115</pub-id></mixed-citation></ref><ref id="prp270037-bib-0053"><label>53</label><mixed-citation publication-type="journal" id="prp270037-cit-0053"><string-name name-style="western"><given-names>R.</given-names><surname>Watanabe</surname></string-name>, <string-name name-style="western"><given-names>T.</given-names><surname>Esaki</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Ohashi</surname></string-name>, et&#160;al., &#8220;<article-title>Development of an In Silico Prediction Model for Pglycoprotein Efflux Potential in Brain Capillary Endothelial Cells Toward the Prediction of Brain Penetration</article-title>,&#8221; <source>Journal of Medicinal Chemistry</source><volume>64</volume>, no. <issue>5</issue> (<year>2021</year>): <fpage>2725</fpage>&#8211;<lpage>2738</lpage>, <pub-id pub-id-type="doi">10.1021/acs.jmedchem.0c02011</pub-id>.<pub-id pub-id-type="pmid">33619967</pub-id></mixed-citation></ref><ref id="prp270037-bib-0054"><label>54</label><mixed-citation publication-type="book" id="prp270037-cit-0054"><string-name name-style="western"><given-names>E. H.</given-names><surname>Kerns</surname></string-name>, <source>Blood&#8208;Brain Barrier in Drug Discovery: Optimizing Brain Exposure of CNS Drugs and Minimizing Brain Side Effects for Peripheral Drugs</source> (<publisher-loc>Maryland, USA</publisher-loc>: <publisher-name>Wiley</publisher-name>, <year>2015</year>).</mixed-citation></ref><ref id="prp270037-bib-0055"><label>55</label><mixed-citation publication-type="journal" id="prp270037-cit-0055"><string-name name-style="western"><given-names>M. L.</given-names><surname>Gargas</surname></string-name>, <string-name name-style="western"><given-names>T. R.</given-names><surname>Tyler</surname></string-name>, <string-name name-style="western"><given-names>L. M.</given-names><surname>Sweeney</surname></string-name>, et&#160;al., &#8220;<article-title>A Toxicokinetic Study of Inhaled Ethylene Glycol Monomethyl Ether (2&#8208;ME) and Validation of a Physiologically Based Pharmacokinetic Model for the Pregnant Rat and Human</article-title>,&#8221; <source>Toxicology and Applied Pharmacology</source><volume>165</volume>, no. <issue>1</issue> (<year>2000</year>): <fpage>53</fpage>&#8211;<lpage>62</lpage>, <pub-id pub-id-type="doi">10.1006/taap.2000.8928856</pub-id>.<pub-id pub-id-type="pmid">10814553</pub-id></mixed-citation></ref><ref id="prp270037-bib-0056"><label>56</label><mixed-citation publication-type="book" id="prp270037-cit-0056"><collab collab-type="authors">WHO, IPCS</collab>
, <source>Characterization and Application of Physiologically Based Pharmacokinetic Models in Risk Assessment, Harmonization Project Document</source> (<publisher-loc>Geneva</publisher-loc>: <publisher-name>World Health Organization</publisher-name>, <year>2010</year>).</mixed-citation></ref><ref id="prp270037-bib-0057"><label>57</label><mixed-citation publication-type="journal" id="prp270037-cit-0057"><string-name name-style="western"><given-names>L.</given-names><surname>Yuan</surname></string-name>, <string-name name-style="western"><given-names>W. C.</given-names><surname>Chou</surname></string-name>, <string-name name-style="western"><given-names>E. D.</given-names><surname>Richards</surname></string-name>, et&#160;al., &#8220;<article-title>A Web&#8208;Based Interactive Physiologically Based Pharmacokinetic (iPBPK) Model for Meloxicam in Broiler Chickens and Laying Hens</article-title>,&#8221; <source>Food and Chemical Toxicology</source><volume>168</volume>, no. <issue>March</issue> (<year>2022</year>): <elocation-id>113332</elocation-id>, <pub-id pub-id-type="doi">10.1016/j.fct.2022.113332</pub-id>.<pub-id pub-id-type="pmid">35940329</pub-id></mixed-citation></ref><ref id="prp270037-bib-0058"><label>58</label><mixed-citation publication-type="journal" id="prp270037-cit-0058"><string-name name-style="western"><given-names>Z.</given-names><surname>Lin</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Jaberi&#8208;Douraki</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>He</surname></string-name>, et&#160;al., &#8220;<article-title>Performance Assessment and Translation of Physiologically Based Pharmacokinetic Models From Acslx to Berkeley Madonna, Matlab, and r Language: Oxytetracycline and Gold Nanoparticles as Case Examples</article-title>,&#8221; <source>Toxicological Sciences</source><volume>158</volume>, no. <issue>1</issue> (<year>2017</year>): <fpage>23</fpage>&#8211;<lpage>35</lpage>, <pub-id pub-id-type="doi">10.1093/toxsci/kfx070</pub-id>.<pub-id pub-id-type="pmid">28402537</pub-id></mixed-citation></ref><ref id="prp270037-bib-0059"><label>59</label><mixed-citation publication-type="journal" id="prp270037-cit-0059"><string-name name-style="western"><given-names>J. G.</given-names><surname>Teeguarden</surname></string-name>, <string-name name-style="western"><given-names>P. J.</given-names><surname>Deisinger</surname></string-name>, <string-name name-style="western"><given-names>T. S.</given-names><surname>Poet</surname></string-name>, et&#160;al., &#8220;<article-title>Derivation of a Human Equivalent Concentration for n&#8208;Butanol Using a Physiologically Based Pharmacokinetic Model for Nbutyl Acetate and Metabolites n&#8208;Butanol and n&#8208;Butyric Acid</article-title>,&#8221; <source>Toxicological Sciences</source><volume>85</volume>, no. <issue>1</issue> (<year>2005</year>): <fpage>429</fpage>&#8211;<lpage>446</lpage>, <pub-id pub-id-type="doi">10.1093/toxsci/kfi103</pub-id>.<pub-id pub-id-type="pmid">15703268</pub-id></mixed-citation></ref><ref id="prp270037-bib-0060"><label>60</label><mixed-citation publication-type="journal" id="prp270037-cit-0060"><string-name name-style="western"><given-names>S. D.</given-names><surname>Harding</surname></string-name>, <string-name name-style="western"><given-names>J. L.</given-names><surname>Sharman</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Faccenda</surname></string-name>, et&#160;al., &#8220;<article-title>The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: Updates and Expansion to Encompass the New Guide to IMMUNOPHARMACOLOGY</article-title>,&#8221; <source>Nucleic Acids Research</source><volume>46</volume>, no. <issue>D1</issue> (<year>2018</year>): <fpage>D1091</fpage>&#8211;<lpage>D1106</lpage>, <pub-id pub-id-type="doi">10.1093/nar/gkx1121</pub-id>.<pub-id pub-id-type="pmid">29149325</pub-id><pub-id pub-id-type="pmcid">PMC5753190</pub-id></mixed-citation></ref><ref id="prp270037-bib-0061"><label>61</label><mixed-citation publication-type="journal" id="prp270037-cit-0061"><string-name name-style="western"><given-names>S. P. H.</given-names><surname>Alexander</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Fabbro</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Kelly</surname></string-name>, et&#160;al., &#8220;<article-title>The Concise Guide to PHARMACOLOGY 2023/24: Enzymes</article-title>,&#8221; <source>British Journal of Pharmacology</source><volume>180</volume>, no. <issue>S2</issue> (<year>2023</year>): <fpage>S289</fpage>&#8211;<lpage>S373</lpage>, <pub-id pub-id-type="doi">10.1111/bph.16181</pub-id>.<pub-id pub-id-type="pmid">38123154</pub-id></mixed-citation></ref><ref id="prp270037-bib-0062"><label>62</label><mixed-citation publication-type="journal" id="prp270037-cit-0062"><string-name name-style="western"><given-names>S. P. H.</given-names><surname>Alexander</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Kelly</surname></string-name>, <string-name name-style="western"><given-names>A. A.</given-names><surname>Mathie</surname></string-name>, et&#160;al., &#8220;<article-title>The Concise Guide to PHARMACOLOGY 2023/24: Introduction and Other Protein Targets</article-title>,&#8221; <source>British Journal of Pharmacology</source><volume>180</volume>, no. <issue>S2</issue> (<year>2023</year>): <fpage>S1</fpage>&#8211;<lpage>S22</lpage>, <pub-id pub-id-type="doi">10.1111/bph.16176</pub-id>.<pub-id pub-id-type="pmid">38123153</pub-id></mixed-citation></ref><ref id="prp270037-bib-0063"><label>63</label><mixed-citation publication-type="journal" id="prp270037-cit-0063"><string-name name-style="western"><given-names>S. P. H.</given-names><surname>Alexander</surname></string-name>, <string-name name-style="western"><given-names>A. A.</given-names><surname>Mathie</surname></string-name>, <string-name name-style="western"><given-names>J. A.</given-names><surname>Peters</surname></string-name>, et&#160;al., &#8220;<article-title>The Concise Guide to PHARMACOLOGY 2023/24: Ion Channels</article-title>,&#8221; <source>British Journal of Pharmacology</source><volume>180</volume>, no. <issue>Suppl 2</issue> (<year>2023</year>): <fpage>S145</fpage>&#8211;<lpage>S222</lpage>, <pub-id pub-id-type="doi">10.1111/bph.16178</pub-id>.<pub-id pub-id-type="pmid">38123150</pub-id><pub-id pub-id-type="pmcid">PMC11339754</pub-id></mixed-citation></ref><ref id="prp270037-bib-0064"><label>64</label><mixed-citation publication-type="journal" id="prp270037-cit-0064"><string-name name-style="western"><given-names>J. M.</given-names><surname>Hutzler</surname></string-name>, <string-name name-style="western"><given-names>B. J.</given-names><surname>Ring</surname></string-name>, and <string-name name-style="western"><given-names>S. R.</given-names><surname>Anderson</surname></string-name>, &#8220;<article-title>Low&#8208;Turnover Drug Molecules: A Current Challenge for Drug Metabolism Scientists</article-title>,&#8221; <source>Drug Metabolism and Disposition</source><volume>43</volume>, no. <issue>12</issue> (<year>2015</year>): <fpage>1917</fpage>&#8211;<lpage>1928</lpage>, <pub-id pub-id-type="doi">10.1124/dmd.115.066431</pub-id>.<pub-id pub-id-type="pmid">26363026</pub-id></mixed-citation></ref><ref id="prp270037-bib-0065"><label>65</label><mixed-citation publication-type="journal" id="prp270037-cit-0065"><string-name name-style="western"><given-names>D. M.</given-names><surname>Scott</surname></string-name> and <string-name name-style="western"><given-names>R. E.</given-names><surname>Taylor</surname></string-name>, &#8220;<article-title>Health&#8208;Related Effects of Genetic</article-title>,&#8221; <source>Alcohol Research &amp; Health</source><volume>30</volume> (<year>2007</year>): <fpage>18</fpage>&#8211;<lpage>22</lpage>.<pub-id pub-id-type="pmid">17718396</pub-id><pub-id pub-id-type="pmcid">PMC3860436</pub-id></mixed-citation></ref><ref id="prp270037-bib-0066"><label>66</label><mixed-citation publication-type="journal" id="prp270037-cit-0066"><string-name name-style="western"><given-names>R. M.</given-names><surname>Venn</surname></string-name>, &#8220;<article-title>Fomepizole for the Treatment of Ethylene Glycol Poisoning</article-title>,&#8221; <source>Critical Care</source><volume>1</volume>, no. <issue>1</issue> (<year>1999</year>): <fpage>1</fpage>&#8211;<lpage>4</lpage>, <pub-id pub-id-type="doi">10.1186/ccf-1999-42</pub-id>.</mixed-citation></ref><ref id="prp270037-bib-0067"><label>67</label><mixed-citation publication-type="journal" id="prp270037-cit-0067"><string-name name-style="western"><given-names>M.</given-names><surname>Chiba</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Ishii</surname></string-name>, and <string-name name-style="western"><given-names>Y.</given-names><surname>Sugiyama</surname></string-name>, &#8220;<article-title>Prediction of Hepatic Clearance in Human From In&#160;Vitro Data for Successful Drug Development</article-title>,&#8221; <source>AAPS Journal</source><volume>11</volume>, no. <issue>2</issue> (<year>2009</year>): <fpage>262</fpage>&#8211;<lpage>276</lpage>, <pub-id pub-id-type="doi">10.1208/s12248-009-9103-6</pub-id>.<pub-id pub-id-type="pmid">19408130</pub-id><pub-id pub-id-type="pmcid">PMC2691463</pub-id></mixed-citation></ref><ref id="prp270037-bib-0068"><label>68</label><mixed-citation publication-type="journal" id="prp270037-cit-0068"><string-name name-style="western"><given-names>N. A.</given-names><surname>Kratochwil</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Meille</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Fowler</surname></string-name>, et&#160;al., &#8220;<article-title>Metabolic Profiling of Human Long&#8208;Term Liver Models and Hepatic Clearance Predictions From in Vitro Data Using Nonlinear Mixed&#8208;Effects Modeling</article-title>,&#8221; <source>AAPS Journal</source><volume>19</volume>, no. <issue>2</issue> (<year>2017</year>): <fpage>534</fpage>&#8211;<lpage>550</lpage>, <pub-id pub-id-type="doi">10.1208/s12248-016-0019-7</pub-id>.<pub-id pub-id-type="pmid">28050713</pub-id></mixed-citation></ref><ref id="prp270037-bib-0069"><label>69</label><mixed-citation publication-type="journal" id="prp270037-cit-0069"><string-name name-style="western"><given-names>I.</given-names><surname>Hultman</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Vedin</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Abrahamsson</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Winiwarter</surname></string-name>, and <string-name name-style="western"><given-names>M.</given-names><surname>Darnell</surname></string-name>, &#8220;<article-title>Use of H&#956;REL Human Coculture System for Prediction of Intrinsic Clearance and Metabolite Formation for Slowly Metabolized Compounds</article-title>,&#8221; <source>Molecular Pharmaceutics</source><volume>13</volume>, no. <issue>8</issue> (<year>2016</year>): <fpage>2796</fpage>&#8211;<lpage>2807</lpage>, <pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.6b00396</pub-id>.<pub-id pub-id-type="pmid">27377099</pub-id></mixed-citation></ref><ref id="prp270037-bib-0070"><label>70</label><mixed-citation publication-type="journal" id="prp270037-cit-0070"><string-name name-style="western"><given-names>K.</given-names><surname>S&#322;oczy&#324;ska</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Gunia&#8208;Krzyzak</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Koczurkiewicz</surname></string-name>, et&#160;al., &#8220;<article-title>Metabolic Stability and Its Role in the Discovery of New Chemical Entities</article-title>,&#8221; <source>Acta Pharmaceutica</source><volume>69</volume>, no. <issue>3</issue> (<year>2019</year>): <fpage>345</fpage>&#8211;<lpage>361</lpage>, <pub-id pub-id-type="doi">10.2478/acph-2019-0024</pub-id>.<pub-id pub-id-type="pmid">31259741</pub-id></mixed-citation></ref><ref id="prp270037-bib-0071"><label>71</label><mixed-citation publication-type="journal" id="prp270037-cit-0071"><string-name name-style="western"><given-names>M. T.</given-names><surname>Donato</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Hallifax</surname></string-name>, <string-name name-style="western"><given-names>L.</given-names><surname>Picazo</surname></string-name>, et&#160;al., &#8220;<article-title>Metabolite Formation Kinetics and Intrinsic Clearance of Phenacetin, Tolbutamide, Alprazolam, and Midazolam in Adenoviral Cytochrome P450transfected HepG2 Cells and Comparison With Hepatocytes and In&#160;Vivo</article-title>,&#8221; <source>Drug Metabolism and Disposition</source><volume>38</volume>, no. <issue>9</issue> (<year>2010</year>): <fpage>1449</fpage>&#8211;<lpage>1455</lpage>, <pub-id pub-id-type="doi">10.1124/dmd.110.033605</pub-id>.<pub-id pub-id-type="pmid">20501911</pub-id></mixed-citation></ref><ref id="prp270037-bib-0072"><label>72</label><mixed-citation publication-type="journal" id="prp270037-cit-0072"><string-name name-style="western"><given-names>L. C.</given-names><surname>Preiss</surname></string-name>, <string-name name-style="western"><given-names>V. M.</given-names><surname>Lauschke</surname></string-name>, <string-name name-style="western"><given-names>K.</given-names><surname>Georgi</surname></string-name>, and <string-name name-style="western"><given-names>C.</given-names><surname>Petersson</surname></string-name>, &#8220;<article-title>Multi&#8208;Well Array Culture of Primary Human Hepatocyte Spheroids for Clearance Extrapolation of Slowly Metabolized Compounds</article-title>,&#8221; <source>AAPS Journal</source><volume>24</volume>, no. <issue>2</issue> (<year>2022</year>): <fpage>1</fpage>&#8211;<lpage>12</lpage>, <pub-id pub-id-type="doi">10.1208/s12248-022-00689-y</pub-id>.<pub-id pub-id-type="pmid">35277751</pub-id></mixed-citation></ref><ref id="prp270037-bib-0073"><label>73</label><mixed-citation publication-type="journal" id="prp270037-cit-0073"><string-name name-style="western"><given-names>T. S.</given-names><surname>Chan</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Yu</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Moore</surname></string-name>, <string-name name-style="western"><given-names>S. R.</given-names><surname>Khetani</surname></string-name>, and <string-name name-style="western"><given-names>D.</given-names><surname>Tweedie</surname></string-name>, &#8220;<article-title>Meeting the Challenge of Predicting Hepatic Clearance of Compounds Slowly Metabolized by Cytochrome P450 Using a Novel Hepatocyte Model, HepatoPac</article-title>,&#8221; <source>Drug Metabolism and Disposition</source><volume>47</volume>, no. <issue>1</issue> (<year>2019</year>): <fpage>58</fpage>&#8211;<lpage>66</lpage>, <pub-id pub-id-type="doi">10.1124/DMD.113.053397FULLARTICLECORRECTION</pub-id>.<pub-id pub-id-type="pmid">30552098</pub-id></mixed-citation></ref><ref id="prp270037-bib-0074"><label>74</label><mixed-citation publication-type="journal" id="prp270037-cit-0074"><string-name name-style="western"><given-names>M.</given-names><surname>Mandon</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Huet</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Dubreil</surname></string-name>, <string-name name-style="western"><given-names>V.</given-names><surname>Fessard</surname></string-name>, and <string-name name-style="western"><given-names>L.</given-names><surname>Le H&#233;garat</surname></string-name>, &#8220;<article-title>Three&#8208;Dimensional HepaRG Spheroids as a Liver Model to Study Human Genotoxicity In&#160;Vitro With the Single Cell Gel Electrophoresis Assay</article-title>,&#8221; <source>Scientific Reports</source><volume>9</volume>, no. <issue>1</issue> (<year>2019</year>): <fpage>1</fpage>&#8211;<lpage>9</lpage>, <pub-id pub-id-type="doi">10.1038/s41598-019-47114-7</pub-id>.<pub-id pub-id-type="pmid">31332230</pub-id><pub-id pub-id-type="pmcid">PMC6646340</pub-id></mixed-citation></ref><ref id="prp270037-bib-0075"><label>75</label><mixed-citation publication-type="journal" id="prp270037-cit-0075"><string-name name-style="western"><given-names>M.</given-names><surname>L&#252;bberstedt</surname></string-name>, <string-name name-style="western"><given-names>U.</given-names><surname>M&#252;ller&#8208;Vieira</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Mayer</surname></string-name>, et&#160;al., &#8220;<article-title>HepaRG Human Hepatic Cell Line Utility as a Surrogate for Primary Human Hepatocytes in Drug Metabolism Assessment In&#160;Vitro</article-title>,&#8221; <source>Journal of Pharmacological and Toxicological Methods</source><volume>63</volume>, no. <issue>1</issue> (<year>2011</year>): <fpage>59</fpage>&#8211;<lpage>68</lpage>, <pub-id pub-id-type="doi">10.1016/j.vascn.2010.04.013</pub-id>.<pub-id pub-id-type="pmid">20460162</pub-id></mixed-citation></ref><ref id="prp270037-bib-0076"><label>76</label><mixed-citation publication-type="journal" id="prp270037-cit-0076"><string-name name-style="western"><given-names>C. H.</given-names><surname>Beckwitt</surname></string-name>, <string-name name-style="western"><given-names>A. M.</given-names><surname>Clark</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Wheeler</surname></string-name>, et&#160;al., &#8220;<article-title>Liver &#8216;Organ on a Chip&#8217;</article-title>,&#8221; <source>Experimental Cell Research</source><volume>363</volume>, no. <issue>1</issue> (<year>2018</year>): <fpage>15</fpage>&#8211;<lpage>25</lpage>, <pub-id pub-id-type="doi">10.1016/j.yexcr.2017.12.023</pub-id>.<pub-id pub-id-type="pmid">29291400</pub-id><pub-id pub-id-type="pmcid">PMC5944300</pub-id></mixed-citation></ref><ref id="prp270037-bib-0077"><label>77</label><mixed-citation publication-type="journal" id="prp270037-cit-0077"><string-name name-style="western"><given-names>B.</given-names><surname>Cox</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Barton</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Class</surname></string-name>, et&#160;al., &#8220;<article-title>Setup of Human Liver&#8208;Chips Integrating 3D Models, Microwells and a Standardized Microfluidic Platform as Proof&#8208;Of&#8208;Concept Study to Support Drug Evaluation</article-title>,&#8221; <source>Biomaterials and Biosystems</source><volume>7</volume>, no. <issue>February</issue> (<year>2022</year>): <elocation-id>100054</elocation-id>, <pub-id pub-id-type="doi">10.1016/j.bbiosy.2022.100054</pub-id>.<pub-id pub-id-type="pmid">36824483</pub-id><pub-id pub-id-type="pmcid">PMC9934436</pub-id></mixed-citation></ref><ref id="prp270037-bib-0078"><label>78</label><mixed-citation publication-type="journal" id="prp270037-cit-0078"><string-name name-style="western"><given-names>P.</given-names><surname>Gunness</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Mueller</surname></string-name>, <string-name name-style="western"><given-names>V.</given-names><surname>Shevchenko</surname></string-name>, <string-name name-style="western"><given-names>E.</given-names><surname>Heinzle</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Ingelman&#8208;Sundberg</surname></string-name>, and <string-name name-style="western"><given-names>F.</given-names><surname>Noor</surname></string-name>, &#8220;<article-title>3D Organotypic Cultures of Human Heparg Cells: A Tool for In&#160;Vitro Toxicity Studies</article-title>,&#8221; <source>Toxicological Sciences</source><volume>133</volume>, no. <issue>1</issue> (<year>2013</year>): <fpage>67</fpage>&#8211;<lpage>78</lpage>, <pub-id pub-id-type="doi">10.1093/toxsci/kft021</pub-id>.<pub-id pub-id-type="pmid">23377618</pub-id></mixed-citation></ref><ref id="prp270037-bib-0079"><label>79</label><mixed-citation publication-type="journal" id="prp270037-cit-0079"><string-name name-style="western"><given-names>M. V.</given-names><surname>Flores</surname></string-name>, <string-name name-style="western"><given-names>C. E.</given-names><surname>Voget</surname></string-name>, and <string-name name-style="western"><given-names>R. J. J.</given-names><surname>Ertola</surname></string-name>, &#8220;<article-title>Permeabilization of Yeast Cells (Kluyveromyces Lactis) With Organic Solvents</article-title>,&#8221; <source>Enzyme and Microbial Technology</source><volume>16</volume>, no. <issue>4</issue> (<year>1994</year>): <fpage>340</fpage>&#8211;<lpage>346</lpage>, <pub-id pub-id-type="doi">10.1016/0141-0229(94)90177-5</pub-id>.</mixed-citation></ref><ref id="prp270037-bib-0080"><label>80</label><mixed-citation publication-type="journal" id="prp270037-cit-0080"><string-name name-style="western"><given-names>P. J.</given-names><surname>Spencer</surname></string-name>, <string-name name-style="western"><given-names>J. W.</given-names><surname>Crissman</surname></string-name>, <string-name name-style="western"><given-names>W. T.</given-names><surname>Stott</surname></string-name>, et&#160;al., &#8220;<article-title>Propylene Glycol Monomethyl Ether (PGME): Inhalation Toxicity and Carcinogenicity in Fischer 344 Rats and B6C3F1 Mice</article-title>,&#8221; <source>Toxicologic Pathology</source><volume>30</volume>, no. <issue>5</issue> (<year>2002</year>): <fpage>570</fpage>&#8211;<lpage>579</lpage>, <pub-id pub-id-type="doi">10.1080/01926230290105848</pub-id>.<pub-id pub-id-type="pmid">12371666</pub-id></mixed-citation></ref><ref id="prp270037-bib-0081"><label>81</label><mixed-citation publication-type="journal" id="prp270037-cit-0081"><string-name name-style="western"><given-names>P. J.</given-names><surname>Spencer</surname></string-name>, &#8220;<article-title>New Toxicity Data for the Propylene Glycol Ethers &#8208; A Commitment to Public Health and Safety</article-title>,&#8221; <source>Toxicology Letters</source><volume>156</volume>, no. <issue>1</issue> (<year>2005</year>): <fpage>181</fpage>&#8211;<lpage>188</lpage>, <pub-id pub-id-type="doi">10.1016/j.toxlet.2003.09.023</pub-id>.<pub-id pub-id-type="pmid">15705495</pub-id></mixed-citation></ref><ref id="prp270037-bib-0082"><label>82</label><mixed-citation publication-type="journal" id="prp270037-cit-0082"><string-name name-style="western"><given-names>U. M.</given-names><surname>Zanger</surname></string-name> and <string-name name-style="western"><given-names>M.</given-names><surname>Schwab</surname></string-name>, &#8220;<article-title>Cytochrome P450 Enzymes in Drug Metabolism: Regulation of Gene Expression, Enzyme Activities, and Impact of Genetic Variation</article-title>,&#8221; <source>Pharmacology &amp; Therapeutics</source><volume>138</volume>, no. <issue>1</issue> (<year>2013</year>): <fpage>103</fpage>&#8211;<lpage>141</lpage>, <pub-id pub-id-type="doi">10.1016/j.pharmthera.2012.12.007</pub-id>.<pub-id pub-id-type="pmid">23333322</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>